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ABSTRACT 
Rebecca Boyd Naumann: Assessing Sustained and Differential Impacts of North Carolina’s 
Medicaid “Lock-In” Program 
 (Under the direction of Stephen Marshall) 
 
 Between 2000 and 2015, half a million people died from a drug overdose in the U.S., and 
most of these deaths involved an opioid. Medicaid beneficiaries are a particularly high-risk 
population. One strategy that nearly all states use to address potential misuse of prescription 
opioids, and other controlled substances (CS), are Medicaid “lock-in” programs (MLIPs). MLIPs 
identify beneficiaries demonstrating potential overutilization of CS and control their access. In 
North Carolina (NC), beneficiaries enrolled in the MLIP are required to use a single prescriber 
and pharmacy to obtain specific CS for a 12-month period. There has been little research 
examining the impact of MLIPs. 
 In this dissertation, we 1) examined the sustained impact of the NC MLIP on dispensed 
CS and dosages of opioids dispensed (in terms of morphine milligram equivalents (MMEs)) and 
2) examined whether trajectories of MMEs differed across time prior to, during, and following 
release from the MLIP for different strata of the population. Data included NC Medicaid claims 
linked to records from NC’s Prescription Drug Monitoring Program from October 2009 through 
June 2013.  
 We found that compared to a period of stable CS dispensing prior to MLIP enrollment, 
the MLIP reduced the average numbers of CS dispensed both during lock-in and following 
iv 
 
release. However, the program was also associated with increased acquisition of dispensed CS 
using non-Medicaid payment (e.g., out-of-pocket) both during lock-in and following release. 
Moreover, beneficiaries acquired greater MMEs of dispensed opioids from both Medicaid and 
non-Medicaid payment sources during lock-in and following release. 
 Considerable heterogeneity existed in trajectories of MMEs of dispensed opioids across 
time prior to, during, and following release from the MLIP. Five trajectory patterns appeared to 
sufficiently describe this underlying heterogeneity. All patterns demonstrated a spike in MMEs 
in the six months prior to lock-in, constituting a trigger for MLIP enrollment; however, patterns 
were dissimilar in overall starting values and slopes. While the trajectories indicated that the 
MLIP may have had little influence on MME patterns across time, strong associations between 
trajectory patterns and beneficiary characteristics were evident. Findings from this dissertation 
thus provide a foundation for informing future MLIP improvements.  
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CHAPTER 1 – INTRODUCTION  
  
Prescription drug overdoses have become a public health epidemic with enormous health, 
social, and economic impacts. Prescription drug overdose deaths have rapidly escalated over the 
past several years (Figure 1.1).1 Between 2000 and 2015, the annual U.S. prescription drug 
overdose death rate tripled from 2.8 to 9.2 deaths per 100,000 population. Of the 29,728 lives 
lost to prescription drug overdoses in 2015, three out of four (76%) deaths involved an opioid 
analgesic (i.e., painkiller) and nearly one-third involved a benzodiazepine, a prescription drug 
often used in the treatment of anxiety.1 (Note: some overdoses involve more than one type of 
drug).  
Figure 1.1 Age-adjusted prescription drug overdose death rates per 100,000 population per year, 
United States, 2000-2015 
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  While prescription drugs, including opioids and benzodiazepines, play a legitimate and 
important role in pain management, particularly for palliative care, endemic misuse and abuse of 
these drugs has become a major public health problem, and arguably the defining public health 
crisis of the early 21st century. In 2011, approximately 1.4 million emergency department (ED) 
visits in the U.S. were related to the nonmedical use of prescriptions,2 and in the year 2013 alone, 
prescription opioid overdose, abuse, and dependence cost the U.S. more than $78 billion in terms 
of health care costs, productivity losses, and criminal justice fees.3  
The drug overdose epidemic in North Carolina (NC) has followed national trends, with 
NC also experiencing a substantial increase in fatal overdoses over the last several years (Figure 
1.2).4  
 
Figure 1.2 Drug overdose death rates per 100,000 population per year, North Carolina, 2000-
2015 
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NC now loses nearly 1,500 people each year to drug overdose, the majority of which are related 
to prescription opioids (n= 854 for the year 2015). Moreover, for each person lost to an overdose 
in NC, there are an additional nine hospitalizations and 17 ED visits related to drug overdose.5,6  
Medicaid beneficiaries are a particularly high-risk population for prescription drug 
misuse, abuse, and overdose. Adults who qualify for Medicaid are generally those with low 
incomes who have dependents, a disability, or some other specific health care need (e.g., 
pregnancy).7 Prescriptions for controlled substances (CS) (i.e., drugs, such as opioids, whose 
manufacture, possession, or use is regulated by the government because of their potential for 
abuse), and specifically for opioids, have increased rapidly over the past several years in the 
Medicaid population. Between 1996 and 2002, opioid dispensing to Medicaid fee-for-service 
enrollees increased approximately threefold.8 Additionally, Medicaid beneficiaries are prescribed 
opioids at roughly twice the rate of non-Medicaid populations, likely due to several factors, 
including higher rates of disability and chronic disease.9,10 It also has been suggested that 
Medicaid beneficiaries may have less access to non-opioid therapies, such as physical therapy, to 
treat pain-related conditions.10,11  
A large proportion of the opioids prescribed to Medicaid beneficiaries are linked to 
potentially inappropriate prescribing.9 Approximately 40% of Medicaid beneficiaries prescribed 
opioids in 2010 had at least one indicator of potentially inappropriate use or prescribing, defined 
as having temporally overlapping opioid and benzodiazepine prescriptions, high daily doses (i.e., 
prescribed daily dose of  ≥ 100 morphine milligram equivalents (MMEs)), or long acting/ 
extended release opioids for acute pain.12 Serious negative health consequences associated with 
the disproportionate and high-risk prescribing and dispensing patterns have been identified in 
this population. Compared to those with other forms of insurance, Medicaid beneficiaries have 
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both higher opioid-related poisoning hospitalization rates and drug poisoning ED visit rates.13,14 
Analyses from New York, Washington, and Montana indicated that Medicaid beneficiaries have 
opioid-related death rates three to eight times as high as non-Medicaid beneficiaries.15-17 In North 
Carolina specifically, an analyses of 2007 data revealed that Medicaid beneficiaries experienced 
a third of the unintentional overdose deaths in the state, while representing approximately 20% 
of the state population.18  
Several policy interventions have been implemented in an attempt to reduce the negative 
impacts associated with prescription drug misuse and abuse.19 Table 1.1 highlights some of the 
most frequently used strategies with a brief explanation of each strategy’s purpose. While some 
of these strategies are supported by a small evidence base of evaluation-related research, most 
are lacking empirical support. This type of research is necessary to determine how best to design 
and apply these strategies in order to optimize public health impact.19,20 
 
Table 1.1 Common policies/strategies used to address prescription drug misuse, abuse, 
diversion, and overdose 
Policy/strategy Purpose 
Prescription drug monitoring 
programs (PDMPs) 
State-run electronic databases used to track the prescribing 
and dispensing of CS. Provides prescribers and pharmacists 
with important information about patients’ CS dispensing 
history.21,22 
“Good Samaritan” legislation Encourages emergency treatment of those experiencing an 
opioid overdose by providing immunity for low level 
criminal offenses when a person who is experiencing an 
overdose or who is present at an overdose calls 911 for 
assistance or seeks medical attention for themselves or 
another person.23 
Naloxone access legislation and 
naloxone distribution programs 
Naloxone is a medication that quickly reverses an opioid-
related overdose by neutralizing opioids in a person’s 
system, allowing them to breathe again. Naloxone laws 
often address criminal, civil, and/or professional immunity 
from legal action related to the administration of naloxone 
in an overdose situation.23,24 
 5 
 
Table 1.1 Common policies/strategies used to address prescription drug misuse, abuse, 
diversion, and overdose 
Policy/strategy Purpose 
Safe disposal/drug “take back” 
events 
Provides a safe, convenient, and responsible means of 
disposing of prescription drugs.25 
“Pill mill” legislation Legislation that often restricts in-office dispensing of CS 
and/or mandates registration or licensure of pain 
management clinics, among other requirements.26  
Provider training and 
education, including Risk 
Evaluation and Mitigation 
Strategy (REMS) materials and 
prescriber guidelines 
The FDA’s REMS program requires risk mitigation plans to 
ensure that benefits of certain prescription drugs outweigh 
their risks. These can include many different components 
but often include development of a one-page Medication 
Guide that is given to a patient when they obtain their opioid 
prescription at the pharmacy.27 Prescriber guidelines have 
been made available at the state level, and the Centers for 
Disease Control and Prevention (CDC) recently released 
guidelines at the national level.28,29 
Improved access to substance 
abuse treatment, including 
medication-assisted treatment 
(MAT) 
MAT includes taking a medication (e.g., buprenorphine, 
methadone) usually once per day to relieve opioid cravings 
and withdrawal symptoms.30,31 Many treatment programs 
also involve a counseling component. 
Abuse-deterrent opioid 
formulations 
Drugs designed to minimize the user’s ability to physically 
alter the drug to extract the active ingredient through 
methods like chewing, crushing, or mixing with a solvent 
(e.g., alcohol).32 
Patient review and restriction 
programs (i.e., “Lock-in” 
programs) 
Programs designed to identify beneficiaries demonstrating 
potential overutilization of prescription drugs and tightly 
regulate their access, generally through the requirement that 
beneficiaries use a single prescriber and/or pharmacy to 
obtain certain CS for a specified period of time.33,34 
 
Of specific interest in this dissertation are “lock-in” programs or patient review and 
restriction programs. These have generally been used to target specific beneficiary populations, 
such as the high-risk Medicaid population. Medicaid “lock-in” programs (MLIPs) identify 
Medicaid beneficiaries demonstrating potential overutilization of prescription drugs and control 
their access, generally through the requirement that beneficiaries use a single prescriber and/or 
pharmacy to obtain certain CS for a specified period of time.33  Because Medicaid legislation has 
long mandated that states safeguard against unnecessary utilization of services, several states 
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have operated some version of a “lock-in” program since the 1970s or early 1980s.35,36 However, 
with the recent substantial increase in CS misuse, abuse, diversion, and overdose, MLIPs have 
received a renewed focus in the last several years.37  
While MLIPs are operational in nearly every state,33,38 there is wide variation in program 
design, and limited research on the long-term impacts on beneficiaries. The diversity in MLIP 
design includes the criteria that trigger enrollment in a state’s MLIP, length of time beneficiaries 
are enrolled in the program, and restrictions placed on beneficiaries while enrolled.33 While each 
state has different specific criteria, beneficiaries are generally flagged for enrollment due to 
filling a certain number of prescriptions and/or visiting a certain number of prescribers and/or 
pharmacies in a specified period of time (e.g., 30 or 60 days). Additionally, once locked-in, 
beneficiaries are generally constrained to obtaining CS prescriptions from one prescriber and/or 
one pharmacy for a 12- to 24-month period. However, as we discuss in detail in Chapter 2, few 
states have rigorously evaluated the impacts of their MLIPs.  
NC’s MLIP was implemented in 2010 in response to a Government Accountability 
Office audit identifying NC as a state with an unusually large number of claims for CS.39 The 
MLIP is administered by NC’s Division of Medical Assistance (DMA), the division 
administering Medicaid in NC. Similar to other states, NC’s MLIP primarily serves three 
purposes: 1) to better coordinate care of selected beneficiaries; 2) to reduce diversion of CS; and 
3) to reduce expenditures for medically unnecessary prescriptions and health care services 
needed to treat adverse outcomes from the nonmedical use of CS.33 NC Medicaid beneficiaries 
who meet the requirements outlined in Table 1.2 are flagged for potential enrollment in the 
state’s MLIP.40 If enrolled, beneficiaries are “locked-in” for a 12-month period and restricted to 
using one prescriber and one pharmacy location to obtain CS prescriptions categorized as opioids 
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or benzodiazepines, as well as certain anxiolytics (e.g., meprobamate). After 12 months in the 
program, beneficiaries are released from lock-in requirements, but can become eligible for re-
enrollment if criteria for enrollment are again met. (Note: In January 2017, the “lock-in” period 
in NC changed from a 12- to a 24-month period.41 This dissertation analyzed data prior to 2017.) 
 
Table 1.2 Criteria for potential inclusion in the NC Medicaid “Lock-In” Program 
 
Few high-quality studies have rigorously evaluated many of the strategies described in 
Table 1.1, including MLIPs.20 This dissertation fills important gaps in our understanding of the 
impacts of MLIPs, and specifically NC’s MLIP. Chapter 2 provides a detailed review of the 
current literature surrounding MLIP impacts, and Chapter 3 outlines the specific aims of this 
dissertation and gaps in the literature that this dissertation fills. 
  
Controlled substance Specifications* 
Opioid analgesics >6 claims in 2 consecutive months 
Benzodiazepines >6 claims in 2 consecutive months 
Opioid analgesics or 
benzodiazepines 
Obtained from >3 unique prescribers in 2 
consecutive months 
 -- 
Referred for enrollment by a provider or the NC 
Division of Medical Assistance 
*Note: Cancer patients are generally exempt from consideration for MLIP enrollment. 
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CHAPTER 2 – LITERATURE REVIEW 
 
2.1 Overview 
A review of the literature, searching PubMed, Google Scholar, and ProQuest’s 
Dissertation and Theses databases, was conducted. Because much of the evaluation information 
on MLIPs is not contained in the peer reviewed literature, but rather involves internal state 
reports, we also used Google searches to search this “grey” literature. Literature searches 
included combinations of the following search terms: “Medicaid,” “lock in,” “opioid,” “drug 
utilization review,” “patient review and restriction,” “evaluation,” “controlled substances,” and 
each of the state names. All searches were initially conducted in November 2015 and repeated in 
June 2017 to capture any new publications. The reference lists of identified articles were 
reviewed for additional relevant articles and resources. 
This critical review of the literature review is organized in three parts (Sections 2.2-2.4). 
The first part summarizes what is known about the impacts of MLIPs from various state-based 
studies, audits, and internal reports (Section 2.2). The second part synthesizes findings from 
evaluations of lock-in programs implemented by specific managed care organizations (MCOs) 
(Section 2.3). The third part focuses on initial evaluation results from studies examining impacts 
of NC’s MLIP (Section 2.4). At the end of each section, we provide a summary of the key 
methodologic limitations of the studies and reports reviewed.  
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Finally, in Section 2.5, findings from a brief review of studies examining heterogeneity in 
trajectories and classes of CS use are provided. This review was conducted to inform hypotheses 
for the second aim of this dissertation.   
 
2.2 Evaluations of MLIPs: State-based (other than NC) Results 
 This section synthesizes evaluation findings from MLIPs in states other than NC. While 
nearly every state has a MLIP in place, there is very little rigorous information available on the 
impacts of these programs. We identified MLIP evaluation results related to healthcare 
utilization or cost savings from fifteen states; however, most evaluation reports and studies had 
poorly documented methods and provided a superficial look at program impacts. We first review 
evaluation results from six states with either peer-reviewed studies of the effects of their MLIPs 
or with state-based reports or presentations that provided reasonably well documented results. 
We specifically highlight the year(s) studied in each subheading below to call attention to the 
fact that results and lessons learned from some of the earlier studies may not be as applicable to 
the current prescription drug overdose epidemic, which began in the mid-1990s.42 Additional 
state-based findings, often from internal state-based reports or audits with very little detail, are 
briefly summarized in Table 2.1.  
 
Missouri (1976) 
 The earliest known MLIP evaluation results come from Missouri.43 In 1977, Singleton 
published a description of how the state’s MLIP operated, as well as the estimated cost savings 
from the program. In determining which beneficiaries to enroll in the program, Missouri’s MLIP 
staff examined claims looking for three specific areas of overutilization: physician and pharmacy 
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shopping; excessive numbers of prescriptions within thirty, sixty, or ninety days; and the number 
of different drugs received vs. the number of physicians prescribing them. Beneficiaries flagged 
for potential misutilization were reviewed by a Medicaid physician and/or pharmacist to 
determine if the beneficiary’s utilization could be justified based on their diagnoses and previous 
medical history. If staff determined that the utilization was unjustifiable, a Medicaid caseworker 
contacted the beneficiary to discuss the MLIP and explain that they would be “locked-in” to 
using one physician and pharmacy. Singleton estimated that the program saved the state between 
$1.8 million and $10.95 million in the year 1976 alone and that these savings reduced the state’s 
Medicaid budget expenditures by at least 2%.34,43,44 
 
Hawaii (1980-1983) 
 Hawaii’s MLIP was implemented in 1980 with the following criteria for program 
enrollment: (1) engaging in “doctor shopping,” defined as consulting multiple providers for the 
same reason in a few days, consulting multiple providers specializing in the same area for the 
same or different reasons, or consulting providers located in geographically diverse areas for the 
same reason; (2) engaging in unnecessary visits for the same reason to the same provider; (3) 
using multiple pharmacies to obtain the same drug dispensed by either the same or different 
physicians; (4) obtaining excessive doses of CS or drugs with street value; or (5) using 
prescription drugs that are inconsistent or inappropriate with a diagnosis (generally, for a long 
period of time).45 Medicaid staff regularly identified beneficiaries meeting misuse criteria, and 
Medicaid caseworkers met with beneficiaries to discuss their overutilization. Beneficiaries were 
given up to six months to voluntarily address identified issues. If, during this period, Medicaid 
staff determined that the issues were resolved, beneficiaries were not formally “locked-in.” 
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However, if misuse appeared to persist, beneficiaries were “locked-in” to using only one primary 
care provider, pharmacy, clinic, and/or hospital. An evaluation of the MLIP published in 1985 
found that from program implementation through 1983, approximately 270 beneficiaries were 
counseled by caseworkers and 137 restrictive actions were taken. Of those who were counseled, 
warned, and asked to voluntarily comply, about 21% were no longer overutilizing services one 
year post-warning. Among those who were enrolled in the MLIP, the degree of abuse was 
reported to decrease on average while enrolled, and the state was estimated to save more than 
$900,000 from the program in one year alone.34,46  
 
Louisiana (1994-1996) 
 Louisiana’s MLIP was established in the 1970s; however, it was not until the mid-1990s, 
when Medicaid costs drastically increased, that the MLIP was utilized to a much greater extent 
with about 2,000 beneficiaries enrolled at any given time. While MLIP beneficiaries could be 
restricted to one primary care provider, one specialist, and/or one pharmacy, the majority of 
beneficiaries were only locked-in to one pharmacy. Blake’s (1997) dissertation research focused 
on examining the impact of Louisiana’s MLIP on economic and clinical outcomes.34,35,47 She 
analyzed claims data for a two year period from mid-1994 to mid-1996 and used t-tests and 
segmented regression to examine differences in utilization and expenditures one year pre-lock-in 
vs. the year following lock-in.  
Beneficiaries in the MLIP were predominantly female (77%) with a mean age of 48 years 
and most received disability assistance (74%). Compared to the one-year pre-lock-in period, 
during lock-in there was an increase in provider continuity (i.e., proportion of services obtained 
from one provider) and a reduction in the number of inpatient days, as well as in physician visits 
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and diagnostic tests. Approximately 65% of locked-in beneficiaries filled their prescriptions at a 
single pharmacy prior to lock-in, as compared to more than 90% during lock-in. Additionally, 
Blake documented reductions in polypharmacy, use of Schedule II CS, and pharmacy costs. Prior 
to lock-in, the number of unique prescriptions per recipient per month ranged from 8-10 
compared to about 6 after enrollment. Moreover, per recipient adjusted monthly pharmacy 
expenditures ranged from $300-$400 prior to enrollment compared to $225-$250 after 
enrollment for those with a physician and pharmacy restriction and about $300 after enrollment 
for those with only a pharmacy restriction.  
 
Wisconsin (1997) 
 Potential candidates for Wisconsin’s MLIP were identified through both automated 
surveillance methods and through referral by physicians, pharmacists, and other providers.48 
Candidates with evidence of CS abuse and/or forgery of prescriptions were placed in the state’s 
MLIP and restricted to using a single provider and a single pharmacy for two years. Hladilek et 
al. (2004) reported that on average, about 130 candidates were reviewed each month, resulting in 
approximately nine MLIP enrollments per month. Moreover, a 1997 cost-benefit analysis of the 
program concluded that the MLIP saved $6.16 per dollar spent. This analysis also indicated that 
the MLIP resulted in a 24% decrease in drug expenditures, 21% decrease in hospitalizations, and 
a 26% decrease in ED visits.48  
 
Washington (2004-2012) 
 A series of presentations and studies from researchers in Washington have summarized 
both health care utilization and expenditure changes resulting from their state’s MLIP.28,49-51 
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Similar to other states, Medicaid beneficiaries are considered for MLIP enrollment as a result of 
either a referral from a health care provider or as a result of being flagged in a claims-based 
analysis that considers numbers of providers visited, prescriptions dispensed, and ED visits, 
among other factors. MLIP beneficiaries can be locked into using one primary care physician, 
one pharmacy, one opioid prescriber, one hospital for non-emergency services, or any 
combination of these for a two-year period. A 2009 analysis revealed that, on average, 
beneficiaries enrolled in the MLIP had a 37% decrease in physician visits, a 33% decrease in ED 
visits, and a 24% decrease in the number of prescriptions. Among 518 beneficiaries enrolled in 
the MLIP in 2006, the average number of opioid prescriptions per beneficiary per month 
decreased from 3.07 to 1.63, the average number of prescribers decreased from 4.8 to 2.8, and 
total MMEs decreased from 312 MME/day to 185 MME/day. Savings from the MLIP were 
estimated at more than $1.5 million per month, and the program was found to save 
approximately $12 for every $1 invested.  
While the state’s MLIP demonstrated many positive findings, additional analyses using 
2004-2007 data highlighted the fact that MLIP enrollees remained a high-risk population, even 
after enrollment.17,45 These analyses indicated that while MLIP enrollees constituted 0.1% of the 
entire Medicaid population, they accounted for 4.5% of all prescription opioid-related deaths. 
The annual fatal overdose risk for individuals in the overall state Medicaid population was 
estimated to be 1 in 6,757, while the estimated risk was 1 in 172 for those enrolled in the MLIP. 
 
Oklahoma (2006) 
 Oklahoma MLIP beneficiaries were selected for enrollment based on their number of ED 
visits; number of unique pharmacies visited; number of prescribers/physicians visited; days’ 
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supply of narcotics, anxiolytics, antidepressants obtained; diagnoses of drug dependence; and 
number of hospital discharges, among other factors. While enrolled, beneficiaries were “locked-
in” to using one pharmacy. A 2009 analysis of 52 MLIP beneficiaries enrolled from January 
2006 through October 2006 found that when compared to the 12 months prior to enrollment, 
beneficiaries had less opioid prescription fills, were less likely to visit multiple pharmacies and 
physicians, and had fewer ED visits during MLIP enrollment.45,52 The average number of opioid 
prescription fills decreased from 2.16 per beneficiary per month to 1.32, all pharmacy claims 
decreased from 4.86 to 3.46, unique pharmacies visited decreased from 2.05 to 0.89, unique 
prescribers visited decreased from 2.48 to 1.63, and ED visits decreased from 1.26 to 0.81. In the 
first 12 months of MLIP enrollment, per member annual savings were estimated at just over 
$600.  
 
 In addition to these state-based studies, several internal reports were identified that 
provided very brief information on estimates of state MLIP impacts, often in terms of Medicaid 
cost savings. These findings are summarized in Table 2.1. 
 
Table 2.1 Brief state-based MLIP evaluation findings 
State Key findings 
Colorado53 A 2015 state audit report estimated that if Colorado’s MLIP, which was not 
functional at the time of the report, had enrolled just 200 beneficiaries prior to 
FY 2012, they would have seen a reduction in General Fund expenditures for 
prescription drugs of $633,725 for FYs 2012 and 2013. 
Conneticut54,55 The state reported that their drug utilization review activities and MLIP had 
saved the state $2.4 million in fiscal year 2011 and more than $4 million in 
fiscal year 2012. 
Florida56,57 Between October 2002 (when FL’s MLIP began) and March 2005, 
approximately 1,315 beneficiaries were enrolled in the program, which 
restricts beneficiaries to one provider and/or one pharmacy for up to one year. 
During that time period, cumulative savings were estimated to be 
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Table 2.1 Brief state-based MLIP evaluation findings 
State Key findings 
approximately $12.7 million. Several years later, the state’s Agency for 
Health Care Administration reported that due to restrictions set on CS and use 
of the state’s PDMP, which is available to both prescribers and pharmacists, 
the number of beneficiaries locked-in decreased over time and the number of 
beneficiaries requiring manual monitoring through the MLIP decreased. As 
of September 30, 2013, the state reported that there were no longer any 
beneficiaries in the MLIP. 
Iowa58,59 Iowa MLIP beneficiaries are restricted to one physician, one pharmacy, and 
one hospital to obtain prescriptions for a 24-month period. In 2008, the state 
reported annual cost savings of approximately $2 million, which increased 
substantially in subsequent years. From July 2010 through September 2012, 
the state estimated that they had saved approximately $14.8 million in terms 
of prescription drug and medical care costs. 
Kentucky60 In 1997, an internal performance audit was carried out on the state’s MLIP. 
Kentucky’s MLIP requires enrollees to be restricted to one physician and one 
pharmacy. The auditors analyzed 170 randomly selected MLIP beneficiaries 
enrolled between January 1994 and March 1997. They found that average 
annual claims in the 12 months pre-lock-in were nearly $15,000 and 
approximately $8,600 in the 12 months following lock-in, for an average 
estimated savings of $6,400 per beneficiary enrolled.  
Louisiana61 MLIP beneficiaries in Louisiana are locked-in to using one pharmacy when 
enrolled. From September 2013 to July 2014, it was estimated that the MLIP 
saved more than $90,000, or about $15.65 per locked-in beneficiary per 
month. During this time, the number of beneficiaries locked-in increased 
from 184 to 884. 
Missouri62 In Missouri, MLIP beneficiaries can be restricted to a physician, pharmacy, 
or both. As of October 2015, the state reported 1,485 active MLIP enrollees 
and a total cost savings, as a result of the MLIP, of more than $550,000 for 
the year.  
South 
Carolina63 
South Carolina MLIP beneficiaries are locked into using one pharmacy. At 
the time of a MLIP review in 2011, the program reported having 199 
beneficiaries enrolled. Additionally, since the MLIP started in January 2009, 
it was estimated that service utilization by beneficiaries in the program 
decreased 29%. This decrease translated to a total savings of $1.1 million or 
about $5,581 per MLIP beneficiary. 
West 
Virginia64 
Beneficiaries enrolled in West Virginia’s MLIP are locked-in to one 
pharmacy for a 12-month period. An analysis of 919 MLIP beneficiaries from 
September 2011 through June 2012 revealed that the amount paid for CS 
decreased $48.04 per member per month when comparing the six months pre-
lock-in to the first six months during lock-in, yielding an overall savings of 
more than $264,000 in Medicaid-related drug expenditures. 
Wyoming65 Wyoming’s MLIP was established in 2003. In the first two months of the 
program, there was an estimated cost savings of nearly $22,000. However, 
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Table 2.1 Brief state-based MLIP evaluation findings 
State Key findings 
the state reported that over the following year, few additional benefits were 
observed. They saw no opioid use declines and no significant cost savings to 
Medicaid during this time.  
 
Summary of Key Limitations 
Three key methodologic limitations emerged from the review of evaluations from MLIPs 
in states other than NC. First, many of the studies reviewed identified cost savings associated 
with MLIPs. However, these savings may be questionable, since few of the studies used 
comparison populations of beneficiaries who were not included in MLIPs, and therefore fail to 
account for decreases that would have occurred even if the beneficiaries had not been enrolled in 
the MLIP. Second, most studies and reports examined administrative metrics, such as changes in 
Medicaid-reimbursed dispensed opioids as the endpoint of interest. None of the reviewed studies 
or reports examined changes in dispensed opioids from other sources of reimbursement, such as 
personal payment. Third, none of these studies or reports addressed key patient-orientated health 
endpoints, such as risk of overdose, use of MAT, or use of non-pharmacologic pain management 
therapies. These limitations leave major gaps in our scientific understanding of the effect of these 
programs. 
 
2.3 Evaluations of MLIPs: Managed Care Organization (MCO) Results 
In addition to studies and reports that took a state-based perspective, we also located 
evaluation results from six MCOs that examined some form of a lock-in program. In 2005, 
Beaubien completed a dissertation focused on examining healthcare utilization among MLIP 
enrollees (n=307) in a Northeastern Medicaid MCO.66 Analyzing data from January 2000 
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through October 2002, he found that two-thirds of the MLIP beneficiaries were female and that 
beneficiaries had a mean age of 46 years (range 17-76 years). The MLIP resulted in a 17% 
reduction in the number of CS claims, a 9% reduction in the number of medical claims for office 
visits, and an 11% reduction in the number of medical claims for outpatient hospital visits. 
Additionally, Beaubien found that while the number of claims for inpatient hospital visits 
increased 14%, the number for ED visit claims remained approximately stable between pre-lock-
in and during lock-in periods.  
  More recently, Dreyer et al. (2015) conducted an observational cohort study of 59 
beneficiaries enrolled in Blue Care Network’s (BCN) MLIP from March 2008 through May 
2013.67 BCN is a Medicaid MCO run by Blue Cross Blue Shield of Michigan. BCN beneficiaries 
were flagged for potential MLIP enrollment quarterly if they had filled more than nine CS 
prescriptions from more than three prescribers within a three-month period. A committee 
reviewed flagged beneficiaries, and if enrolled, the review committee contacted the beneficiary’s 
primary care provider to ask him or her to be the beneficiary's sole opioid prescriber. Upon 
physician agreement, beneficiaries were informed via letter that only CS prescriptions obtained 
from the one provider would be covered by BCN, and beneficiaries were locked-in to this 
provider for a 36-month period. Dreyer et al. found that over half (n=32 of 59) of enrolled 
beneficiaries left the MCO during the study period. In fact, 29% (n=17) of all MLIP-enrolled 
beneficiaries left within the first six months of enrollment.  The attrition rates observed over this 
time were higher than in the general Medicaid population. The authors also measured changes in 
appropriate CS use (defined as steady use, decreasing or stopping use, or enrollment in 
maintenance replacement therapy) and “unstable” use (defined as submitting claims for opioids 
written by other providers or paying cash for opioids prescribed by other providers) during the 
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study time period. While the percentage of those with appropriate CS use increased, from 31% at 
six months to 78% at 36 months, and the percentage with “unstable” use decreased, from 37% at 
six months to none at 36 months, the authors acknowledged that selection bias likely contributed 
to these results. The authors suggested that beneficiaries who were more likely to continue 
unstable or risky opioid use may have been the ones that were also more likely to terminate their 
BCN coverage in order to leave the MLIP.  
 Most recently, in 2014, the Association for Community Affiliated Plans worked with 
several MCOs to implement pilot projects aimed at reducing prescription drug abuse in the 
Medicaid population.68 Four MCOs in California, New York, New Jersey, and Ohio chose to 
implement MLIPs. Table 2.2 provides key results from these four pilot projects. 
 
Table 2.2 Association for Community Affiliated Plan’s pilot projects involving 
implementation of MLIPs in MCOs 
MCO MLIP pilot project 
specifics 
Results Strengths/Limitations 
 Affinity 
Medicaid 
MCO, based in 
New York 
(NY), is one of 
the largest 
Medicaid MCO 
programs in the 
NY metro area.  
 6 provider sites 
with a total of 
10-15 
prescribers and 
about 250 
beneficiaries 
participated in 
the pilot 
project. 
 MLIP beneficiaries 
received written 
notice of enrollment 
in the program, as did 
the NY State 
Medicaid office. 
 During initial visits 
with MLIP-enrolled 
beneficiaries, 
participating pain 
management 
specialists conducted 
risk assessments and 
pain screenings. 
 MLIP beneficiaries 
signed pain contracts 
and were required to 
undergo random 
testing to check for 
 Pain management 
specialists reported 
an increased ability 
to retain 
beneficiaries who 
previously would 
have been 
discharged from 
care due to 
difficulties with 
adherence to pain 
contracts. 
 Costs for CS 
prescriptions 
declined 18% 
among MLIP 
beneficiaries.  
 No beneficiaries 
received opioid 
 Strength: multiple layers 
of MLIP beneficiary 
support. 
 Limitation: high 
beneficiary turnover. 
Because Medicaid 
beneficiaries were 
allowed to change health 
plans every month, 
addressing addiction 
problems was 
challenging. However, 
when a beneficiary who 
had been enrolled in a 
MLIP changed health 
plans, the new plan was 
informed of their lock-in 
status.  
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Table 2.2 Association for Community Affiliated Plan’s pilot projects involving 
implementation of MLIPs in MCOs 
MCO MLIP pilot project 
specifics 
Results Strengths/Limitations 
use of drugs and 
doses beyond those 
prescribed.  
 Beneficiaries were 
required to remain 
under one designated 
prescriber’s care in 
order to obtain CS 
prescriptions. 
prescriptions in 
combination with 
buprenorphine or 
benzodiazepines 
(high-risk 
combinations).  
 Average morphine 
equivalent dose 
declined 31 mg. 
 Limitation: lack of pain 
medicine specialists in 
NY (pain medicine 
specialists administered 
this pilot project). 
Shortage could limit 
future program 
dissemination. 
 CalOptima 
based in 
Orange 
County, 
California, 
operates a 
health care 
network called 
Monarch 
HealthCare, 
which piloted 
the MLIP  
 Pharmacy staff 
identified 
beneficiaries who 
exhibited drug-
seeking behavior and 
referred them for 
enrollment. 
 Enrolled beneficiaries 
were assigned to pain 
management 
specialists and were 
required to sign pain 
management 
contracts to indicate 
consent with the 
MLIP and 
commitment to 
comply with 
requirements. 
 Among 87 MLIP 
beneficiaries, there 
was a 50% 
reduction in the 
average number of 
opioid prescriptions 
obtained per 
beneficiary per 
month (from 3.6 to 
1.8) and a 32% 
reduction in the 
average number of 
opioid prescriber 
groups visited per 
beneficiary (from 
2.5 to 0.8). 
 Limitation: beneficiaries 
who changed health care 
networks or who lost 
eligibility for Medicaid 
were disenrolled from 
the MLIP.  
 Horizon New 
Jersey Health 
(backed by 
Horizon Blue 
Cross Blue 
Shield of NJ) 
enrolled 171 
beneficiaries in 
their MLIP 
pilot by the end 
of 2014. 
 Pilot included support 
services for 
beneficiaries, 
pharmacies, and 
prescribers. 
 Beneficiaries were 
enrolled based on 
prescription histories. 
Notification letters 
were sent to enrolled 
members, their 
primary care provider, 
 Physicians 
provided positive 
feedback about 
notification letters. 
 Preliminary 
analyses on MLIP-
enrolled 
beneficiaries found 
reductions in the 
number of CS 
dispensed per 
member, spending 
 Strength: program 
integration in a managed 
care model. Recognizing 
that MLIP beneficiaries 
often have a range of 
unmet health and quality 
of life-related needs, 
when case managers 
contacted MLIP-enrolled 
beneficiaries to inquire 
about their pain 
management care and 
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Table 2.2 Association for Community Affiliated Plan’s pilot projects involving 
implementation of MLIPs in MCOs 
MCO MLIP pilot project 
specifics 
Results Strengths/Limitations 
and pharmacy they 
were locked-in to. 
 When a MLIP 
beneficiary filled two 
or more prescriptions 
from two or more 
prescribers for CS 
within the same 
therapeutic class, the 
prescriber was sent a 
notification letter 
asking if they were 
aware and whether 
they would consider 
modifying the 
beneficiary’s 
medication in light of 
the information. 
 Physicians 
encouraged to discuss 
treatment plans with 
beneficiaries and each 
other. 
per CS claim, and 
the number of 
pharmacies used. 
appointments, they also 
evaluated beneficiaries’ 
needs for critical 
resources (e.g., food, 
transportation, housing). 
 CareSource, a 
nonprofit 
managed health 
care plan 
headquartered 
in Dayton, 
Ohio 
 Largest 
Medicaid 
managed health 
care plan in 
Ohio and 
second largest 
in US. 
 270 
beneficiaries 
enrolled in 
 Beneficiaries who 
obtained 
prescriptions from 
multiple pharmacies 
and prescribers were 
enrolled in the MLIP.  
 Program included a 
pharmacy lock-in 
restriction with a case 
management 
“wraparound.” 
 Beneficiaries 
received letters 
informing them that 
they had to fill all 
prescriptions at one 
pharmacy and have 
 Program 
administrators 
acknowledged that 
many MLIP-
enrolled 
beneficiaries paid 
cash for 
prescriptions to 
avoid lock-in and 
bypass the MLIP 
approval process. 
They reported that 
they were trying to 
find effective ways 
to address this 
issue. 
 Strength: case 
management 
“wraparound” 
component connected 
beneficiaries with 
community resources, 
social services, and 
health care professionals.  
 Case managers were 
trained in effective 
communication and 
listening strategies and 
worked to build long-
term, supportive 
relationships with 
beneficiaries. Worked to 
help beneficiaries 
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Table 2.2 Association for Community Affiliated Plan’s pilot projects involving 
implementation of MLIPs in MCOs 
MCO MLIP pilot project 
specifics 
Results Strengths/Limitations 
their pilot 
MLIP. 
medical services 
coordinated by their 
primary care 
provider. 
 Beneficiaries were 
generally locked-in 
for 18 months. 
acknowledge potential 
substance abuse and 
engage in treatment. 
 
Summary of Key Limitations 
 Similar to the studies reviewed in Section 2.2, key methodologic limitations included lack 
of comparison populations. As noted above, without such a group, differences due to MLIP 
enrollment and differences due to other causes (e.g., changing prescribing trends) could not be 
disentangled. Additionally, the evaluations reviewed in this section, again, failed to examine key 
patient-oriented health endpoints (e.g., use of MAT, overdose). Finally, while two evaluations 
considered beneficiary acquisition of CS using non-Medicaid payment sources (e.g., out-of-
pocket payment),67,68 these evaluations were limited to either anecdotal reports or small samples 
with large losses to follow-up, preventing rigorous examination of this issue. 
 
2.4 Evaluations of MLIPs: North Carolina Results 
High CS utilization and associated negative consequences among NC Medicaid 
beneficiaries prompted the establishment of the NC MLIP. In fiscal year 2010 alone, 
approximately 273,000 Medicaid beneficiaries filled a prescription for at least one opioid, and 
opioid claims cost NC Medicaid about $48 million.69 Additionally, 170,000 beneficiaries filled a 
prescription for at least one benzodiazepine, and Medicaid spent $16 million on benzodiazepine 
claims. At the time of NC’s MLIP establishment in 2010, the state identified about 3,000 
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beneficiaries meeting criteria for MLIP enrollment due to potentially inappropriate or high-risk 
CS use, as determined by the state’s MLIP enrollment criteria (see Table 1.2).  However, due to 
resource constraints, only about 200 beneficiaries were enrolled each month.  
In March 2011, around 950 of 3,000 eligible NC Medicaid beneficiaries were reported to 
be "locked-in."70 Early evaluation analyses indicated that the MLIP resulted in fewer prescription 
claims, as well as fewer visits to hospitals, clinics, physician offices and EDs. The reduction in 
resource utilization translated to a total cost savings of approximately $4,620 per locked-in 
beneficiary per year.70 In May 2012, the NC Department of Health and Human Services (DHHS) 
issued a press release on initial MLIP impacts.71 They found that nearly 2,500 beneficiaries had 
been enrolled in the program, and when prescription claims for the three months before MLIP 
enrollment were compared to claims for the three months after enrollment, they found that 
beneficiaries received 2.3 million fewer opioid pills, or approximately 1,000 fewer pills per 
beneficiary. Additionally, MLIP beneficiaries had fewer hospital, ED, and dental visits and 
underwent fewer radiology scans and lab tests after enrollment in the program. Lastly, the NC 
DHHS estimated that more than $5.2 million in medical and pharmacy claim costs were saved in 
the first year of MLIP operation alone.71  
Similar to MLIP evaluation findings from other states, these early NC specific analyses 
indicated positive impacts in the form of cost reductions, as well as reductions in medical and 
pharmacy utilization measures.43,46,47,49,57,59,72,73 However, much of this previous literature, 
including the preliminary NC analyses, lacked critical information on all CS dispensed to MLIP 
beneficiaries, as they only examined CS prescriptions reimbursed by Medicaid.43,46,47,49,57,59,72,73 
To address this issue in NC, Skinner et al. were awarded CDC grant #U01 CE002160-01 to 
establish a unique, linked database, allowing for comprehensive examination of Medicaid 
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beneficiaries’ dispensed CS prescriptions.74 This database linked NC Medicaid Claims data from 
October 2008 through June 2013 to data from NC’s Controlled Substances Reporting System 
(CSRS) from October 2009 through June 2013 for beneficiaries enrolled in NC’s MLIP. 26,27 
NC’s CSRS is a rich database that provides detailed information on each CS dispensed in the 
state through the aggregation of patient, provider, prescription, and pharmacy data, regardless of 
source of payment.75  
The primary aims of this project were focused on gaining a better understanding of how 
the NC MLIP operates through stakeholder (i.e., pharmacist) interviews and understanding 
changes in beneficiaries’ prescription dispensing behaviors while enrolled in the MLIP, as 
compared to periods prior to MLIP enrollment.74 Overall, findings from this project suggested 
that paying out-of-pocket for CS prescriptions, and not filing with Medicaid, was not a rare 
practice among MLIP beneficiaries and that integration of this information in MLIP evaluations 
had the potential to substantially affect our understanding of MLIP impacts.76-78 Below we 
summarize additional key findings from this project, as well as findings from a UNC dissertation 
recently completed by Andrew Roberts,79 who also made use of this unique database. 
Using Medicaid claims only, Skinner et al. (2015) first set out to determine the effect of 
the NC MLIP on the number, characteristics, and cost of opioid prescriptions received by 
beneficiaries.76,80 Claims data from October 2008 through June 2013 were analyzed on 
beneficiaries who were ever enrolled in the MLIP (n=6,148). Compared to pre-enrollment, they 
found that during MLIP enrollment, beneficiaries had fewer opioid prescriptions on average each 
month (1.6 vs. 0.8), visited fewer pharmacies to obtain opioid prescriptions per month (1.0 vs. 
0.5), and had a reduced days’ supply of opioids per month (23.4 vs. 19.5). Additionally, using 
maximum likelihood mixed effects models with an autoregressive residual error structure and 
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controlling for race/ethnicity, sex, age, and living arrangement, they found that enrollment in the 
MLIP resulted in a lower odds of having any opioid prescription. 
Building from these analyses, the study team then went on to examine how enrollment in 
the MLIP might affect circumvention of opioid prescriptions.77,81 Circumvention was defined as 
paying cash for one’s opioid prescriptions, instead of using the Medicaid payment system. To 
identify cases of circumvention, Skinner et al. looked for records of Medicaid beneficiaries’ 
dispensed prescriptions in the CSRS for which there was no corresponding Medicaid claim. They 
analyzed 4,352 people who were enrolled in the MLIP at some point during the first two years of 
the program (i.e., from October 2010 through September 2012). Using maximum likelihood 
mixed effects models with an autoregressive residual error structure and controlling for several 
demographic variables, they found that enrollment in the MLIP was associated with an increased 
odds of prescription circumvention. The odds of having a circumvented prescription per 
beneficiary per month while enrolled in the MLIP was about 5 times the odds of having one prior 
to MLIP enrollment. Additionally, they found when compared to the pre-enrollment period, 
during enrollment in the MLIP, about 0.58 more prescriptions per beneficiary per month were 
circumvented, 23 additional pills per beneficiary per month were circumvented, and about 0.47 
additional prescribers per beneficiary per month were used in obtaining circumvented 
prescriptions.  
Finally, to supplement findings from these quantitative analyses, qualitative data 
collection and analyses were carried out to gain a better understanding of provider perceptions of 
the MLIP and of overall program operation. Structured qualitative interviews were conducted 
with twelve NC pharmacists. Overall, pharmacists reported a positive experience with the MLIP; 
however, they generally expressed skepticism regarding its larger impact on substance misuse 
 25 
 
and abuse in the state.82  Additionally, pharmacists identified several areas needing improvement 
with respect to MLIP operation, including improved communication by the DMA as to the 
MLIP’s purpose and specific operating procedures, as well as improved procedures to allow 
beneficiaries to see multiple prescribers in the same practice and multiple physicians to assist 
with complex health problems. 
To extend the work of the original project, Roberts’ dissertation focused on exploring the 
characteristics of both beneficiaries who circumvented the MLIP, as well as characteristics of the 
prescriptions that were circumvented.78,79,83 Roberts constructed a cohort of beneficiaries 
enrolled in the MLIP at some point between October 1, 2010 and March 31, 2012. To be 
included in the cohort, beneficiaries were required to be continuously enrolled in Medicaid from 
October 1, 2009 through a minimum of six months after their entry into the MLIP. Using general 
estimating equations, he found that MLIP enrollment was associated with a four-fold increase in 
the rate of obtaining circumvented CS per beneficiary per month. Additionally, he found that 
having circumvented CS fills was more common among MLIP beneficiaries who were younger, 
who lived in areas with high supplies of dispensing pharmacies, who had an anxiety disorder 
diagnoses, and who had a high physical comorbidity burden, as measured by the Charlson co-
morbidity score. Roberts also completed a prescription-level analysis to examine whether certain 
opioids were targeted more often for circumvention after enrollment in the MLIP. He found that 
“riskier” prescriptions (i.e., long-acting opioids, Schedule II opioids, and higher average daily 
doses of opioids) were not obtained more often by circumvention after MLIP enrollment. In fact, 
he found that for opioids obtained through circumvention, the likelihood that they were a long-
acting product declined after MLIP enrollment, as did the average daily dose. Roberts suggested 
that this might have been due to cost, as many of these high-risk prescriptions may have been too 
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cost prohibitive to pay for out-of-pocket. He concluded that although MLIP enrollment caused 
beneficiaries to engage in circumvention more often, the risk profile of the specific drugs 
circumvented did not appear to increase.  
 
Summary of Key Limitations 
 While initial research evaluating NC’s MLIP improved on key limitations from previous 
evaluations (e.g., consideration of all CS prescriptions dispensed to beneficiaries, as opposed to 
just Medicaid-reimbursed CS prescriptions), gaps remain in our understanding of NC MLIP 
effects. Specifically, improvement in disentangling MLIP effects from secular trend effects is 
one potential area for methodologic advancement. Other developments could include 
consideration of a larger range of patient-oriented health endpoints (e.g., use of MAT, overdose) 
and examination of effects over longer time periods (i.e., both immediate and sustained effects). 
 
2.5 Key findings from Studies Examining CS Use Classes and Trajectories 
 Finally, to inform hypotheses for the second aim of this dissertation, this section provides 
a brief review of studies examining heterogeneity in trajectories and classes of CS use.  
Research has demonstrated that substance use trajectories and types of users are often 
heterogeneous across populations, but there has been no research on whether and how substance 
use trajectories might differ for different types of beneficiaries both while enrolled in the MLIP 
and following release from the program.84-91 To inform hypotheses of how trajectories might 
differ for beneficiaries enrolled in the MLIP over time, a brief literature review on heterogeneity 
in CS use trajectories for other populations (i.e., not MLIP-enrolled populations) and classes of 
CS users was conducted. Findings from this review are briefly summarized below. 
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Research examining trajectories of benzodiazepine use among adolescents identified four 
distinct types of users: occasional, decelerating, accelerating, and chronic users.86 Factors 
predicting the accelerating or chronic trajectories included having a history of psychosis or 
epilepsy, having benzodiazepine prescriptions provided by physicians from multiple specialties, 
and taking benzodiazepine medications with a long half-life. Additionally, research on 
trajectories of drug use—including cocaine, opioid, and/or amphetamine use—identified non-
user, early occasional users, persistent occasional users, and early frequent/later occasional user 
types.87 Several characteristics were predictive of continued drug use over time, including 
demographic characteristics (i.e., black men) and social characteristics (e.g., whether the family 
of origin was characterized by abuse/neglect and parental substance use).  
Using cross-sectional study designs, researchers have also examined typologies of 
prescription opioid users in various populations. One study of a large sample of adults assessed 
for substance abuse treatment found that opioid users were best grouped as: using as prescribed, 
prescribed misusers, medically healthy abusers, and illicit users.91 The different strata of users 
varied according to race/ethnicity, gender, concurrent substance abuse, duration of prescription 
opioid abuse, mental health problems, and addiction severity index scores. Another study 
examined chronic opioid users in a large health maintenance organization in Washington State.90 
They identified three types of chronic opioid users: a “typical” group, in which beneficiaries 
tended to have persistent, moderate mental health and pain symptoms; an “addictive behaviors” 
group, in which beneficiaries tended to have elevated mental health symptoms and opioid 
problems but pain symptoms similar to the “typical” group; and a “pain dysfunction” group with 
significantly higher pain interference as well as elevated mental health and opioid problems. 
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Prescribed average daily doses of opioids were three times higher for those in the two latter 
groups and was strongly associated with class membership after adjusting for other variables. 
 
2.6 Summary 
Little information is available on MLIP impacts on beneficiaries’ healthcare utilization 
and health outcomes; studies have largely examined cost savings to Medicaid. While MLIPs 
appear to be a promising approach that may reduce prescription drug misuse, abuse, and 
diversion, there is much we do not know about their impacts on beneficiaries enrolled.20 Studies 
have documented Medicaid-related cost reductions associated with MLIP implementation, as 
well as reductions in certain medical and pharmacy utilization measures. 35,43,46-52,54,55,57,59-67,69-73 
However, these studies have lacked potentially critical information on all CS dispensed to MLIP 
beneficiaries by only examining CS prescriptions reimbursed by Medicaid. 35,43,46-52,54,55,57,59-67,69-
73 Moreover, studies have failed to examine patient-orientated health endpoints, such as risk of 
overdose or use of MAT. 
The novel, linked NC Medicaid claims-CSRS database provided by the Skinner et al. 
grant (i.e., the parent study for this dissertation) is among the first of its kind and provides a more 
complete understanding of Medicaid beneficiaries’ dispensed CS prescriptions.74 While initial 
analyses by the parent study team and Roberts et al. have provided important insights concerning 
the impact of MLIP enrollment on CS prescription fills while enrolled,76-80,83 additional gaps 
persist in understanding the sustained and differential impacts of the NC MLIP. Given that these 
programs affect thousands of beneficiaries on an annual basis, there is a pressing need to address 
key gaps in the evidence base. Chapter 3 outlines the specific aims of this dissertation and key 
gaps filled.  
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CHAPTER 3 – SPECIFIC AIMS 
 
In this dissertation, we examined the impact of the NC MLIP on numbers of dispensed 
CS prescriptions and the dosages of opioids dispensed following release from the MLIP, 
providing important information on the sustained impacts of the program. Understanding 
whether beneficiaries’ CS prescription fills and opioid dosages decreased, increased, or returned 
to similar levels following release from the MLIP, as compared to prior to MLIP enrollment, 
provides important information on larger program impacts. Moreover, comparing CS dispensing 
and opioid dosages following release from the MLIP to during MLIP-enrolled periods allowed 
us to examine the extent to which program impacts (i.e., overall reductions in dispensed CS 
prescriptions but increased out-of-pocket payments) were sustained or attenuated following 
release from the MLIP.  
Additionally, we examined whether trajectories of beneficiaries’ dispensed opioid 
dosages differed across MLIP-related periods (i.e., prior to, during, and following release from 
the MLIP) for different strata of the beneficiary population. Our study was designed to extend 
previous work on underlying heterogeneity within populations of substance users and was the 
first to investigate potential heterogeneity of opioid dosage trajectories in a MLIP population. 
Findings from our trajectory analyses can be used to provide information that may help further 
focus the design of the MLIP by detecting attributes of beneficiaries who might need additional 
targeted intervention, such as increased case management services, complementary or alternative 
treatment approaches (e.g., physical therapy), and screening for medication-assisted therapy. 
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Aim 1: Assess the impact of exposure to the NC MLIP on numbers of dispensed CS 
prescriptions and the dosages of opioids dispensed in the year following release from the 
MLIP. Using generalized estimating equations (GEE) to account for within-individual 
correlation over time, we examined numbers of dispensed CS prescriptions and dosages of 
opioids dispensed in the 12-month period following release from the MLIP, compared to a pre-
MLIP period. We also estimated measures of association comparing the during MLIP enrollment 
period to a pre-MLIP period. While we expected that the MLIP had different impacts for 
different types of beneficiaries across program periods (e.g., no change in CS use for some, 
decreased use for others), we hypothesized that we would observe the following average impacts 
described below. 
 
Hypothesis 1a: On average, the number of CS prescriptions reimbursed by Medicaid and the 
dosage of opioids obtained from Medicaid-reimbursed prescriptions would be lower following 
release from the MLIP than prior to enrollment, but greater than during MLIP enrollment. 
 
Hypothesis 1b: On average, the number of CS prescriptions not reimbursed by Medicaid and the 
dosage of opioids obtained from non-reimbursed prescriptions would be greater following 
release from the MLIP than prior to enrollment, but lower than during MLIP enrollment. 
Rationale: Analyses from the parent study suggested that some MLIP beneficiaries obtained 
some opioid and benzodiazepine prescriptions through out-of-pocket payments while in the 
MLIP; the extent to which this behavior persisted following release from the MLIP was 
unknown. 
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Aim 2: Examine heterogeneity in beneficiaries’ trajectories of dispensed opioid dosages 
across periods prior to, during, and following release from the MLIP. Using latent class 
growth analyses, we estimated average opioid dosage trajectories across MLIP-related periods in 
order to approximate the underlying distribution of trajectories across the MLIP-enrolled 
beneficiary population. We quantified and described detected patterns of longitudinal change, as 
well as the attributes of beneficiaries that were best captured by different trajectories.  
 
Hypothesis: At least three trajectories of dispensed opioid dosages would be identified: a 
trajectory that quickly declined during MLIP enrollment and remained low and stable, even post-
MLIP; a trajectory that remained at a high but steady level across program periods with little 
change at program enrollment or disenrollment; and a trajectory that declined during MLIP 
enrollment and increased post-MLIP, however not to the same level as pre-MLIP. These 
trajectories were hypothesized to differ according to the following covariates: age, comorbidity 
burden, and recent history of mental health disorders, pain conditions, and substance use 
disorders. 
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Table 3. Overview of Dissertation Aims 
 Objective Data Analysis Overview 
Overall 
To examine 
sustained impacts of 
a MLIP and to gain a 
detailed 
understanding of 
heterogeneity in 
dispensed opioid 
dosages across 
periods prior to, 
during, and 
following release 
from the MLIP. 
Linked NC Medicaid claims-NC 
CSRS records (i.e., PDMP data) 
was used for the period of 
10/1/2009 through 6/30/2013 
(3.75 years of data). 
 
Data included persons enrolled 
in the MLIP at some point 
between 10/1/2010 (when the 
program started) through 
9/30/2012. 
Observational prospective 
cohort study design used. See 
cohort definitions below. 
 
Aim 1 
(Chapter 
6)  
 
Assess the impact of 
exposure to the NC 
MLIP on numbers of 
dispensed CS 
prescriptions and the 
dosages of opioids 
dispensed in the year 
following release 
from the MLIP. 
 
Exposure: 12 months in the 
MLIP 
 
Outcomes: number of opioid and 
benzodiazepine prescriptions 
dispensed per person per month 
(total #, # reimbursed by 
Medicaid, # not reimbursed by 
Medicaid); average daily dosage 
of opioids dispensed per person 
(in terms of average daily 
morphine milligram equivalents 
(MMEs)) (overall amount, 
amount obtained from Medicaid-
reimbursed prescriptions, 
amount obtained from 
prescriptions not reimbursed by 
Medicaid) 
 
Covariates: age, sex, race, 
urbanicity of the beneficiary’s 
county of residence, overdose 
death rate in the beneficiary’s 
county of residence, Medicaid 
aid category, Medicaid class 
code, history of alcohol or other 
substance use-related disorders, 
history of medication-assisted 
treatment for opioid addiction, 
history of an overdose event, 
number of unique pharmacies 
visited, number of emergency 
department visits, number of 
inpatient admissions, history of 
 
Cohort: independent living 
adults (e.g., excluded those 
living in skilled nursing 
facilities) between the ages of 
18 and 64 years who were 
enrolled in the NC MLIP 
between October 2010 and 
September 2012. Followed 
from the first day of receiving 
any CS prescription (for 
outcome of CS dispensed) or 
opioid prescription (for 
outcome of MMEs dispensed) 
on or after October 1, 2009, 
throughout their period of 
lock-in, and up to one year 
following program release or 
until June 30, 2013, 
whichever came first. To 
avoid conflating program 
effects for those who 
remained continuously 
enrolled in the MLIP and 
those who exited the MLIP 
prior to completion, analyses 
were restricted to those who 
remained in the MLIP for a 
full 12 months or were 
administratively censored in 
June 2013, the last month for 
which we had data. 
 
Outcome measures (listed to 
the left) following MLIP 
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  In Chapter 4, we provide an overview of the methods used to fulfill these aims. 
Additional details about the methods, as well as results and discussion of results can be found in 
Chapters 5-7.  
To construct an appropriate cohort for Aim 1 and Aim 2 analyses, we conducted a 
detailed analysis of those eligible for, enrolled in, and retained in the NC MLIP. Chapter 5 is the 
specific pain-related diagnoses 
(e.g., arthritis, back, neck, 
headache/migraine, 
fibromyalgia, sickle cell), history 
of specific mental health-related 
diagnoses (e.g., depression, 
anxiety, bipolar, schizophrenia), 
Charlson comorbidity index, and 
temporal trend measures. 
release and during MLIP 
enrollment were compared to 
those in a pre-MLIP 
enrollment period 
 
GEE were used to provide 
estimates of measures of 
association (e.g., count 
differences, count ratios). 
 
 
Aim 2 
(Chapter 
7) 
 
Examine 
heterogeneity in 
beneficiaries’ 
trajectories of 
dispensed opioid 
dosages across 
periods prior to, 
during, and 
following release 
from the MLIP. 
 
To examine dispensed opioid 
dosages, we calculated average 
daily MMEs of dispensed 
opioids (paid for using any 
payment source). For modeling 
purposes, we averaged each 
beneficiary’s average daily 
MMEs across each calendar 
month. We then log transformed 
this monthly average to obtain an 
approximately normal 
distribution for improved model 
estimation. Trajectories were 
estimated across months prior to, 
during, and following release 
from the MLIP. 
 
Latent classes were characterized 
by the covariates described 
above in Aim 1.   
 
Cohort same as above (i.e., 
followed from first day of 
receiving any opioid 
prescription on or after 
October 1, 2009, throughout 
their period of lock-in, and up 
to one year following 
program release or until June 
30, 2013, whichever came 
first. Followed only those 
who remained in the MLIP 
for a full 12 months or were 
administratively censored in 
June 2013, the last month for 
which we had data). 
 
Latent class growth analysis 
was used to disentangle and 
describe the number and 
shape of different trajectories 
of dispensed opioid dosages 
across periods prior to, 
during, and following release 
from the MLIP, as well as to 
characterize trajectory groups 
by important covariates. 
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result of that analysis and was essential to informing cohort inclusion/exclusion criteria for Aim 
1 and Aim 2 analyses (Chapters 6 and 7, respectively).  
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CHAPTER 4 – METHODS 
 
4.1 Overview 
 In this dissertation, we applied advanced modeling methods to gain insight into the 
sustained impacts of NC’s MLIP and to explore heterogeneity in trajectories of dosages (MMEs) 
of opioids dispensed across periods prior to, during, and following release from the MLIP. To 
accomplish these aims, we utilized linked data that provided a comprehensive picture of 
dispensed CS acquired by beneficiaries.74 This data set allowed for more valid estimation of a 
MLIP’s impacts by accounting for all CS dispensed, data which other studies have lacked.35,43,46-
52,54,55,57,59-67,69-73 Capturing information on all CS prescriptions dispensed, including those not 
submitted for Medicaid reimbursement, allowed us to understand how prescription dispensing is 
truly changing over time, as compared to how dispensing might appear to be changing in 
Medicaid claims. Analyses from the parent study indicated that paying for prescriptions out-of-
pocket, as opposed to filing with Medicaid, was not a rare practice among NC MLIP 
beneficiaries, and therefore, having information on prescriptions filled by all payment methods, 
as compared to only those paid for by Medicaid, can notably change our understanding of MLIP 
impacts.76-79,83   
 Additionally, the large and multi-year nature of this data set allowed us to examine 
sustained impacts. This was the first study to examine the sustained impacts of a MLIP in the 
months following disenrollment, contributing important information about the larger influence of 
the program.  
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 Finally, our study used an advanced analytic method, latent class growth analysis 
(LCGA), to model and explore heterogeneity in beneficiaries’ dosages of opioids dispensed 
across MLIP-related periods. Latent class growth analysis has become an increasingly popular 
exploratory tool that can be used to approximate and describe different patterns of change within 
a larger population.92-98 While the approach has been successfully used to understand 
longitudinal change in other substance use-related behaviors for different subpopulations,85-
91,99,100 it has never been used to examine different patterns of change associated with MLIP 
enrollment. Identification of different patterns of longitudinal change and the types of 
beneficiaries that tend to follow these trajectories can help inform future MLIP improvements.  
 
4.2 Data Sources 
 In this section, we describe the two databases linked by the parent study (i.e., the CSRS 
and Medicaid claims), the linking process, and the final dataset available for analysis, including 
how beneficiaries were enrolled in the MLIP and therefore our analytic dataset. As previously 
mentioned, the parent study linked NC Medicaid claims to records from NC’s CSRS from 
October 2009 through June 2013 for all beneficiaries enrolled in NC’s MLIP at some point 
between October 2010 and September 2012.74  
 
4.2.1 Controlled Substances Reporting System (CSRS) 
NC’s CSRS is a rich database that provides detailed information on each CS dispensed in 
the state through the aggregation of patient, provider, prescription, and pharmacy data.75 The NC 
legislature gave authority for the establishment of the CSRS in late 2005 through passage of the 
NC CSRS Act (NCGS 90-113.70).101 Under this Act, the purpose of the CSRS was defined as 
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follows: “to improve the State's ability to identify controlled substance abusers or misusers and 
refer them for treatment, and to identify and stop diversion of prescription drugs in an efficient 
and cost-effective manner that will not impede the appropriate medical utilization of licit 
controlled substances.” Additionally, under this Act, the Drug Control Unit in the Division of 
Mental Health, Developmental Disabilities, and Substance Abuse Services in the NC DHHS was 
given the responsibility of administering the CSRS. The CSRS began operation on July 1, 2007, 
and all pharmacies dispensing CS (schedules II-V) in NC began reporting to the system 
monthly.102 On August 1, 2008 pharmacy reporting increased to bimonthly, and as of, January 2, 
2012, all pharmacies were required to report weekly. Prescribers and dispensers of CS are able to 
access information on CS to assist and help guide in the care of their patients.103 The following 
information is captured in the CSRS: unique identifiers for prescribers, dispensers, and patients; 
location (county-level) for dispensers and patients; the prescription’s quantity, days’ supply, 
indication of a new fill or refill, National Drug Code (NDC), and date prescribed and dispensed; 
and the age and gender of the beneficiary. While the CSRS has recently started collecting 
information on the method of payment for each CS dispensed, this information was not available 
for this study. 
 
4.2.2 Medicaid Claims 
In 2015, 18% of the NC population was covered by Medicaid.104 Medicaid benefits were 
available to the following major groups of NC residents: 1) those who were pregnant and had 
household incomes up to about 200% of the federal poverty level; 2) parents with dependent 
children and household incomes up to about 45% of the federal poverty level (e.g., for a family 
of three, income cannot exceed $667/month); 3) blind persons with incomes below the poverty 
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limit; 4) persons under the age of 65 years who were unable to work due to a severe disability 
that was expected to last at least 12 months and had incomes below the poverty limit; 5) persons 
aged 65 years or older with incomes below the poverty limit; 6) certain adults with long-term 
care needs (e.g., nursing care for older adults, others with long-term disabilities); and 7) children 
whose caregivers’ incomes fell below 133% or 210% of the poverty limit, depending on the 
child’s age.7 Those in the latter three groups were not included in our analyses (see Section 4.3). 
NC Medicaid claims data were obtained from the DMA’s Data Retrieval Information and 
Validation Engine (DRIVE).105 DRIVE is a Medicaid data warehouse that contains Medicaid 
eligibility information, prior authorization data, drug data, and other reference information. 
DRIVE is updated weekly, pulling information from the Medicaid Management Information 
System (MMIS), which processes claims for Medicaid.106 Data available through DRIVE 
includes beneficiary demographic information, beneficiaries’ periods of enrollment, and 
adjudicated pharmacy and medical claims. Additionally, information on enrollment in the MLIP 
is recorded in DRIVE.  
 
4.2.3 Linkage and Final Database 
To link the DRIVE data to the CSRS data, the parent study hired a programmer external 
to the study. Manual linkage was performed using a standardized protocol that included 
deterministically matching records based on the first five letters of the beneficiary’s last name, 
date of birth within six months, and the first two or three letters of the beneficiary’s first name. 
The protocol included rigorous data integrity checks and steps to help ensure that all of a given 
beneficiary’s records were linked and that issues such as minor misspellings or use of a common 
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nickname would not prevent linkage. Once linked, dummy identifiers were assigned to all 
beneficiaries and identifying information was deleted prior to delivery to parent study staff.  
The final linked data set contains comprehensive information on Medicaid beneficiaries 
enrolled in the MLIP at some point between October 2010 and September 2012, including all 
claims data and information on all CS dispensed to these beneficiaries, at any point from October 
2009 through June 2013. Beneficiaries were enrolled in the MLIP on a monthly basis. While 
approximately 3,000 Medicaid beneficiaries were initially eligible for MLIP enrollment, the 
DMA only enrolled approximately 200 beneficiaries per month, due to resource constraints.69,107 
Eligibility for the program was determined each month by a vendor who contracted with 
Medicaid. The vendor examined the prescription dispensing history of all Medicaid beneficiaries 
for the previous two months and determined which beneficiaries met the eligibility criteria 
outlined in Table 1.2 (i.e., based on number of prescriptions obtained and prescribers visited). 
From those eligible, beneficiaries were then ranked and selected for enrollment using a 
proprietary beneficiary review algorithm that factored in the number of prescriptions obtained, 
quantity received, days’ supply received, paid amounts, and distinct prescribers and pharmacies 
visited, combined with a clinical review process by pharmacists employed by the vendor. The 
vendor submitted its selected list of 200 beneficiaries each month to the DMA, and upon 
approval by the DMA, the vendor then sent each beneficiary a letter notifying them of their 
enrollment in the program. Enrolled beneficiaries were restricted to using one prescriber and one 
pharmacy location to obtain prescriptions categorized as opioids, benzodiazepines, or certain 
anxiolytics for a 12-month period. Beneficiaries were given 30 days to choose and nominate a 
preferred prescriber and pharmacy before restrictions began. If they did not respond to the DMA 
with their preferred prescriber and pharmacy, they were assigned one of each.  
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4.3 Study Design 
Study designs for Aims 1 and 2 are discussed in the “Methods” subsections of Chapters 6 
and 7, respectively. We briefly summarize study designs for Aims 1 and 2 here.  
For Aim 1 (Chapter 6), we used an observational prospective cohort study design. We 
established and followed a cohort of independent living adults (e.g., excluded those living in 
skilled nursing facilities) between the ages of 18 and 64 years who were enrolled in the NC 
MLIP between October 2010 and September 2012. We estimated program effects while locked-
in and following MLIP release on numbers of dispensed CS per person-month and the dosage 
(average daily MMEs) of dispensed opioids per person, as compared to a period prior to MLIP 
enrollment.  
When examining MLIP impacts on dispensed CS, beneficiaries in our cohort were 
followed from the first day of receiving any CS prescription (i.e., opioid or benzodiazepine) on 
or after October 1, 2009, throughout their period of lock-in, and up to one year following 
program release or until June 30, 2013, whichever came first. When examining MLIP impacts on 
dosages (average daily MMEs) of dispensed prescription opioids per person, beneficiaries were 
followed in the same manner, except that their start of follow-up was the first day of receiving 
any opioid prescription, as opposed to any opioid or benzodiazepine prescription.  
To avoid conflating program effects for those who remained continuously enrolled in the 
MLIP and those who exited the MLIP prior to completion (see Chapter 5), we restricted the 
analysis to those who remained in the MLIP for a full 12 months or were administratively 
censored in June 2013, the last month for which we had data. We defined continuous enrollment 
 41 
 
as no more than a 7-day gap in coverage. These beneficiaries constituted 62% of all beneficiaries 
ages 18-64 years with an independent living arrangement who were ever enrolled in the MLIP 
between October 2010 and September 2012. There were no requirements regarding continuous 
Medicaid coverage in the time prior to MLIP enrollment or in the year after MLIP release. 
However, previous analyses indicated that those with continuous coverage while enrolled in the 
MLIP had, on average, close to complete Medicaid coverage prior to enrollment as well (see 
Chapter 5). 
For Aim 2 (Chapter 7), we used the same cohort specified above. Because we examined 
trajectories of dosages (average daily MMEs) of dispensed prescription opioids, beneficiaries in 
this cohort were followed from the first day of receiving any opioid prescription, as outlined 
above. 
 
4.4 Study Population 
 Chapter 5 provides detailed descriptive information on demographics, comorbidities, and 
healthcare utilization of beneficiaries eligible for and enrolled in the NC MLIP. Specifically, 
beneficiaries enrolled in the MLIP were compared to those who were MLIP-eligible but not 
enrolled. Additionally, among enrolled beneficiaries, those completing the 12-month MLIP were 
compared to those who exited prior to 12 months.  
 Key findings included that MLIP-enrolled beneficiaries were more likely to have 1) 
substance use and mental health disorders, 2) obtained controlled substances from multiple 
pharmacies, and 3) visited emergency departments, as compared to beneficiaries who were 
eligible for, but not enrolled in the MLIP. Additionally, we found that compared to those who 
completed the 12-month MLIP, those who exited the MLIP early were 1) younger, 2) more 
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likely to obtain controlled substances from multiple pharmacies, 3) reside in counties with high 
opioid overdose death rates, and 4) have less stable Medicaid coverage prior to MLIP 
enrollment. Chapter 5 provides additional details on the study population. The descriptive 
analyses in Chapter 5 were helpful in understanding the composition of the cohort and informed 
the analysis conducted in Chapters 6 and 7.  
 
4.5 Exposure Assessment  
For Aim 1, the exposure of interest was having 12 months of exposure to the MLIP. We 
divided person-time into four segments: two pre-MLIP periods (>6 months pre-enrollment, or 
“pre-spike,” and 0-6 months pre-enrollment, or “spike”), a 12-month program period (“lock-in”), 
and a period (up to 12 months) after program release (“post-release”). Descriptive analyses 
revealed a specific period with large spikes in numbers and dosages of CS dispensed, in the 
months just prior to program enrollment. This spike period precipitated MLIP enrollment for 
many beneficiaries. During this period, a sudden escalation was met by a similar de-escalation 
just prior to MLIP enrollment, resulting in dispensing that appeared to largely return to pre-spike 
levels just prior to actual enrollment. Moreover, additional analyses revealed that this pattern of 
escalation, triggering of MLIP criteria, and a nearly equal de-escalation was not unique to the 
MLIP-enrolled population (see Appendix A). It also occurred in Medicaid beneficiaries who 
were never enrolled in the MLIP but met the MLIP eligibility criteria. While this spike period 
revealed critical information regarding the average CS utilization trajectory leading to eligibility 
for the MLIP, this volatile period of utilization was likely not the most appropriate reference 
period for MLIP effect estimation. Rather, understanding the extent to which the MLIP was 
associated with CS utilization during and upon release, as compared to a more stable utilization 
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period prior to program enrollment provides a more suitable comparison. Therefore, we stratified 
pre-MLIP enrollment time into pre-spike and spike periods and focused our MLIP effect 
estimation on dispensing during lock-in and post-release periods as compared to the pre-spike 
period. 
Enrollment in the MLIP and delineation of these four time periods were determined using 
the comprehensive, linked data set from the parent study. The DRIVE data set contained 
information on when beneficiaries were enrolled in Medicaid, as well as when they were 
enrolled in the MLIP.105  
Aim 2 was also accomplished with the data assembled into pre-MLIP (i.e., pre-spike and 
spike periods), during lock-in, and post-MLIP release periods. For Aim 2, we used data on 
beneficiaries in the year prior to MLIP enrollment to assess covariates. These data allowed us to 
examine attributes of beneficiaries associated with heterogeneous patterns of longitudinal 
change. Because these covariates were assessed at the same time as trajectory pattern estimation, 
they are not considered predictors, but rather reveal key covariate associations. 
 
4.6 Outcome Assessment 
The outcomes of interest for Aims 1 and 2 included monthly numbers of dispensed CS 
prescriptions by payer source— Medicaid-reimbursed, not Medicaid-reimbursed (e.g., out-of-
pocket), and those paid for using any source, as well as average daily dosages of dispensed 
opioid prescriptions, measured in terms of average daily MMEs.  
Numbers of dispensed CS prescriptions were identified in Medicaid claims using NDCs, 
as well as a comprehensive list of 3-digit therapeutic class codes and 5-digit generic codes 
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provided by MLIP personnel. This list included all opioid medications, defined as having a 
therapeutic class code of H3A, H3H, H3J, H3M, H3N, H3U, or H3X. These include medications 
containing codeine, oxycodone, oxymorphone, hydrocodone, hydromorphone, fentanyl, 
morphine, and methadone, among others. Tramadol, also an opioid medication, was excluded 
from the list by excluding generic codes: 07221, 26387, 50417, 50427, 13909, as tramadol was 
not classified as a CS until mid-2014 and therefore would not have been included in the MLIP 
eligibility criteria for the study period. Benzodiazepine medications included in the list were 
those with therapeutic class codes of H2F (anti-anxiety class). However, Buspar/buspirone was 
excluded from the list by excluding 5-digit generic codes: 28891, 28892, 92121, 28890, 13037, 
and 19224, as it is not classified as a CS, and clonazepam/Klonopin was added to the list by 
including therapeutic class code H4B (anticonvulsant class) with generic codes 19467, 19468, 
19469, 19470, 19472, 17470, 17471, or 17472, as it is a CS benzodiazepine.  Additionally, NC 
MLIP restrictions specifically include “certain anxiolytics.” While all benzodiazepine anxiolytics 
were included in the MLIP CS restrictions, the “certain anxiolytic” language was specifically 
added to the MLIP requirements to ensure meprobamate/Miltown was also captured under MLIP 
restrictions, as this medication is an anxiolytic but not a benzodiazepine.108 Because this 
medication is also included in the H2F therapeutic class, it was easily captured in our analysis 
through the inclusion of that code. 
To identify these same medications in the CSRS database, a crosswalk obtained through 
the UNC Lineberger’s Comprehensive Cancer Center’s Cancer Information & Population Health 
Resource that links therapeutic class codes, generic codes, and NDCs was used. Using the linked 
Medicaid-CSRS dataset, we obtained the number of opioid, benzodiazepine, and specific 
anxiolytic prescriptions dispensed per month to each beneficiary, stratified according to 
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reimbursement by Medicaid or not (i.e., those prescriptions captured in the CSRS without a 
corresponding Medicaid claim). 
To examine dosages of opioids dispensed, we calculated the average daily MMEs 
dispensed per beneficiary. Because morphine has long been used as the standard of treatment for 
moderate to severe pain, it is often used as a reference or comparison point for other opioid 
medications.109 MME conversion factors serve as a useful research tool to help compare opioid 
medication regimens, and research has suggested that a dose-dependent relationship exists 
between average daily MMEs and opioid overdose risk.110-113 To calculate average daily MMEs, 
we used the following formula109,114 
 
Average Daily MMEs= (Drug strength)*(Drug quantity)*(MME conversion factor) 
                                                                             Days’ supply 
 
Drug quantity and days’ supply were obtained from the Medicaid claims-CSRS database, 
while drug strength and the MME conversion factors were available from CDC reference tables 
for each NDC. Table 4 displays the MME conversion factors used.114-116  
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Table 4. Opioid MME conversion factors 
Opioid 
MME conversion 
factor 
Buprenorphine  
 patch 12.6 
 tab or film 10 
Butorphanol 7 
Codeine 0.15 
Dihydrocodeine 0.25 
Fentanyl  
 buccal or sublingual tablets, or  
   lozenges/troche 0.13 
 film or oral spray 0.18 
 nasal spray 0.16 
 patch 7.2 
Hydrocodone 1 
Hydromorphone 4 
Levorphanol tartrate 11 
Meperidine hydrochloride 0.1 
Methadone 3 
Morphine 1 
Nalbuphine 1 
Opium 1 
Oxycodone 1.5 
Oxymorphone 3 
Pentazocine 0.37 
Tapentadol 0.4 
 
For Aim 1, the average daily MME for each prescription was applied to all days for 
which the prescription was active (i.e., all days in which the prescription was to be taken, 
according to the days’ supply). If a beneficiary had more than one opioid prescription active on a 
given day, the MMEs for that day were summed. For Aim 2, we averaged each beneficiary’s 
average daily MMEs across each calendar month. We then log transformed this monthly average 
to obtain an approximately normal distribution for improved model estimation, consistent with 
previous research.88 
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Similar dosing equivalencies for benzodiazepines are less evidence-based, poorly 
described, and often based on expert opinion. Moreover, the majority of CS prescriptions 
received by MLIP-enrolled beneficiaries consisted of opioids (approximately 75-80%); therefore, 
we did not calculate similar dosage estimates for benzodiazepines.  
 
4.7 Covariate Assessment 
 To elucidate potential confounding variables that could have impacted our estimation of 
the effect of exposure to the NC MLIP on dispensed CS prescriptions and dosages of opioids 
dispensed (i.e., Aim 1), we developed a conceptual figure (Figure 4). This figure was based on 
the best available literature and our understanding of factors affecting MLIP exposure and post-
MLIP CS utilization.  
Additionally, for Aim 2, we examined heterogeneity in trajectories of beneficiaries’ 
dispensed opioid dosages across periods prior to, during, and following release from the MLIP, 
as well as the attributes of beneficiaries that are best captured by the different trajectories. By 
exploring characteristics of beneficiaries in the year prior to MLIP enrollment, we were able to 
develop insight into the trajectories that different groups of beneficiaries might follow when 
enrolled and upon disenrollment, as well as the attributes of those who could potentially benefit 
from additional or different types of public health interventions (e.g., increased case management 
support; complementary or alternative treatment approaches, such as physical therapy; screening 
for medication-assisted therapy). As previously mentioned, we hypothesized that trajectories 
would differ according to the following covariates: age, comorbidity burden, and recent history 
of mental health disorders, pain conditions, and substance use disorders. 
 48 
 
Figure 4. Conceptual model of general relationships between exposure, outcomes, and 
covariates 
 
 
Chapter 5 and Appendix B provide specific information on covariate categories and claims-
related codes used to define covariates, as well as information on the prevalence of these 
characteristics in the MLIP population.  Below, we briefly provide general information about 
each of these covariates, as well as what is known regarding associations between each of these 
covariates and CS use and overdose. 
 Age: Research indicates that young and middle-aged adults are most likely to 
nonmedically use prescription drugs and experience overdose events.42,117,118 According 
to the CDC, drug overdose death rates are highest among those ages 45-49 years.119  
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 Sex: The literature indicates a complex relationship between sex and prescription drug 
misuse, abuse, and overdose.42 While men report nonmedical use of prescription drugs 
more often than women, some studies suggest that women are more likely to be 
prescribed opioids, to use them chronically, and to doctor-shop and pharmacy-shop (i.e., 
obtain prescriptions from many different doctors or pharmacies), as compared to 
men.117,120-122 Additionally, while men are more likely to experience a fatal drug 
overdose, women and men experience similar rates of ED visits due to nonmedical use of  
prescriptions.1,123 
 Race/ethnicity: American Indians, Alaska Natives, and non-Hispanic Whites are more 
likely to report nonmedical use of prescription drugs and have the highest fatal overdose 
rates.1,42 Additionally, research suggests that African Americans and Hispanics are less 
likely to be prescribed any drug, including CS.42,124,125 
 Medicaid eligibility category: Provides information on criteria met to qualify for 
Medicaid benefits. Medicaid benefits were available to the following major groups of NC 
residents: 1) those who were pregnant and had household incomes up to about 200% of 
the federal poverty level; 2) parents with dependent children and household incomes up 
to about 45% of the federal poverty level (e.g., for a family of three, income cannot 
exceed $667/month); 3) blind persons with incomes below the poverty limit; 4) persons 
under the age of 65 years who were unable to work due to a severe disability that was 
expected to last at least 12 months and had incomes below the poverty limit; 5) persons 
aged 65 years or older with incomes below the poverty limit; 6) certain adults with long-
term care needs (e.g., nursing care for older adults, others with long-term disabilities); 
and 7) children whose caregivers’ incomes fell below 133% or 210% of the poverty limit, 
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depending on the child’s age.7 Those in the latter three groups were not included in our 
analyses (see Section 4.3).  
 Medicaid class code: Provides further information on Medicaid qualification. Most 
Medicaid beneficiaries qualify for Medicaid under a “categorically needy” class code, 
indicating that certain income requirements were met as determined by the specific aid 
category (e.g., families with dependent children, disabled). However, other routes 
through which individuals may qualify include a “medically needy” classification in 
which a person may have not satisfied financial eligibility requirements (i.e., their income 
was too high) but significant medical expenses reduced their income below a certain level 
that then qualified them as "medically needy.”126  
 Urbanicity in county of residence: Research suggests that prescription opioid misuse and 
abuse may disproportionately affect rural, as compared to urban areas.127-129 In North 
Carolina specifically, higher rates of both prescription opioid sales and overdoses have 
been detected in the rural southern and western corners of the state.130 The U.S. 
Department of Agriculture’s 2013 rural-urban continuum codes were used to classify 
counties into one of nine categories.131 This classification system assigns categories to 
metropolitan counties based on their population size and assigns categories to 
nonmetropolitan counties based on their degree of urbanization and how close they are to 
a metropolitan area. 
 Overdose death rate in county of residence: County overdose death rates were obtained 
from the NC Division of Public Health (DPH).132 Death rates were averaged over the 
period of 2008 through 2013 and counties were grouped into quintiles according to their 
average rate. Death rates were reported as per 100,000 population per year. 
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 Overdose prevention policies and activities: During the time period under study (i.e., 
2009-2013), several overdose prevention and awareness-raising activities took place in 
the state of NC. These included the statewide implementation of Project Lazarus, a 
community-based, multi-component overdose prevention intervention; increased 
availability of medicine drop boxes and drug take-back events, passage of a 911 Good 
Samaritan law; and increased used of naloxone distribution programs; among other 
activities.133 To help control for time trends that may be due to these prevention activities, 
as well as general changes in awareness and CS prescribing culture and use during this 
time, we generated temporal trend measures that allowed us to control for changes in 
outcomes occurring over calendar time. We generated these measures from temporal 
trends in outcome measures in the population of Medicaid beneficiaries who were 
eligible to enter the MLIP, but were never enrolled. These temporal trend measures were 
included in all Aim 1 models (see Chapter 6). For further details on temporal trend 
generation, see Appendix C. 
 Substance use disorders: Several studies have suggested that substance abuse or 
dependence disorders are associated with prescription opioid use, misuse, and abuse.45,134-
138 These disorders include those related to illicit substances (e.g., heroin, cocaine), 
alcohol, tranquilizers, and sedatives. Chapter 5 and Appendix B provide information on 
the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) codes used to capture substance use disorders in our data. These codes were 
identified from the Agency for Healthcare Research and Quality’s (AHRQ) Clinical 
Classification Software (CCS). The CCS provides a diagnosis categorization scheme for 
ICD-9-CM codes to collapse coding into clinically meaningful categories.139 
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 Medication-assisted treatment: Defined as any prescription claim for a buprenorphine 
product indicated for use of opioid addiction treatment or any mention of Current 
Procedural Terminology (CPT) code H0020, “Alcohol and/or drug services; methadone 
administration and/or service (provision of the drug by a licensed program).”140,141  
 Overdose events: We used an ICD-9-CM definition for medication and drug-related 
overdoses developed by the NC DPH, in collaboration with the UNC’s Injury Prevention 
Research Center, through a CDC-funded surveillance quality improvement initiative to 
improve injury surveillance for outcomes, such as overdoses.142-144 The definition was 
developed using existing state and national organization definitions; advice from content 
experts in injury epidemiology, surveillance methods, and public health informatics; and 
end user feedback. 
 Pain conditions: Specific types of pain, namely back and headache pain, are specifically 
associated with heavy opioid use in Medicaid populations.136,138 As the number of pain 
diagnoses increases, the likelihood of heavy opioid use has also been found to increase. 
Chapter 5 and Appendix B provide information on the ICD-9-CM codes that were used to 
capture specific pain diagnoses in our data. These categorizations have been used in 
previous research and have been shown to be the most commonly reported chronic pain 
sites and reasons for long-term opioid use in a general medical population.135,136,145  
 Mental health disorders: Research suggests that the presence of mental health disorders 
are associated with increased use of opioids and nonmedical use of opioids.10,45,134,146-151  
These mental health conditions included mood (e.g., depression, bipolar) disorders, as 
well as conditions characterized by panic symptoms, social phonic/agoraphobic 
symptoms, and a history of severe psychological distress. Consistent with previous 
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research, AHRQ’s CCS definitions were used in classifying beneficiaries’ as having 
mood and/or anxiety disorders.139,152 Mood disorders included depressive and bipolar 
conditions, and anxiety disorders included panic disorder, generalized anxiety disorder, 
social phobia, and obsessive-compulsive disorder, among others.152 Chapter 5 and 
Appendix B provide further information on definitions used. 
 General comorbidity: The Charlson comorbidity score was used as a measure of a given 
beneficiary’s overall medical comorbidity.153,154 Research has shown that patients 
prescribed greater doses of opioids also have higher Charlson comorbidity scores on 
average.111,155 Moreover, using this same CSRS-Medicaid linked data set, Roberts (2015) 
found that having a high Charlson comorbidity score was associated with having a 
circumvented prescription fill.79  
 Healthcare utilization and access: To assess overall healthcare utilization and access to 
healthcare,156-158 we examined beneficiaries’ number of pharmacies visited, number of 
ED visits, and number of inpatient admissions in the year prior to MLIP enrollment. 
Appendix B provides additional information on codes that were used to capture counts of 
unique pharmacies used, ED visits, and inpatient admissions. 
 
4.8 Statistical Analysis  
To accomplish Aims 1 and 2, we used models that took advantage of the rich, 
longitudinal nature of our data. Specifically, for Aim 1, we used GEE to estimate measures of 
association between MLIP-related time periods and the average number of CS prescriptions 
dispensed per person-month and the dosage (average daily MMEs) of dispensed opioids per 
person. To examine changes in numbers of CS dispensed per person-month, we used both linear-
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Poisson and log-Poisson GEE models to estimate count differences and count ratios, 
respectively. A linear regression GEE (identity link, Gaussian residual distribution) was used to 
estimate changes in average daily MMEs per person while locked-in and in the year following 
release, as compared to a pre-MLIP period (i.e., the pre-spike period).  
For Aim 2, LCGA models, also known as group-based trajectory models, were used to 
examine heterogeneity in trajectories of dosages (MMEs) of opioids dispensed across periods 
prior to, during, and following release from the MLIP.85-90,94 Conventional modeling often 
assumes that a sample is drawn from a single population, characterized by a single set of 
parameters (e.g., means, variances, covariances).159 Finite mixture modeling, which LCGA is an 
application of, relaxes these assumptions and allows for the estimation of different sets of 
parameters across dissimilar subgroups for which there are no deterministic classifiers 
observed.96,160 While certain finite mixture modeling applications, such as growth mixture 
modeling, assume that the population is composed of distinct subgroups (e.g., true substance 
abusers, non-abusers, diverters), which can be defined by their trajectories over time, LGCA 
takes a less literal interpretation.160,161 LCGA is still used to disentangle and describe underlying 
heterogeneity by identifying qualitatively and quantitatively different patterns of change within a 
larger population; however, it does not assume that different trajectories represent specific 
subgroups. Rather, it can be thought of as a “statistical approximation tool” that uses trajectory 
groups to estimate an unknown distribution of trajectories across the larger population.95-98,161 
These trajectory groups, or “points of support,” help summarize and depict regions across the 
underlying distribution. Nagin, who first proposed the LCGA approach, was careful to 
emphasize the interpretation of results from these models: “…that the groups should not be 
interpreted as literal entities. Instead, they should be thought of as latent longitudinal strata in the 
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data that are composed of individuals following approximately the same development course on 
the outcome of interest. These strata identify distinctive longitudinal features of the data.” 96,97,161 
As with the analysis approach used for Aim 1, LCGA models are well-suited to our study 
design, as they can accommodate data available at irregular intervals and missing data, assuming 
data are missing at random.92 Additionally, LCGA has been previously used to study substance 
use trajectories and types of users, as discussed in Chapter 3. While LCGA has not been used to 
study how beneficiaries’ trajectories of dosages of dispensed opioids might differ and change 
across MLIP pre-enrollment, enrollment, and disenrollment periods for different strata of the 
beneficiary population, previous research on characteristics related to CS use trajectories across 
time for other populations, as well as previous NC MLIP research, provided a general basis for 
hypothesizing what we might find, as outlined in Chapter 3.79,84-91 
A key difference in the analytic approaches for Aims 1 and 2 is that in Aim 1, we were 
ultimately interested in estimating average population measures of effect to understand policy 
impacts of exposure to the MLIP on average CS-related measures. However, for Aim 2, we 
explored whether summary population measures of effect do not tell the whole story for this 
beneficiary population, and we allowed for different underlying trajectories across the 
population.  
In Chapters 5-7, we provide additional details on analytic methods used to fulfill Aims 1 
and 2. All analyses were carried out in SAS version 9.4 (Cary, NC) and Mplus version 7.4. This 
dissertation was approved by the University of North Carolina at Chapel Hill’s Institutional 
Review Board. 
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CHAPTER 5 – CHARACTERISTICS OF NORTH CAROLINA MEDICAID 
BENEFICIARIES ELIGIBLE, ENROLLED, AND RETAINED IN A “LOCK-IN” 
PROGRAM (MANUSCRIPT 1) 
 
5.1 Overview 
Objective: Describe characteristics of North Carolina (NC) beneficiaries in a Medicaid “lock-in” 
program (MLIP) 
Data Source: NC Medicaid claims, June 2009-June 2013 
Study Design: Prospective cohort 
Methods: Demographics, co-morbidities, and healthcare utilization were extracted from 
Medicaid claims. Beneficiaries enrolled in the MLIP were compared to those who were MLIP-
eligible but not enrolled. Among enrolled beneficiaries, those completing the 12-month MLIP 
were compared to those who exited prior to 12 months. 
Principal Findings: Compared to beneficiaries who were eligible for, but not enrolled in the 
MLIP, enrolled beneficiaries were more likely to have 1) recorded diagnoses of substance use 
and mental health disorders, 2) obtained controlled substances from multiple pharmacies, and 3) 
visited emergency departments. Compared to those who completed the 12-month MLIP, those 
who exited the MLIP early were 1) younger, 2) more likely to obtain controlled substances from 
multiple pharmacies, 3) reside in counties with high opioid overdose death rates, and 4) have less 
stable Medicaid coverage prior to MLIP enrollment. 
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Conclusions: NC’s MLIP appears to be successful in identifying subpopulations that may benefit 
from provision and coordination of services, such as substance abuse and mental health services. 
However, there are challenges in retaining this population for the entire MLIP duration.  
 
5.2 Introduction 
 The public health epidemic of prescription drug misuse carries enormous health, social, 
and economic impacts. Between 2000 and 2015, the annual prescription drug overdose death rate 
in the U.S. more than tripled from 2.8 to 9.2 deaths per 100,000 population.1 Of the 29,728 lives 
lost to prescription drug overdoses in 2015, three out of four deaths involved an opioid analgesic 
and nearly one-third involved a benzodiazepine.1 Because both types of drugs act as central 
nervous system depressants, combined use considerably increases a person’s risk of overdose.110 
Medicaid beneficiaries are a particularly high-risk population for prescription drug 
overdose. Medicaid beneficiaries are prescribed opioids at twice the rate of persons without 
Medicaid benefits, and their prescription opioid overdose death rates are three to eight times that 
of those without Medicaid benefits.9,10,15-17 State-based Medicaid “lock-in” programs (MLIPs) 
are a widely used strategy for addressing the potential misuse and abuse of prescription drugs in 
Medicaid populations.33,34 MLIPs are designed to identify Medicaid beneficiaries demonstrating 
potential overutilization of prescription drugs and to limit their access, generally through 
requiring beneficiaries to use a single prescriber and/or pharmacy to obtain certain types of 
prescribed drugs (e.g., opioids, benzodiazepines) for a specified period of time.34  
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“Lock-in” programs are increasingly being implemented or proposed in non-Medicaid 
populations, such as those who are privately insured and those who receive Medicare,162-164 
despite limited evaluation of these programs and knowledge of the populations impacted.20,165 
Initial “lock-in” program studies largely focused on cost savings to Medicaid, as well as 
documenting some reductions in medical and pharmacy utilization measures.34,35,48,72 More 
recent research indicates that MLIPs may have unintended consequences in the form of increased 
out-of-pocket prescription fills for opioids and benzodiazepines, which potentially could 
attenuate the utility of these programs as an overdose prevention measure.83 
In order to understand and improve the utility of MLIPs, we need more information about 
the attributes of beneficiaries selected into these programs, including their health care needs. The 
purpose of this study was to examine and compare demographic and clinical characteristics of 
beneficiaries enrolled in North Carolina’s (NC) MLIP, as compared to individuals found eligible 
for enrollment but not enrolled into the program. Additionally, we sought to compare those who 
were retained in the MLIP for the entire 12-month program period relative to those who exited 
the MLIP prior to program completion. 
 
5.3 Methods 
NC Medicaid claims data from June 2009 through June 2013 were obtained from the NC 
Division of Medical Assistance (DMA). 
North Carolina MLIP Enrollment 
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NC’s MLIP originated in October 2010.40 Eligibility criteria for the program included 
meeting any of the following criteria within a two consecutive calendar month period: (1) filling 
more than six opioid prescriptions, (2) filling more than six benzodiazepine prescriptions, or (3) 
filling opioid or benzodiazepine prescriptions that were written by more than three different 
prescribers.40 Each month a vendor, contracting with the DMA, reviewed prescription dispensing 
data for all NC Medicaid beneficiaries in the previous two calendar months to determine who 
met MLIP eligibility criteria. The vendor then ranked the MLIP-eligible pool of beneficiaries 
using a proprietary algorithm that factored in the number, quantity, and days’ supply of 
prescriptions obtained, paid amounts, and distinct prescribers and pharmacies visited, combined 
with a clinical review process by pharmacists employed by the vendor. Each month, 
approximately 200 of the highest ranking beneficiaries were then recommended to DMA for 
MLIP enrollment. Therefore, not everyone who was eligible was selected for MLIP enrollment. 
The specific algorithm and review process details were proprietary and thus unavailable; 
however, as outlined below, our analysis was structured to gain insight into the attributes 
considered in these processes, as well as characteristics that may not have been included in these 
processes but could indicate important health needs of the beneficiaries examined. Upon 
approval from the DMA, the approximately 200 selected beneficiaries each month were each 
sent a letter notifying them of their upcoming enrollment in the program and that the MLIP 
restricted them to using one prescriber and one pharmacy location to obtain prescriptions 
categorized as opioids or benzodiazepines for a one-year period. Beneficiaries were given 30 
days to choose a preferred prescriber and pharmacy before restrictions began. Those who did not 
respond to the DMA were assigned to a prescriber and pharmacy. These administrative processes 
took approximately two months to complete.  That is, beneficiaries who were selected for 
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enrollment based on meeting eligibility criteria in the two-month period of June and July were 
generally enrolled in the MLIP in October.  
Study cohorts 
 The overall study population consisted of adults ages 18-64 years enrolled in Medicaid at 
any point between June 2010 and December 2012. We first identified the MLIP-eligible 
population by examining Medicaid-reimbursed prescription fills from June 2010 through 
December 2012 to determine who would have been eligible for MLIP enrollment when the 
program began in October 2010 through the end of our dataset in June 2013.  For each two 
calendar month period, we examined the number of opioid and benzodiazepine prescriptions 
obtained by each beneficiary. Consistent with MLIP eligibility criteria, beneficiaries with more 
than six opioid or benzodiazepine prescriptions in a consecutive two-month period were defined 
as MLIP-eligible (Figure 5.1). While beneficiaries could also become eligible by obtaining these 
prescriptions from more than three unique prescribers (see third criterion above), the data 
available did not provide accurate information on numbers of unique prescribers. Therefore, we 
were unable to use the third criterion in constructing our MLIP-eligible population.  
 Within the MLIP-eligible population, we then identified a second study cohort that was 
actually enrolled in the MLIP (Figure 5.1). As specified in this figure, this cohort was then 
further stratified based on time spent in the MLIP, categorized as (Group 1) those spending no 
time in the MLIP, because they no longer possessed Medicaid coverage during the time they 
would have been enrolled; (Group 2) those who were enrolled in the MLIP for part of their 
assigned period but discontinued Medicaid coverage at some point during their entire observed 
and assigned MLIP period; (Group 3) those who possessed Medicaid coverage during the 
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proportion of their MLIP period observed in our data (i.e., through June 2013), but their entire 
one year MLIP period exceeded the time observed in our dataset (i.e., they were administratively 
censored); and (Group 4) those who were observed for their full 12-month MLIP enrollment 
period and possessed Medicaid coverage during the entire time. Due to similarities, the first two 
groups and last two groups were collapsed in several analyses in which the combined first two 
groups were termed the “early exiters” and the combined last two groups, the “completers.” 
Finally, to place our findings within the context of the larger Medicaid population, we 
compared these distinct cohorts to a sample of the general Medicaid population restricted to the 
same age range and within the same time period (i.e., any Medicaid beneficiary ages 18-64 years 
with at least one pharmacy claim between October 2009 and September 2010). 
Measures 
 For MLIP-eligible beneficiaries, all demographic and clinical characteristics were 
assessed at the time they became MLIP-eligible. For the general Medicaid sample, all 
demographic characteristics were assessed at the time of the first pharmacy claim between 
October 2009 and September 2010. 
Demographic measures 
Demographic characteristics included age, sex, race, urbanicity of county of residence, 
drug overdose death rate in county of residence, Medicaid aid category, and Medicaid class code. 
The U.S. Department of Agriculture’s 2013 rural-urban continuum codes were used to classify 
counties according to urbanicity.131 County overdose death rates were obtained from the NC 
Division of Public Health.4 Death rates were averaged over the period of 2008 through 2013 and 
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counties were grouped into quintiles according to their average rate. Medicaid aid categories and 
class codes provide information on criteria met to qualify for Medicaid benefits. The most 
common NC Medicaid aid categories include (1) parents with dependent children and a 
household income < 45% of the federal poverty level, (2) persons under the age of 65 years who 
are unable to work due to a severe disability that is expected to last at least 12 months, and (3) 
pregnant women with household incomes < 196% of the federal poverty level. Class codes 
provide further information on Medicaid qualification. Most Medicaid beneficiaries qualify for 
Medicaid under a “categorically needy” class code, indicating that certain income requirements 
were met as determined by the specific aid category (e.g., families with dependent children, 
disabled). However, other routes through which individuals may qualify include a “medically 
needy” classification in which a person may have not satisfied financial eligibility requirements 
(i.e., their income was too high) but significant medical expenses reduced their income below a 
certain level that then qualified them as "medically needy.”126 
Substance use-related utilization, overall healthcare utilization, and comorbid condition 
measures 
 For the MLIP-eligible population, we also examined beneficiary-level clinical 
characteristics, including controlled substance-related characteristics, overall health care 
utilization, and other comorbid conditions in the 12 months prior to MLIP eligibility. Controlled 
substance-related characteristics included MLIP eligibility criteria met, number of unique 
pharmacies visited in the two-month period prior to MLIP eligibility, and history of medication-
assisted treatment or overdose in the previous year. Beneficiaries were classified as having 
received medication-assisted treatment in the prior year if they had filled a prescription for a 
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buprenorphine product indicated for use of opioid addiction treatment or if there was any 
mention in their claims of Current Procedural Terminology (CPT) code H0020 for methadone 
treatment, consistent with previous research.114,166 The International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) definitions used to determine which 
beneficiaries had experienced an overdose were developed by the NC Division of Public Health, 
in collaboration with the UNC’s Injury Prevention Research Center, through a CDC-funded 
surveillance quality improvement initiative to improve injury surveillance for outcomes, such as 
overdoses.167 Slight modifications were made to also specifically include benzodiazepine-related 
overdoses (a target of the MLIP).   
Healthcare utilization measures included numbers of emergency department (ED) visits 
and inpatient admissions and the number of days with Medicaid coverage in the prior year. 
Finally, we estimated the prevalence of various pain-related, mental health, substance use-
related, and other comorbid diagnoses. Detailed reference information regarding the ICD-9-CM 
definitions used to define each specific condition can be found in the footnotes below Table 5.3.  
Statistical Methods 
 We estimated and compared the prevalence of demographic and clinical characteristics of 
NC Medicaid beneficiaries enrolled in the MLIP to those who were eligible, but not ultimately 
enrolled. We also compared these groups to the general Medicaid population with respect to key 
demographic characteristics. Lastly, we compared the prevalence of demographic and clinical 
characteristics of beneficiaries enrolled in the MLIP, stratified by time spent in the MLIP. For 
categorical variables, we obtained counts and percentages. For continuous variables, we 
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calculated means and standard deviations. For heavily skewed continuous variables (i.e., health 
care utilization measures), we report means and 25th, 50th (median), and 75th percentiles.  
For all variables, we calculated standardized differences between those enrolled in the 
MLIP and those eligible but not enrolled, as well as between MLIP “early exiters” and 
“completers.”168 Standardized differences provide a measure of the similarity or dissimilarity of 
two groups with respect to specific covariates. For continuous and binary covariates, 
standardized differences were used to compare the means of two groups in units of the pooled 
standard deviation of the two groups. For categorical variables with more than two levels, an 
overall standardized difference was calculated, using a multivariate Mahalanobis distance 
method.168 All analyses were completed in SAS 9.4. This study was approved by the University 
of North Carolina at Chapel Hill’s Institutional Review Board. 
 
5.4 Results 
Demographics of MLIP-eligible, MLIP-enrolled, and MLIP-completers 
 Between June 2010 and December 2012, a total of 17,407 NC Medicaid beneficiaries 
ages 18-64 years received more than 6 opioid prescriptions and/or more than 6 benzodiazepine 
prescriptions through Medicaid in a two consecutive calendar month period, qualifying them for 
the MLIP (Table 5.1).  Compared to the general NC Medicaid population, those who met MLIP 
eligibility criteria tended to be older, more often male, more often white, more often from 
counties with high overdose death rates, and less likely to receive Medicaid benefits due to a 
pregnancy.  
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Among those eligible for the MLIP, 31% were enrolled in the MLIP (Table 5.1). 
Compared to those not enrolled, MLIP-enrolled beneficiaries were more often younger (mean 
age 37.1 vs. 41.0), more often female (69.1% vs. 63.2%), less often qualified for Medicaid 
benefits due to disability (36.1% vs. 48.3%), and more often as a family with dependent children 
(60.8% vs. 48.5%) (Table 5.1, Figure 5.2A). 
Among those enrolled, 41% remained in the program for a full 12 months, and another 
25% remained in the MLIP until the point of administrative censoring. Together, we refer to 
these beneficiaries as “completers.” Another 25% spent less than 12 months in the MLIP despite 
our ability to follow them and observe them for a longer period of time, and 8% spent no time in 
the MLIP. Together, we refer to these beneficiaries as “early exiters.” The two groups 
constituting MLIP “completers” were generally similar in terms of major demographic and 
clinical characteristics, as were the two groups constituting “early exiters.”  
Compared to MLIP “completers,” the “early exiters” tended to be younger (34.1-34.4 vs. 
38.6-38.5), white (82.9-84.9% vs. 72.5-73.7%), more often from counties with high overdose 
death rates (46.4-46.8% vs. 38.1-39.8% in the top 2 overdose death rate quintiles), more often 
received aid as a family with dependent children or due to a pregnancy, and more often qualified 
as medically needy (11.1-15.8% vs. 3.0-3.8%) (Table 5.1, Figure 5.2B).  
Substance-related and health care utilization of MLIP-eligible, MLIP-enrolled, and MLIP-
completers 
Nearly all of those who became eligible for the MLIP met the opioid eligibility criterion; 
however, those enrolled in the MLIP also visited more unique pharmacies to fill their opioid 
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and/or benzodiazepine prescriptions than did those not enrolled (Table 5.2; Figure 5.2). Twenty-
nine percent of those enrolled obtained these drugs from more than three different pharmacies in 
a two-month period, as opposed to 7.8% of those not enrolled. Moreover, “early exiters” had an 
even higher prevalence than “completers” of using many different pharmacies (i.e., 35.8-40.4% 
vs. 23.7-26.3%).  
With the exception of ED use, other healthcare utilization measures were generally 
similar between those who were and were not enrolled in the MLIP. Those enrolled had, on 
average, twice as many ED visits (mean=8.3 vs. 4.2) in the year prior to becoming eligible 
(Table 5.3; Figure 5.2). MLIP-enrolled and non-enrolled cohorts tended to have similar Medicaid 
coverage in the prior year. However, stratification by time spent in the MLIP revealed that “early 
exiters” tended to have less stable Medicaid coverage in the prior year (i.e., fewer days enrolled 
in Medicaid in the prior year). 
Comorbid conditions of MLIP-eligible, MLIP-enrolled, and MLIP-completers 
Beneficiaries enrolled in the MLIP tended to a have a higher prevalence of pain, mental 
health, and substance use-related conditions (Table 5.3; Figure 5.2). Of note, nearly a quarter of 
those enrolled had a substance use disorder diagnosis in the year prior (23.3%), almost double 
that of those not enrolled (13.5%). The prevalence of other comorbid conditions was generally 
similar between MLIP-enrolled and non-enrolled cohorts except that the latter had a higher 
proportion of recent cancer diagnoses (13.3% vs. 0.8%). Stratification by time spent in the MLIP 
revealed an even higher prevalence of pain, mental health, and substance use-related conditions 
among those who completed the MLIP.  
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5.5 Discussion 
This study identified many differences between the NC MLIP target population (as 
defined by program selection criteria) and the actual population enrolled in and impacted by the 
program. Selection for the MLIP included a prioritization process of all eligible beneficiaries 
since, due to resource constraints, only a limited number of those eligible could be enrolled in 
any given month. Those enrolled in the MLIP tended to be younger, female, and less often 
qualified for Medicaid benefits due to a disability and more often as a family with dependent 
children. Additionally, those enrolled tended to visit more pharmacies to fill their opioid and/or 
benzodiazepine prescriptions, have more ED visits, have a higher prevalence of pain-, mental 
health-, and substance use-related conditions, and have a lower prevalence of recent cancer 
diagnoses relative to those eligible but not enrolled in the MLIP. Beneficiaries with cancer 
diagnoses were generally excluded from MLIP enrollment.  
To further understand the extent to which beneficiaries were exposed to the program, we 
stratified the population of those enrolled by time spent in the MLIP. Those who exited the 
program early were more often younger, white, and from counties with high overdose death 
rates, compared to those who remained in the program. Additionally, we found that “early 
exiters” more often received aid as a family with dependent children or due to a pregnancy, 
qualified as medically needy, visited more unique pharmacies to fill their opioid and/or 
benzodiazepine prescriptions, had less stable Medicaid coverage in the prior year, and a lower 
prevalence of diagnoses for pain-, mental health-, and substance use-related conditions. These 
population profiles not only illuminate important generalizability considerations but also care 
coordination opportunities for future MLIP design. 
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The generalizability of MLIP evaluation findings is an important consideration as the 
medical community continues to grapple with the surging opioid epidemic and “lock-in” 
programs are implemented more broadly. “Lock-in” programs have been increasingly utilized in 
new and different beneficiary populations, including private insurance plans, other Medicaid 
populations, and will soon be incorporated into Medicare.162-164 While the evidence base for 
these programs is sparse, recent evaluation findings from NC’s MLIP have begun to provide a 
more holistic understanding of both intended and unintended consequences of the MLIP. Skinner 
et al. (2016) reported that when compared to pre-enrollment, enrollment in the NC MLIP was 
associated with obtaining fewer Medicaid-reimbursed opioid prescriptions, visiting fewer unique 
pharmacies to obtain these medications, and reductions in Medicaid expenditures.80 However, 
Roberts et al. (2016) provided a different perspective, finding that compared to pre-enrollment, 
enrollment in the NC MLIP was associated with a four-fold increase in the rate of paying cash 
for one’s opioids or benzodiazepines despite having Medicaid coverage, revealing a key 
weakness of the program.83 These are the first known findings to highlight and contrast the 
intended and unintended consequences of an MLIP and should alert current and future “lock-in” 
program administrators to consider the full range of the program’s potential impacts. As the 
evidence base develops and as these programs are designed and refined, evaluations from other 
“lock-in” programs are needed that not only present a range of program impacts, but also provide 
a clear depiction of the affected population. Our findings indicate a largely young, white, female 
population is selected for MLIP enrollment that has a high prevalence of mental health 
comorbidities, high ED use, and often utilizes many different pharmacies to obtain controlled 
substances. Moreover, about one-third of this population was characterized by unstable Medicaid 
coverage, including incomplete enrollment in the MLIP and incomplete Medicaid coverage in 
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the year prior. The extent to which observed impacts (e.g., reductions in Medicaid-reimbursed 
opioid prescriptions but increases in out-of-pocket opioid prescriptions) in this beneficiary 
population transfer to “lock-in” programs in private insurance, older adult, and other populations 
is not known and will be an important consideration for future research.  
Even with our limited view of complete “lock-in” program impacts, these programs 
theoretically provide a unique opportunity to efficiently deliver services capable of improving 
beneficiary health and saving healthcare dollars. We found that beneficiaries enrolled in the 
MLIP tended to have a high prevalence of comorbidities, including pain-, mental health-, and 
substance use-related conditions, and tended to show signs of uncoordinated care (e.g., high use 
of EDs and multiple pharmacies). The ability of “lock-in” programs to more effectively target 
the complex health needs of this beneficiary population is unknown, but has strong potential. In 
2014, the Association for Community Affiliated Plans supported implementation of innovative 
MLIP pilot projects in Medicaid populations in four different states.68 These pilot projects 
offered a more holistic MLIP model, as compared to the more traditional MLIP model (like the 
one administered in NC). Program elements included connections to pain specialists, risk 
screenings, evaluation of barriers to critical needs (e.g., transportation, housing) and connection 
to resources, and screening and referral to substance abuse treatment resources. Moreover, case 
managers were assigned to MLIP beneficiaries in at least two of these projects to help further 
coordinate care. While evaluation research was limited to short-term outcomes, preliminary 
results revealed cost savings and improved care coordination. Pending further evaluation, such 
models, particularly when targeted to the needs of specific “lock-in” program beneficiary 
populations, may serve as a more effective framework. Based on our findings, inclusion and 
coordination of substance abuse and mental health screenings and connection to substance abuse, 
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mental health, and alternative pain therapy services could serve as a useful starting point for 
improving and piloting a more comprehensive MLIP model in NC.  
Our findings should be viewed in light of four limitations. First, as noted above, the 
Medicaid data available did not include accurate information on numbers of unique prescribers, 
as the claims data provided did not possess a reliable prescriber identifier. Therefore, we were 
unable to use the third criterion in constructing our MLIP-eligible population. However, given 
that almost all of the MLIP-enrolled cohort met the first criterion (i.e., more than six opioid 
prescriptions) and given that there were likely relatively few people who visited several unique 
prescribers but did not also meet the prescription thresholds, we would not expect this missing 
information to have excluded many beneficiaries from our analysis. Second, our measurement of 
overdoses in the prior year only captured overdoses involving some interaction with the health 
care system while a person had Medicaid coverage. Third, the extent to which pain-related 
diagnoses represented actual pain-related conditions is unknown. It is possible that some 
beneficiaries were drug-seeking and did not have a painful condition; therefore, the prevalence of 
these conditions may be overestimated. However, poor coding of the conditions on claims could 
also lead to underestimation. Fourth, the presence of diagnoses in the year prior to meeting MLIP 
eligibility may be underestimated, particularly for “early exiters,” as they also tended to have less 
Medicaid coverage in the prior year. Findings stratified by time spent in the MLIP should be 
viewed with this limitation in mind. However, research suggests that inclusion of any available 
data in a lookback period to assess presence of covariates results in less misclassification than 
restricting the data to a common lookback period for all persons (i.e., a restricted period in which 
everyone has Medicaid coverage for the entire time).169  
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Attributes of the population impacted by the MLIP provide key insights into the 
generalizability of observed MLIP impacts to other target populations and opportunities for 
improved care models among “lock-in” program populations. Future work should aim to 
examine a broad range of potential positive and negative impacts of these programs, combined 
with a clear description of studied populations, so that future program designs can be informed 
by the most comprehensive and relevant research. While “lock-in” program administrators 
should aim to gain a thorough understanding of the specific beneficiary populations impacted by 
their programs, our findings can help prepare administrators of new, similar “lock-in” programs 
for the magnitude of substance use and comorbidity that may be likely in their populations. 
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Figure 5.1 Classification of persons who qualified for the North Carolina Medicaid Lock-in Program (MLIP) from June 2010 through 
December 2012, stratified by enrollment in the MLIP and time spent in the MLIP (among those enrolled) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Dark grey boxes represent groups compared. Light grey boxes represent processes.   * 44 persons were enrolled in the MLIP for longer than a year and are 
not included in the analysis stratified by time spent in the MLIP.
“Completers” “Early exiters” 
MLIP-eligible: Adults <65 years with 
Medicaid coverage who met opioid and/or 
benzodiazepine MLIP eligibility criteria 
between June 1, 2010 and December 31, 2012 
(n=17,407)  
Enrolled in the MLIP (n=5,424)  Not enrolled in the MLIP (n=11,983)  
Group 1: No time spent 
enrolled in MLIP (n=411)  
MLIP prioritization process  
Group 2: <12 months 
enrolled in MLIP without 
administrative censoring 
(i.e., exited prior to end of 
our data) (n=1,365) 
Group 3: <12 months 
enrolled in MLIP with 
administrative censoring 
(i.e., enrolled up until the 
end of our data) (n=1,373) 
Group 4: Enrolled full 12 
months in MLIP and 
observed entire time (n= 
2,231) 
Followed through end of our data set (June 
2013) to examine time spent in MLIP * 
For overall context and 
comparison: One-year 
cross-section of Medicaid 
population of adults <65 
years (n= 448,082)  
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Table 5.1 Demographic characteristics* of adults <65 years with Medicaid coverage overall and who met Medicaid Lock-in 
Program (MLIP) eligibility criteria from June 2010 through December 2012, stratified by enrollment in the MLIP and time spent 
in the MLIP (among those enrolled) 
 
 
 
General 
Medicaid 
adult 
population** 
Medicaid population 
eligible for MLIP 
enrollment 
MLIP-enrolled*** 
 
 
Medicaid 
beneficiary 
adult 
population 
<65 years  
(N= 448,082) 
Not 
enrolled in 
the MLIP  
(n= 11,983) 
Enrolled in 
the MLIP  
(n=5,424) 
No time in 
MLIP 
(n=411) 
<12 
months in 
MLIP 
without 
administra
tive 
censoring 
(n=1,365) 
<12 
months in 
MLIP 
with 
administra
tive 
censoring 
(n=1,373) 
Full 12 
months in 
MLIP  
(n= 2,231) 
  N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Age Group (years)        
 18-24 130,467 (29.1) 1,048 (8.8) 597 (11.0) 71 (17.3) 197 (14.4) 124 (9.0) 199 (8.9) 
 25-29 62,764 (14.0) 1,404 (11.7) 890 (16.4) 86 (20.9) 286 (21.0) 191 (13.9) 322 (14.4) 
 30-34 51,173 (11.4) 1,638 (13.7) 993 (18.3) 79 (19.2) 306 (22.4) 238 (17.3) 363 (16.3) 
 35-39 44,446 (9.9) 1,523 (12.7) 826 (15.2) 73(17.8) 212 (15.5) 197 (14.4) 340 (15.2) 
 40-44 36,889 (8.2) 1,462 (12.2) 727 (13.4) 40 (9.7) 144 (10.6) 210 (15.3) 330 (14.8) 
 45-49 35,917 (8.0) 1,476 (12.3) 567 (10.5) 24 (5.8) 96 (7.0) 155 (11.3) 278 (12.5) 
 50-54 33,226 (7.4) 1,505 (12.6) 442 (8.2) 18 (4.4) 72 (5.3) 128 (9.3) 223 (10.0) 
 55-64 53,200 (11.9) 1,927 (16.1) 382 (7.0) 20 (4.9) 52 (3.8) 130 (9.5) 176 (7.9) 
         
Age (years), mean (SD) 35.1 (13.5) 41.0 (11.9) 37.1 (10.6) 34.1 (10.0) 34.4 (9.7) 38.6 (10.8) 38.5 (10.7) 
Gender        
 Women 332,735 (74.3) 7,577 (63.2) 3,750 (69.1) 284 (69.1) 933 (68.4) 932 (67.9) 1,568 (70.3) 
 Men 115,347 (25.7) 4,406 (36.8) 1,674 (30.9) 127 (30.9) 432 (31.7) 441 (32.1) 663 (29.7) 
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Race        
 
White 235,845 (52.6) 8,980 (74.9) 4,155 (76.6) 349 (84.9) 
1,131 
(82.9) 
996 (72.5) 1,644 (73.7) 
 Black 173,945 (38.8) 2,381 (19.9) 966 (17.8) 45 (11.0) 156 (11.4) 308 (22.4) 450 (20.2) 
 American Indian 8,917 (2.0) 275 (2.3) 169 (3.1) 7 (1.7) 45 (3.3) 36 (2.6) 80 (3.6) 
 
Other (e.g., Asian, Pacific 
Islander) 
4,339 (1.0) 26 (0.2) 13 (0.2) 2 (0.5) 3 (0.2) 2 (0.2) 6 (0.3) 
 Unreported 25,036 (5.6) 321 (2.7) 121 (2.2) 8 (2.0) 30 (2.2) 31 (2.3) 51 (2.3) 
Urbanicity of county of residence 
† 
 
      
 
Counties in metro areas of ≥ 1 
million population 
109,402 (24.4) 2,718 (22.7) 1,399 (25.8) 114 (27.7) 362 (26.5) 361 (26.3) 553 (24.8) 
 
Counties in metro areas of < 1 
million population 
197,021 (44.0) 5,550 (46.3) 2,457 (45.3) 190 (46.2) 580 (42.5) 606 (44.1) 1,059 (47.5) 
 
Nonmetro, urban population of 
≥ 20,000 
74,873 (16.7) 2,081 (17.4) 891 (16.4) 64 (15.6) 218 (16.0) 241 (17.6) 358 (16.1) 
 
Nonmetro, urban population of 
<20,000 or rural population 
66,786 (14.9) 1,628 (13.6) 677 (12.5) 43 (10.5) 205 (15.0) 165 (12.0) 261 (11.7) 
Overdose death rate in county of 
residence (per 100,000 py) ‡ 
 
      
 20.0-32.2  70,733 (15.8) 2,407 (20.1) 1,020 (18.8) 89 (21.7) 290 (21.3) 227 (16.5) 408 (18.3) 
 15.0-19.9  85,091 (19.0) 3,131 (26.1) 1,234 (22.8) 103 (25.1) 343 (25.1) 296 (21.6) 479 (21.5) 
 11.1-14.9  100,266 (22.4) 2,433 (20.3) 1,268 (23.4) 83 (20.2) 282 (20.7) 348 (25.4) 538 (24.1) 
 8.7-11.0  107,900 (24.1) 2,501 (20.9) 1,133 (20.9) 76 (18.5) 269 (19.7) 296 (21.6) 488 (21.9) 
 2.6-8.6  84,092 (18.8) 1,505 (12.6) 769 (14.2) 60 (14.6) 181 (13.3) 206 (15.0) 318 (14.3) 
Aid category code §        
 
Aid to families with dependent 
children 
212,931 (47.5) 5,809 (48.5) 3,298 (60.8) 335 (81.5) 
1,072 
(78.5) 
725 (52.8) 1,144 (51.3) 
 Aid to disabled 162,792 (36.3) 5,793 (48.3) 1,956 (36.1) 44 (10.7) 226 (16.6) 617 (44.9) 1,048 (47.0) 
 Aid to pregnant women 44,714 (10.0) 282 (2.4) 142 (2.6) 29 (7.1) 59 (4.3) 22 (1.6) 31 (1.4) 
 Other (e.g., aid to blind) 27,645 (6.2) 99 (0.8) 28 (0.5) 3 (0.7) 8 (0.6) 9 (0.7) 8 (0.4) 
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Medicaid class code §        
 
Categorically needy 369,806 (82.5) 
10,904 
(91.0) 
5,084 (93.7) 344 (83.7) 
1,213 
(88.9) 
1,321 
(96.2) 
2,164 (97.0) 
 Medically needy 19,509 (4.4) 1,015 (8.5) 337 (6.2) 65 (15.8) 152 (11.1) 52 (3.8) 67 (3.0) 
 
Other (e.g., “qualified 
beneficiary” with Medicare & 
Medicaid benefits) 
58,767 (13.1)  64 (0.5) 3 (0.1) 2 (0.5) 0  0 0  
 
 
PY=person-years; SD= standard deviation 
* Demographic characteristics assessed at time of first pharmacy claim between Oct 2009 and Sept 2010 for general Medicaid population and at 
time of first becoming eligible for MLIP for MLIP-eligible population. 
** Cross-section of Medicaid population taken as beneficiaries ages 18-64 years who had at least one pharmacy claim between Oct 2009-Sept 
2010.  
*** 44 people were enrolled in the MLIP for >12 months and are not included in analyses stratified by time spent in the MLIP. 
† 6 persons in the “not enrolled in the MLIP” group were missing county information. 
‡ North Carolina has 100 counties. Counties were categorized in overdose rate quintiles (i.e., 20 counties per quintile). Rates are presented as 
deaths per 100,000 population per year. 
§ The aid category codes and Medicaid class codes provide information on reasons people became eligible for Medicaid. Those who were 
classified as “categorically needy” met Medicaid income requirements under a specific aid category (e.g., families with children, disabled, etc.) to 
qualify. Those qualifying as “medically needy” satisfied Medicaid’s categorical eligibility requirements (e.g., disability) but may have not satisfied 
financial eligibility requirements (i.e., income was too high). However, these individuals may have stilled qualified for Medicaid if they had 
significant medical expenses that reduced their income below a certain level, through "medically needy" programs.  
 
  
7
6
 
Table 5.2 Controlled substance-related characteristics of adults <65 years who met Medicaid Lock-in Program (MLIP) 
eligibility criteria from June 2010 through December 2012, stratified by enrollment in the MLIP and time spent in the MLIP 
(among those enrolled) 
 
Medicaid population 
eligible for MLIP 
enrollment 
MLIP-enrolled* 
 
 
Not enrolled 
in the MLIP  
(n= 11,983) 
Enrolled in 
the MLIP  
(n=5,424) 
No time in 
MLIP 
(n=411) 
<12 months 
in MLIP 
without 
administrativ
e censoring 
(n=1,365) 
<12 months in 
MLIP with 
administrative 
censoring 
(n=1,373) 
Full 12 
months in 
MLIP  
(n= 2,231) 
N (%) N (%) N (%) N (%) N (%) N (%) 
MLIP eligibility criteria met**       
 Opioid criteria only met 11,197 (93.4) 5,260 (97.0) 403 (98.1) 1,327 (97.2) 1,325 (96.5) 2,162 (96.9) 
 Benzodiazepine criteria 
only met 
755 (6.3) 139 (2.6) 6 (1.5) 32 (2.3) 42 (3.1) 58 (2.6) 
 Both opioid and 
benzodiazepine criteria 
met 
31 (0.3) 25 (0.5) 2 (0.5) 6 (0.4) 6 (0.4) 11 (0.5) 
       
Pharmacy utilization       
 Obtained opioid and/or 
benzodiazepine 
prescriptions from >3 
unique pharmacies when 
MLIP eligibility met 
931 (7.8) 1,574 (29.0) 166 (40.4) 488 (35.8) 326 (23.7) 587 (26.3) 
       
Medication-assisted treatment in 
past year 
      
 Methadone treatment***  112 (0.9) 94 (1.7) 8 (2.0) 25 (1.8) 18 (1.3) 43 (1.9) 
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Buprenorphine 
prescription fill† 
154 (1.3) 206 (3.8) 9 (2.2) 69 (5.1) 46 (3.4) 79 (3.5) 
       
Overdose in past year       
 
Any medication or drug-
related‡  
432 (3.6) 290 (5.4) 18 (4.4) 68 (5.0) 72 (5.2) 130 (5.8) 
 
Opioid- or benzodiazepine-
related§ 
188 (1.6) 125 (2.3) 10 (2.4) 27 (2.0) 26 (1.9) 61 (2.7) 
 
Prescription opioid- or 
benzodiazepine-related^ 
163 (1.4) 110 (2.0) 8 (2.0) 24 (1.8) 21 (1.5) 56 (2.5) 
 
* 44 people were enrolled in the MLIP for >12 months and are not included in analyses stratified by time spent in the MLIP. 
** Captures MLIP criteria met in first 2-month period of becoming MLIP-eligible 
*** Any mention of CPT code H0020, “Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a 
licensed program)”.  
† Any prescription claim for a buprenorphine product indicated for use of opioid addiction treatment (i.e., medication assisted treatment). 
‡ Any mention of the following ICD-9 diagnosis codes 960-979 or e-codes E850-E858, E950.0-E950.5, E962.0, E980.0-E980.5. 
§ Any mention of the following ICD-9 diagnosis codes 965.00-965.09 (or 965.0), 969.4 or e-codes E850.0-E850.2. 
^ Any mention of the following ICD-9 diagnosis codes 965.02, 965.09, 969.4 or e-codes E850.1-E850.2. 
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Table 5.3 Overall health care utilization and comorbid conditions * of adults <65 years who met Medicaid Lock-in Program (MLIP) 
eligibility criteria from June 2010 through December 2012, stratified by enrollment in the MLIP and time spent in the MLIP (among 
those enrolled) 
 
Medicaid population 
eligible for MLIP 
enrollment 
MLP-enrolled** 
 
 
Not 
enrolled in 
the MLIP  
(n= 11,983) 
Enrolled in 
the MLIP  
(n=5,424) 
No time in 
MLIP 
(n=411) 
<12 months in MLIP 
without 
administrative 
censoring (n=1,365) 
<12 months in 
MLIP with 
administrative 
censoring (n=1,373) 
Full 12 
months in 
MLIP  
(n= 2,231) 
 Mean [25th, 
50th, 75th 
percentiles]  
Mean [25th, 
50th, 75th 
percentiles] 
Mean [25th, 
50th, 75th 
percentiles] 
Mean [25th, 50th, 75th 
percentiles] 
Mean [25th, 50th, 75th 
percentiles] 
Mean [25th, 
50th, 75th 
percentiles] 
Health care utilization 
in past year       
 
Emergency 
department visits  
4.2 
[1, 3, 5] 
8.3 
[2, 5, 11] 
7.5 
[2, 5, 10] 
8.0 
[3, 6, 11] 
8.0 
[2, 5, 10] 
8.9 
[2, 6, 11] 
 
Inpatient admissions 1.0 
[0, 0, 1] 
1.1  
[0, 1, 1] 
0.9 
[0, 0, 1] 
0.9  
[0, 0, 1] 
1.2  
[0, 1, 1] 
1.2  
[0, 1, 2] 
 
Days with Medicaid 
coverage 
308.7  
[273, 365, 
365] 
310.1  
[274, 365, 
365] 
252.7  
[153, 273, 
365] 
282.9  
[202, 335, 365] 
319.4  
[305, 365, 365] 
331.2  
[365, 365, 
365] 
        
 n (%) n (%) n (%) n (%) n (%) n (%) 
Pain-related diagnoses 
in past year 
      
 
Any joint pain or 
arthritis*** 
9,620 (80.3) 4,608 (85.0) 316 (76.9) 1,087 (79.6) 1,193 (86.9) 1,972 (88.4) 
 Back pain***   7,498 (62.6) 4,219 (77.8) 307 (74.7) 1,029 (75.4) 1047 (76.3) 1,797 (80.6) 
 Neck pain*** 3,247 (27.1) 1,919 (35.4) 112 (27.3) 443 (32.5) 496 (36.1) 852 (38.2) 
 
Headache/migraine 
pain***  
1,652 (13.8) 1,053 (19.4) 67 (16.3) 264 (19.3) 255 (18.6) 460 (20.6) 
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Fibromyalgia, chronic 
pain, or fatigue † 
3,990 (33.3) 2,248 (41.5) 114 (27.7) 468 (34.3) 591 (43.0) 1,051 (47.1) 
 
Rheumatoid arthritis 
or osteoarthritis ‡  
2,091 (17.5) 1,074 (19.8) 47 (11.4) 195 (14.3) 303 (22.1) 519 (23.3) 
 Sickle cell § 87 (0.7) 84 (1.6) 0 7 (0.5) 28 (2.0) 49 (2.2) 
       
Mental health and 
substance use-related 
diagnoses in past year 
      
 Depression^ 5,349 (44.6) 2,871 (52.9) 177 (43.1) 650 (47.6) 704 (51.3) 1,315 (58.9) 
 Bipolar disorder † 1479 (12.3) 932 (17.2) 48 (11.7) 188 (13.8) 221 (16.1) 469 (21.0) 
 Personality disorder † 230 (1.9) 175 (3.2) 7 (1.7) 29 (2.1) 36 (2.6) 99 (4.4) 
 
Schizophrenia and 
other psychotic 
disorders † 
482 (4.0) 169 (3.1) 5 (1.2) 25 (1.8) 52 (3.8) 84 (3.8) 
 Anxiety disorder †
 
3,017 (25.2) 1,946 (35.9) 113 (27.5) 430 (31.5) 522 (38.0) 862 (38.6) 
 
Post-traumatic stress 
disorder † 
444 (3.7) 319 (5.9) 17 (4.1) 59 (4.3) 76 (5.5) 164 (7.4) 
 
Alcohol-related 
disorder # 
795 (6.6) 347 (6.4) 19 (4.6) 78 (5.7) 94 (6.9) 152 (6.8) 
 
Other substance-
related disorder  # 
1,620 (13.5) 1,261 (23.3) 78 (19.0) 297 (21.8) 343 (25.0) 530 (23.8) 
       
Other comorbid 
conditions in past year  
      
 
Mean Charlson co-
morbidity index (SD) 
~ 
1.68 (2.8) 0.79 (1.5) 0.47 (1.3) 0.59 (1.4) 0.91 (1.6) 0.90 (1.5) 
 
Mean Charlson co-
morbidity index 
without cancer (SD)  
0.90 (1.6) 0.76 (1.4) 0.42 (1.1) 0.55 (1.2) 0.90 (1.6) 0.85 (1.4) 
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 Cancer ∞
 
1,598 (13.3) 42 (0.8) 3 (0.7) 11 (0.8) 4 (0.3) 23 (1.0) 
 
Congestive heart 
failure  
531 (4.4) 195 (3.6) 6 (1.5) 36 (2.6) 58 (4.2) 94 (4.2) 
 
Chronic obstructive 
pulmonary disease 
2,744 (22.9) 1,219 (22.5) 55 (13.4) 208 (15.2) 365 (26.6) 581 (26.0) 
 
Diabetes with 
complications 
374 (3.1) 135 (2.5) 4 (1.0) 24 (1.8) 41 (3.0) 66 (3.0) 
 
Diabetes without 
complications 
1,886 (15.7) 682 (12.6) 31 (7.5) 117 (8.6) 205 (14.9) 322 (14.4) 
 Mild liver disease 640 (5.3) 284 (5.2) 13 (3.2) 61 (4.5) 71 (5.2) 135 (6.1) 
 Renal disease 364 (3.0) 122 (2.3) 6 (1.5) 18 (1.3) 37 (2.7) 60 (2.7) 
SD= standard deviation 
* Comorbid conditions and characteristics assessed in year prior to fully meeting MLIP eligibility criteria. 
** 44 people were enrolled in the MLIP for >12 months and are not included in analyses stratified by time spent in the MLIP. 
*** Pain categorizations used in previous research (Sullivan et al., 2008) and have been shown to be the most commonly reported chronic 
pain sites and reasons for long-term opioid use in a general medical population. Required any mention of specific ICD-9 diagnosis codes; 
see Sullivan et al. (2008) for additional details.145 
† Centers for Medicare & Medicaid Services’ (CMS) Chronic Conditions Data Warehouse definition used. Definition required at least 1 
inpatient or 2 non-inpatient claims with specific ICD-9 diagnosis codes appearing more than once over a time span exceeding 30 days.170 
‡ CMS Chronic Conditions Data Warehouse definition used with slight modification. Required at least 1 inpatient or 2 non-inpatient claims 
with specific ICD-9 diagnosis codes appearing more than once over a time span exceeding 30 days.170 
§ Consistent with other studies (Reeves et al., 2014) and Agency for Healthcare Research and Quality’s (AHRQ) Clinical Classification 
Software (CCS) definition, required at least 1 inpatient or 2 non-inpatient claims with specific ICD-9 diagnosis codes that appear more than 
once over a time span exceeding 30 days.139,171 
^ CMS Chronic Conditions Data Warehouse definition used. Definition requires at least 1 inpatient, skilled nursing facility, home health 
agency, hospital outpatient, or service/carrier claims with specific ICD-9 diagnosis codes within 1 year.170 
# AHRQ's CCS definition used, which required at least 1 inpatient or 2 non-inpatient claims with the specific ICD-9 diagnosis codes that 
appear more than once over a time span exceeding 30 days.139 
~ The Charlson Comorbidity Index (CCI) is a method of categorizing comorbidities based on ICD codes. Each comorbidity is associated 
with a weight (from 1 to 6), and weights are based on the adjusted risk of mortality or resource use. CCI scores are calculated by summing 
an individual’s weights; a score of zero indicates no comorbidities were detected. We used Quan’s enhanced CCI macro which looks at 17 
comorbidities. An individual comorbidity was considered present if there was at least 1 inpatient or 2 non-inpatient claims with the specific 
ICD-9 diagnosis codes that appeared more than once over a time span exceeding 30 days. Select specific comorbidities are listed below the 
mean indices and definitions can be found in Quan et al. (2005).154 
∞ Captures any malignancy, including lymphoma and leukemia, except malignant neoplasms of the skin.
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A.    B.  
Figure 5.2 Standardized differences in characteristics* of beneficiaries who were enrolled vs. not enrolled (reference group) in the 
Medicaid Lock-in Program (MLIP) (Panel A) and among those enrolled, differences in characteristics between MLIP “early exiters” 
vs. “completers” (reference group) (Panel B)
  
8
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* Additional variable details and definitions for demographic characteristics can be found in Table 5.1, for controlled substance-related 
characteristics in Table 5.2, and for all other variables in Table 5.3. 
OD=overdose; benzo=benzodiazepine; rx=prescription; ED=emergency department; fibromyalgia, etc.= fibromyalgia, chronic pain, and fatigue; 
RA/OA=rheumatoid arthritis/osteoarthritis; PTSD=post-traumatic stress disorder; CCI=Charlson comorbidity index; CHF=congestive heart 
failure; COPD=chronic obstructive pulmonary disease
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CHAPTER 6 – EVALUATING SHORT- AND LONG-TERM IMPACTS OF A 
MEDICAID “LOCK-IN” PROGRAM ON CONTROLLED SUBSTANCES DISPENSED 
TO BENEFICIARIES (MANUSCRIPT 2) 
 
6.1 Overview 
Background: Insurance-based “lock-in” programs (LIPs) have become a popular strategy to 
address controlled substance (CS) (e.g., opioid) misuse. However, little is known about their 
impacts. We examined changes in CS dispensing to beneficiaries in the 12-month North Carolina 
Medicaid LIP. 
Methods: We analyzed Medicaid claims linked to Prescription Drug Monitoring Program 
(PDMP) records for beneficiaries enrolled in the LIP between October 2010 and September 2012 
(n= 2,702). Outcomes of interest were 1) number of dispensed CS prescriptions and 2) morphine 
milligram equivalents (MME) of dispensed opioids while a) locked-in and b) in the year 
following release. 
Results: Compared to a period of stable CS dispensed prior to LIP enrollment, numbers of 
dispensed CS during lock-in and post-release were lower (count difference per person-month: -
0.05 (95% CI: -0.11, 0.01); -0.23 (95% CI: -0.31, -0.15), respectively). However, beneficiaries’ 
average daily MMEs of opioids were elevated during both lock-in and post-release (daily mean 
difference per person: 18.7 (95% CI: 13.9, 23.6); 11.1 (95% CI: 5.1, 17.1), respectively). 
Stratification by payer source revealed increases in using non-Medicaid (e.g., out-of-pocket) 
payment during lock-in that persisted following release.  
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Conclusions: While the LIP reduced the number of CS dispensed, the program was also 
associated with increased acquisition of CS prescriptions using non-Medicaid payment. 
Moreover, beneficiaries acquired greater dosages of dispensed opioids from both Medicaid and 
non-Medicaid payment sources during lock-in and post-release. Refining LIPs to increase 
beneficiary access to substance use disorder screening and treatment services and provider use of 
PDMPs may address these important unintended consequences. 
 
6.2 Introduction 
 Between 2000 and 2015, half a million Americans died from a drug overdose, and the 
majority of these deaths involved an opioid (57%).1 The rapid escalation in opioid deaths during 
this period was due to multiple factors, one of which was that previous perceptions and cautions 
related to the risks and addictive potential of opioid prescription drugs were inappropriately 
dismissed, and opioid prescribing rapidly escalated.172  
Several policies and programs have been implemented in an attempt to curb opioid 
misuse, abuse, and addiction. One strategy used by insurers across the U.S., and especially by 
Medicaid, is a “lock-in” program (LIP). LIPs are designed to identify beneficiaries 
demonstrating potential overutilization of opioids and other controlled substance (CS) 
prescription drugs (e.g., benzodiazepines) and to limit the beneficiaries’ access, typically by 
requiring them to use a single prescriber and/or pharmacy to obtain CS for a specified period of 
time, such as 12 months.33,34   
 Because LIPs are designed primarily to reduce waste and abuse of CS prescriptions in 
healthcare systems, evaluations have largely been limited to understanding changes in 
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prescription utilization and cost savings to insurers.34,35,43,46,48,66,67,72 However, studies to date 
have failed to provide a comprehensive picture of LIP impacts from a beneficiary perspective, 
including a clear understanding of short and long-term LIP impacts on beneficiaries’ CS 
prescription regimens.   
Our team has been evaluating North Carolina’s (NC) Medicaid LIP with the goal of 
providing a more complete understanding of LIP impacts on beneficiaries 80,83. However, 
analyses to date have been limited to the “lock-in” period, and focused mainly on numbers of 
dispensed CS during this period. While examining dispensed CS prescriptions can provide 
insight into overall prescription coordination within this population, understanding total dosages 
received helps us more closely assess beneficiary treatment regimens and the potency of all 
prescriptions acquired. Thus, the purpose of this study was to: 1) expand estimation of LIP 
effects by exploring sustained LIP effects in the year following release from the program, and 2) 
estimate both immediate and sustained LIP effects on the dosage of opioid prescriptions 
dispensed to beneficiaries, in terms of average daily morphine milligram equivalents (MMEs).  
  
6.3 Methods 
Study design overview 
Using an observational prospective cohort study design, we established and followed a 
cohort of independently living adults (e.g., excluding those living in residential facilities) 
between the ages of 18 and 64 who were enrolled in the NC Medicaid LIP between October 
2010 and September 2012. In order to obtain a more complete picture of LIP effects, we used 
NC Medicaid claims linked to records from the NC Controlled Substance Reporting System 
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(CSRS), the state’s Prescription Drug Monitoring Program (PDMP). To understand sustained 
LIP influence, we included up to 12 months of person-time on beneficiaries following release 
from the program. We estimated program effects while locked-in and following LIP release on 
numbers of dispensed CS per person-month and average daily MMEs of dispensed opioids per 
person. 
North Carolina’s Medicaid LIP 
The NC Medicaid LIP was first implemented in October 2010.173 Medicaid beneficiaries 
were eligible for the LIP if they met any of the following criteria within a two consecutive 
calendar month period: if they filled (1) more than six opioid prescriptions, (2) more than six 
benzodiazepine prescriptions, or (3) either opioid or benzodiazepine prescriptions that were 
written by more than three different prescribers.173 Each month, LIP-eligible beneficiaries, as 
determined from Medicaid prescription dispensing information for the previous two months, 
were prioritized for LIP enrollment using a proprietary algorithm combined with a review 
process by pharmacists. Based on this prioritization, approximately 200 of the highest-ranking 
beneficiaries were selected for LIP enrollment each month. Beneficiaries were notified of their 
selection for program enrollment and that LIP enrollment restricted them to using one prescriber 
and one pharmacy location to obtain prescriptions categorized as opioids or benzodiazepines for 
a one-year period. Beneficiaries were given 30 days to choose a preferred prescriber and 
pharmacy before restrictions began. If they did not choose a preferred prescriber and pharmacy, 
they were assigned one of each. Additional details of the implementation and administration of 
NC’s Medicaid LIP have been previously provided.174  
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Linked Medicaid claims and Prescription Drug Monitoring Program data 
Our research team linked NC Medicaid claims to records from the NC CSRS. Linked 
data for the period of October 2009 through June 2013 were obtained for beneficiaries enrolled 
in the LIP between October 2010 and September 2012. NC Medicaid claims included 
beneficiaries’ demographics, periods of Medicaid enrollment, adjudicated pharmacy and medical 
claims, and assigned LIP enrollment and release dates. NC CSRS records included data on all CS 
(schedules II-V) dispensed to LIP beneficiaries, regardless of source of payment (e.g., Medicaid-
reimbursed, out-of-pocket). Data were linked manually using a standardized protocol that 
included deterministically matching records based on the first five letters of the beneficiary’s last 
name, date of birth within six months, and the first two or three letters of the beneficiary’s first 
name. The protocol included rigorous data integrity checks and steps to help ensure that all of a 
given beneficiaries’ records were included and that issues such as minor misspellings or use of a 
common nickname would not prevent linkage. Once linked, dummy identifiers were assigned to 
all beneficiaries and identifying information was deleted. Additional details on the linkage have 
been previously documented.83 
Study subjects and design details 
To estimate the association between LIP-related periods and numbers of CS dispensed 
per person-month, beneficiaries in our cohort were followed from the first day of receiving any 
CS prescription (i.e., opioid or benzodiazepine) on or after October 1, 2009, throughout their 
period of lock-in, and up to one year following program release or until June 30, 2013, 
whichever came first. To estimate the association between LIP-related periods and average daily 
MMEs of dispensed prescription opioids per person, beneficiaries were followed in the same 
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manner, except that their start of follow-up was the first day of receiving any opioid prescription, 
as opposed to any opioid or benzodiazepine prescription.  
To avoid conflating program effects for those who remained continuously enrolled in the 
LIP and those who exited the LIP prior to completion,174 we restricted this analysis to those who 
remained in the LIP for a full 12 months or were administratively censored in June 2013, the last 
month for which we had data. We defined continuous enrollment as no more than a 7-day gap in 
coverage. These beneficiaries constituted 62% of all beneficiaries ages 18-64 years with an 
independent living arrangement who were ever enrolled in the LIP between October 2010 and 
September 2012. There were no requirements regarding continuous Medicaid coverage in the 
time prior to LIP enrollment or in the year after LIP release. However, previous analyses 
indicated that those with continuous coverage while enrolled in the LIP had, on average, close to 
complete Medicaid coverage prior to enrollment as well.174  
“Lock-in” status over time 
 To examine changes in the numbers of CS dispensed per person-month and average daily 
MMEs of dispensed opioids per person, we divided time into four segments: two pre-enrollment 
periods (>6 months pre-enrollment, or “pre-spike,” and 0-6 months pre-enrollment, or “spike”), a 
12-month program period (“lock-in”), and a period (up to 12 months) after program release 
(“post-release”). Descriptive analyses revealed a specific period with large spikes in numbers 
and dosages of CS dispensed, in the months just prior to program enrollment. This spike period 
precipitated LIP enrollment for many beneficiaries. During this period, a sudden escalation was 
met by a similar de-escalation just prior to LIP enrollment, resulting in dispensing that appeared 
to largely return to pre-spike levels just prior to actual enrollment (Figure 6). Moreover, 
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additional analyses revealed that this pattern of escalation, triggering of LIP criteria, and a nearly 
equal de-escalation was not unique to the LIP-enrolled population. It also occurred in Medicaid 
beneficiaries who were never enrolled in the LIP but met the LIP eligibility criteria. While this 
spike period reveals critical information regarding the average CS utilization trajectory leading to 
eligibility for the LIP, this volatile period of utilization is likely not the most appropriate 
reference period for LIP effect estimation. Rather, understanding the extent to which the LIP was 
associated with CS utilization during and upon release, as compared to a more stable utilization 
period prior to program enrollment provides a more suitable comparison. Therefore, we stratified 
pre-enrollment time into pre-spike and spike periods and focused our LIP effect estimation on 
dispensing during lock-in and post-release periods as compared to the pre-spike period.  
Outcome measures 
 We examined monthly numbers of dispensed CS prescriptions by payer source— 
Medicaid-reimbursed, not Medicaid-reimbursed (e.g., out-of-pocket), and those paid for using 
any source. In addition to examining LIP effects on numbers of CS obtained, we also quantified 
the effect on the average dosage of dispensed opioid prescriptions. Average daily MME is a 
research measure commonly used to compare diverse opioid medication regimens using a 
standardized unit, morphine equivalents.109 To calculate the average daily MME of a given 
opioid prescription, we multiplied the drug’s strength by the quantity received and a medication-
specific MME conversion factor and divided by the days’ supply received.114 The average daily 
MME for each prescription was then applied to all days for which the prescription was active 
(i.e., all days in which the prescription was to be taken, according to the days’ supply). If a 
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beneficiary had more than one opioid prescription active on a given day, the MMEs for that day 
were summed. Average daily MMEs were also stratified by source of payment.  
Similar dosing equivalencies for benzodiazepines are less evidence-based, poorly 
described, and often based on expert opinion. Moreover, the majority of CS prescriptions 
received by LIP-enrolled beneficiaries consisted of opioids (approximately 75-80%); therefore, 
we did not calculate similar dosage estimates for benzodiazepines.  
Covariates       
To elucidate potential sources of confounding that could impact our estimation of LIP 
effects on CS prescription utilization, we developed a conceptual figure based on the best 
available literature and our understanding of factors affecting LIP exposure and the outcome 
measures of interest. The figure included demographic, Medicaid eligibility-related, and clinical 
characteristics, which we evaluated as sources of confounding. Demographic and Medicaid-
related characteristics were assessed at the time of LIP enrollment and included age, sex, race, 
urbanicity of the beneficiary’s county of residence, overdose death rate in the beneficiary’s 
county of residence, Medicaid aid category, and Medicaid class code. Clinical characteristics 
were assessed using a one-year lookback period from the date of LIP enrollment and included 
history of alcohol or other substance use-related disorders, history of medication-assisted 
treatment for opioid addiction, history of an overdose event, number of unique pharmacies 
visited, number of emergency department visits, number of inpatient admissions, history of 
specific pain-related diagnoses (e.g., arthritis, back, neck, headache/migraine, fibromyalgia, 
sickle cell), history of specific mental health-related diagnoses (e.g., depression, anxiety, bipolar, 
schizophrenia), and Charlson comorbidity index. Specific information on variable categories and 
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claims-related codes used to define clinical characteristics, as well as information on the 
prevalence of these characteristics in the LIP population, can be found in Chapter 5.174 
 To help control for confounding by time due to changes in awareness and CS prescribing 
culture and use during this time, we generated temporal trend measures that allowed us to control 
for changes in outcomes occurring over calendar time. We generated these measures from 
temporal trends in outcome measures in the population of Medicaid beneficiaries who were 
eligible to enter the LIP, but were never enrolled. These temporal trend measures were included 
in all models. For further details, see Appendix C.  
Statistical Analyses 
 To visualize changes in the outcomes across pre-spike, spike, lock-in, and post-release 
periods, we plotted outcome means across these LIP-related time periods and according to payer 
source. To further descriptively examine and compare outcome measures over time, we 
calculated crude means of average daily MMEs per dispensed opioid per person by LIP-related 
time period and payer source. 
We used generalized estimating equations (GEE) to estimate measures of association 
between LIP-related time periods (compared to the pre-spike referent period) and the average 
number of CS prescriptions dispensed per person-month and average daily MMEs of dispensed 
opioids per person. To examine changes in numbers of CS dispensed per person-month, we used 
both linear-Poisson and log-Poisson GEE models to estimate count differences and count ratios, 
respectively, with 95% confidence intervals (95% CI). A linear regression GEE (identity link, 
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Gaussian residual distribution) was used to estimate changes in average daily MMEs per person 
while locked-in and in the year post-release, as compared to the pre-spike period.   
All models were specified with an exchangeable correlation matrix and used restricted 
cubic spline terms with five knots to adjust for temporal trend. For each model, we assessed the 
impact of confounding by including each potential confounder described above and examining 
measures of association for meaningful changes, defined as more than a 10% change in the beta 
estimates for measures of association. However, we observed no meaningful changes; therefore, 
these variables were not included in final models. Temporal trend measures described above 
were included in all models, including those in which we assessed confounding.  
This study was approved by the University of North Carolina at Chapel Hill’s 
Institutional Review Board. 
 
6.4 Results 
Between October 2010 and September 2012, 2,702 beneficiaries were enrolled in the LIP 
and remained enrolled in the LIP for a full one-year period (or remained continuously enrolled 
prior to being administratively censored in June 2013). As previously described,174 beneficiaries 
were largely white (74%), female (70%), and had a mean age of 39 years. Half received 
Medicaid due to a disability, and they exhibited a high prevalence of pain and mental health-
related diagnoses (e.g., more than half had a diagnosis of depression) in the year prior to LIP 
enrollment.  
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Pre-modeling results 
 Figure 6 displays crude means of monthly CS dispensed per person and average daily 
MMEs dispensed per person across LIP-related time (i.e., months/days from LIP enrollment) and 
by prescription payment source. The overall pattern in the mean numbers of all CS dispensed, 
paid for using any payment source, indicated a stable mean just over 2 prescriptions per month in 
the pre-spike period. This more than doubled to 5.2 prescriptions per month at the peak of the 
spike period, followed by a sudden decline just prior to LIP enrollment. There was with a slight 
decline while locked-in, and the mean post-release was similar to the pre-spike mean.  
Crude means of average daily MMEs across program time revealed a similar pattern in 
terms of the spike and general stabilization of means during lock-in (Figure 6b). However, the 
pattern was dissimilar in that mean average daily MMEs increased across both pre-spike and 
post-release periods.  
When stratified by payment source, crude means indicated an increase in the proportion 
of dispensed CS obtained through non-Medicaid sources while locked-in, which then largely, 
although not completely, reverted to pre-spike levels in the post-release period. However, for 
mean average daily MMEs, the increase in using non-Medicaid payment sources did not appear 
to revert to pre-spike levels in the post-release period. 
Crude means of average daily MMEs per dispensed opioid per person from all payer 
sources indicated a steady increase in the mean across LIP-related periods (Table 6.1). However, 
stable medians suggested the mean increase was largely driven by a smaller subset of 
beneficiaries at the upper end of the distribution. Stratification by payment source revealed a 
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similar finding for non-Medicaid reimbursed opioids, in that a substantial increase in the mean 
was observed post-release while the median remained similar to other LIP-related periods. 
Finally, results for Medicaid-reimbursed opioids indicated an upward shift in the mean and 
median while enrolled in the lock-in. 
Frequency and dosage of dispensed CS 
Controlling for temporal trend in dispensed CS prescriptions, numbers of CS dispensed 
per person-month during lock-in and post-release were slightly lower than the pre-spike period 
(count difference per person-month: -0.05; 95% CI: -0.11, 0.01 and -0.23; 95% CI: -0.31, -0.15, 
respectively) (Table 6.2). Stratification by payer source revealed that large decreases in 
Medicaid-reimbursed prescriptions during lock-in and post-release were considerably offset by 
increases in non-Medicaid-reimbursed prescriptions during these periods. For example, 
compared to the pre-spike period, there were 0.61 (95% CI: -0.66, -0.55) and 0.38 (95% CI: -
0.45, -0.31) fewer Medicaid-reimbursed prescriptions per person-month during lock-in and post-
release, respectively. However, non-Medicaid-reimbursed prescriptions increased by 0.56 (95% 
CI: 0.52, 0.59) and 0.12 (95% CI: 0.08, 0.16) per person-month during lock-in and post-release, 
respectively. Similar patterns were observed in analyses restricted to opioids alone. 
The average daily MME of opioids dispensed to beneficiaries was elevated during lock-in 
and post-release relative to pre-spike (daily mean difference per person: 18.7; 95% CI: 13.9, 23.6 
and 11.1; 95% CI: 5.1, 17.1, respectively) (Table 6.3). Similar to dispensed CS, there were 
notable increases in reimbursement using non-Medicaid payment sources. Compared to the pre-
spike period, 6.6 (95% CI: 4.8, 8.5) more average daily MMEs per person were purchased using 
non-Medicaid payment during lock-in and 6.2 (95% CI: 3.7, 8.6) more post-release. 
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6.5 Discussion 
Key Findings 
 Consistent with previous research, we found that from an insurance-based perspective, 
LIPs appear to reduce CS prescriptions dispensed to beneficiaries enrolled in a state’s Medicaid 
LIP. 34,35,46,48,66,67,72,83 This paper provides the first evidence that such reductions, although 
somewhat attenuated, persist in the year following disenrollment. For example, the average 
number of Medicaid-reimbursed CS dispensed per person-month was 31% lower during lock-in 
and 18% lower post-release, as compared to a stable period of dispensing prior to lock-in.  
 A strength of this study was access to information on prescriptions obtained through 
Medicaid and non-Medicaid payment sources, which revealed insights on intended and 
unintended consequences of the LIP. We found that while CS dispensing decreased overall, 
beneficiaries acquired more CS prescriptions outside of the Medicaid payment system while 
locked-in, compared to prior to LIP enrollment. The increased acquisition of CS from non-
Medicaid sources persisted following program release. Concerns about increased acquisition of 
CS from non-Medicaid sources during lock-in have previously been noted;83 however, this is the 
first study to indicate that these effects persist post-release.  
We also found that beneficiaries received larger dosages of opioids in terms of average 
daily MMEs, during lock-in and post-release, regardless of payment source. The percent of 
average daily MMEs dispensed while locked-in increased by approximately 28% compared to 
the pre-enrollment (and pre-spike) period, and by about 17% post-release. While the majority of 
average daily MMEs were acquired through Medicaid payment, there were large increases in 
average daily MMEs obtained outside of the Medicaid payment system during these periods. 
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Approximately 12% of all average daily MMEs were paid for using non-Medicaid sources prior 
to enrollment, which increased to roughly 20% during lock-in and post-release.  
The overall decline in numbers of dispensed CS and opioids and parallel increases in 
average daily MMEs suggests that opioids acquired during LIP and following release were 
characterized by greater average daily MMEs per prescription, relative to those obtained prior to 
the LIP. Descriptive analyses supported this finding but also revealed that increases may have 
been driven by select beneficiaries at the upper end of the dosage per prescription distribution.  
From an insurance-based perspective, the increase in average daily MMEs per Medicaid-
reimbursed opioid during lock-in could signal improved care coordination for some 
beneficiaries. In other words, LIP restrictions may have encouraged lock-in providers to more 
carefully assess beneficiaries’ prescriptions regimens, reducing numbers of prescriptions (e.g., 
continuous 30-day prescriptions rather than multiple shorter-term prescriptions), while not 
reducing overall MMEs. Moreover, overall increases in MMEs dispensed to certain beneficiaries 
during lock-in and following release could indicate a natural progression of opioid tolerance in a 
population with a high prevalence of chronic pain. However, this increase may also indicate 
increases in average overdose risk for this population. Given that research suggests a dose-
dependent relationship between average daily MMEs and opioid overdose risk,110-112 future 
studies should explore potential changes in overdose risk across LIP-related periods. 
Our finding that average daily MMEs per opioid obtained outside of the Medicaid system 
increased post-release may signal that some beneficiaries began acquiring more potent opioids 
outside of the purview of the Medicaid system following release from the program. Future 
research exploring heterogeneity underlying these population-level averages may help further 
disentangle subgroups experiencing potential unintended LIP effects.  
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Implications for LIP designs and policies 
 Our findings of LIP impacts on CS prescription measures provide key indications for 
intervention and LIP improvements. First, our finding that a substantial proportion of 
beneficiaries’ average daily MMEs were obtained outside of the Medicaid payment system 
highlights the need for increased use of PDMPs. We lack data on how often NC Medicaid LIP 
providers, specifically, accessed the CSRS during this time. However, a 2012 evaluation of the 
CSRS indicated that prescribers and pharmacists used the CSRS less than 6% of the time that a 
CS was either prescribed or dispensed,107 suggesting a missed opportunity to provide better 
informed care. 
Second, given our finding of increased acquisition of MME dosages during lock-in and 
findings from previous analyses indicating that nearly a quarter of LIP enrollees had a diagnosis 
of a substance use-related disorder in the year prior to enrollment,174 further research is needed 
on access to substance use disorder treatment, such as medication-assisted therapy, prior to, 
during, and following LIP release. If found to be underutilized, providing opportunities to 
discuss substance use behaviors (e.g., motivational interviewing) with LIP enrollees, a strategy 
that has been included in previous LIP models,68 and ensuring access to substance use disorder 
treatment could potentially improve care and health outcomes. 
Finally, our findings indicate that beneficiary behavior changes occurring during lock-in 
tend to persist following program release. Investment in a more comprehensive LIP model could 
produce benefits realized by both beneficiaries and insurers that are not limited to the one-year 
lock-in period. In addition to the elements discussed above, LIP models that incorporate case 
managers to help manage the complex and unique needs 174 of LIP enrollees (e.g., through 
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connection to alternate pain therapy services, mental health disorder treatment) may produce 
improved outcomes.68   
Limitations   
Our results should be viewed in light of three main limitations. First, we did not have 
linked claims-CSRS data on persons who were never enrolled in the LIP. While this group would 
have been useful as a control, we compensated by incorporating a novel method to control for 
changes in secular trend over time using Medicaid claims data from those eligible but never 
enrolled in the LIP.  
Second, while the CSRS database captures almost all CS dispensed to these beneficiaries, 
there are some gaps in understanding beneficiaries’ complete CS use. We do not have 
information on CS prescriptions acquired across state lines or from pharmacies located on 
military bases or veterans’ administration hospitals, or CS that beneficiaries obtained through 
illicit sources (diversion). If these CS acquisitions increased during lock-in and post-release, our 
measures of association would be underestimated.  
Finally, administrative censoring resulted in loss of follow-up in the one-year post-release 
period. It is possible that losses to follow-up were related to our outcome measures and could 
have introduced some bias when estimating measures of association involving the post-release 
period. 
Conclusions 
NC’s Medicaid LIP reduced overall numbers of CS prescriptions dispensed during lock-
in, and this reduction was sustained in the year following program release. However, the LIP was 
associated with acquiring a greater proportion of CS prescriptions using non-Medicaid payment 
sources both during lock-in and post-release. Moreover, beneficiaries acquired greater dosages of 
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dispensed opioids, in terms of average daily MMEs, from both Medicaid and non-Medicaid 
payment sources, both during lock-in and post-release. Refining LIPs to increase provider 
utilization of PDMP data, ensure access to substance use disorder treatment services, and 
incorporate complementary beneficiary support services may help address important unintended 
consequences and increase the overall utility of these programs. Future research is needed as to 
the short- and long-term impacts of alternate LIP designs and more comprehensive LIP models, 
incorporating measures that assess program impacts from both insurer and beneficiary 
perspectives. Additionally, future research exploring the potential heterogeneity underlying 
average population effects may help further refine and target LIPs to those most likely to benefit.  
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Figure 6. Average number of dispensed controlled substance (CS) prescriptions per person per 
month^ (Panel A) and average daily morphine milligram equivalents (MMEs) of dispensed 
opioid prescriptions (Panel B) per person across pre-spike, spike, lock-in, and post-release 
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periods* among North Carolina Medicaid “lock-in” program enrollees (n=2702), October 2009-
June 2013  
 
^ Includes CS prescriptions regulated by the lock-in program (LIP), specifically opioids and 
benzodiazepines 
*Pre-spike period= more than 6 months prior to LIP enrollment; Spike period= 0-6 months prior to LIP 
enrollment; lock-in period= months enrolled in the LIP (up to 12 months); Post-release period= months 
after disenrollment from the LIP (up to 12 months following release) 
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Table 6.1 Means of average daily morphine milligram equivalents (MMEs) per dispensed opioid 
prescription per person among North Carolina Medicaid “lock-in” program (LIP) enrollees 
(n=2,702) by LIP-related time period# and payer source, October 2009-June 2013 
 
Period# 
All payer 
sources 
Medicaid-
reimbursed 
Not Medicaid-
reimbursed 
 Mean (25th, 50th, 75th percentile) 
Pre-spike 58 (33, 44, 63) 58 (32, 44, 62) 58 (30, 43, 64) 
Spike              62 (36, 48, 69) 62 (36, 48, 69) 59 (30, 45, 64) 
Lock-in                  67 (34, 47, 77) 75 (34, 55, 94) 55 (31, 41, 60) 
Post-release  69 (32, 46, 83) 70 (31, 46, 86) 68 (30, 45, 75) 
 
# Pre-spike period= more than 6 months prior to LIP enrollment; Spike period= 0-6 months prior to LIP 
enrollment; Lock-in period= months enrolled in the LIP (up to 12 months); Post-release period= months 
after disenrollment from the LIP (up to 12 months following release) 
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Table 6.2 Means, count differences, and count ratios of monthly numbers of controlled substance prescriptions§ dispensed to North 
Carolina Medicaid “lock-in” program (LIP) enrollees (n=2,702) by payer source and LIP-related time period#, October 2009-June 
2013 
 All payer sources Medicaid-reimbursed Not Medicaid-reimbursed 
Period# 
Model-
estimated mean 
(95% CI)^ 
Count difference 
(95% CI)* 
Count ratio 
(95% CI)* 
Model-
estimated mean 
(95% CI)^ 
Count difference 
(95% CI)* 
Count 
ratio 
(95% CI)* 
Model-
estimated mean 
(95% CI)^ 
Count difference 
(95% CI)* 
Count ratio 
(95% CI)* 
Pre-spike 2.30 (2.24, 2.35) Ref Ref 2.01 (1.96, 2.05) Ref Ref 0.28 (0.26, 0.29) Ref Ref 
Spike              3.65 (3.60, 3.70) 1.41 (1.36, 1.47) 
1.63 (1.60, 
1.67) 
3.32 (3.28, 3.37) 1.37 (1.32, 1.42) 
1.71 (1.75, 
1.83) 
0.32 (0.30, 0.35) 0.05 (0.03, 0.07) 
1.20 (1.12, 
1.29) 
Lock-in                  2.11 (2.06, 2.16) -0.05 (-0.11, 0.01) 
0.98 (0.95, 
1.01) 
1.29 (1.25, 1.34) -0.61 (-0.66, -0.55) 
0.69 (0.67, 
0.71) 
0.82 (0.79, 0.86) 0.56 (0.52, 0.59) 
3.16 (2.92, 
3.42) 
Post-
release  
1.87 (1.81, 1.93) -0.23 (-0.31, -0.15) 
0.90 (0.86, 
0.93) 
1.47 (1.42, 1.52) -0.38 (-0.45, -0.31) 
0.82 (0.78, 
0.85) 
0.39 (0.36, 0.42) 0.12 (0.08, 0.16) 
1.56 (1.41, 
1.73) 
§ Includes controlled substance prescriptions regulated by the LIP, specifically opioids and benzodiazepines 
# Pre-spike period= more than 6 months prior to LIP enrollment; Spike period= 0-6 months prior to LIP enrollment; Lock-in period= months 
enrolled in the LIP (up to 12 months); Post-release period= months after disenrollment from the LIP (up to 12 months following release) 
^ Estimated with linear Poisson GEE model, used average value of secular trend variable for each LIP time period 
* Estimated with GEE model, adjusted for secular trend
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Table 6.3 Means and changes in average daily morphine milligram equivalents (MME) of opioid prescriptions dispensed to North 
Carolina Medicaid “lock-in” program (LIP) enrollees (n=2,702) by payer source and LIP-related time period#, October 2009-June 
2013 
 All payer sources Medicaid-reimbursed Not Medicaid-reimbursed 
Period# 
Model-estimated 
mean 
(95% CI)^ 
Mean difference (95% CI)* 
Model-estimated 
mean 
(95% CI)^ 
 
Mean difference (95% 
CI)* 
Model-estimated 
mean 
(95% CI)^ 
Mean difference (95% 
CI)* 
Pre-spike 66.2 (60.4, 72.0) Ref 58.0 (52.5, 63.6)  Ref 8.2 (7.0, 9.3) Ref 
Spike              98.2 (91.7, 104.7) 32.3 (28.4, 36.1) 91.2 (84.9, 97.5)  34.2 (30.4, 38.0) 7.0 (6.1, 7.8) -1.9 (-3.2, -0.7) 
Lock-in                  84.6 (79.0, 90.1) 18.7 (13.9, 23.6) 68.8 (63.7, 74.0)  12.1 (7.4, 16.8) 15.7 (14.1, 17.4) 6.6 (4.8, 8.5) 
Post-release  77.4 (71.6, 83.3) 11.1 (5.1, 17.1) 62.0 (56.9, 67.1)  5.0 (-0.9, 10.8) 15.4 (12.8, 18.1) 6.2 (3.7, 8.6) 
# Pre-spike period= more than 6 months prior to LIP enrollment; Spike period= 0-6 months prior to LIP enrollment; Lock-in period= months 
enrolled in the LIP (up to 12 months); Post-release period= months after disenrollment from the LIP (up to 12 months following release) 
^ Estimated with GEE model, used average value of secular trend variables for each LIP time period 
* Estimated with GEE model, adjusted for secular trend 
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CHAPTER 7 – TRAJECTORIES OF DISPENSED PRESCRIPTION OPIOIDS AMONG 
BENEFICIARIES ENROLLED IN A MEDICAID CONTROLLED SUBSTANCE 
“LOCK-IN” PROGRAM (MANUSCRIPT 3) 
 
7.1 Overview 
Background: “Lock-in” programs (LIPs) are used by health insurers to address potential opioid 
and substance misuse among beneficiary populations. However, little is known about whether 
the effects of LIPs on beneficiaries’ opioid utilization trajectories are heterogeneous across 
subpopulations.  
Aims: (1) To examine heterogeneity in trajectories of dispensed opioids (in terms of average 
daily morphine milligram equivalents (MMEs)) over time: prior to, during, and following release 
from a LIP; and (2) to assess associations between trajectory patterns and key beneficiary 
characteristics. 
Methods: Medicaid claims were linked to Prescription Drug Monitoring Program records for a 
cohort of beneficiaries enrolled in the North Carolina Medicaid LIP (n=2,701). Using latent class 
growth analyses, we estimated trajectories of average daily MMEs of opioids dispensed to 
beneficiaries across specific time periods of interest. 
Results: Five trajectory patterns appeared to sufficiently describe underlying heterogeneity. All 
patterns demonstrated a spike in MMEs in the six months prior to lock-in, which appeared to 
trigger LIP enrollment. Starting values and slopes varied across the five trajectory groups, which 
followed these overall patterns: (1) start at a high level of MMEs, end at a high level of MMEs 
(13.1% of the cohort); (2) start medium, end medium (13.2%); (3) start medium, end low 
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(21.5%); (4) start low, end medium (22.6%); and (5) start low, end low (29.6%). We observed 
strong associations between patterns and beneficiaries’ demographics, substance use-related 
characteristics, comorbid conditions, and overall healthcare utilization. 
Conclusions: In its current form, the Medicaid “lock-in” program (LIP) appeared to have limited 
impact on beneficiaries’ opioid trajectories. However, strong associations between trajectory 
patterns and beneficiary characteristics provide insight into potential LIP design modifications 
that might improve program impact. Modifications could include LIP integration of substance 
use disorder assessment and subsequent referral to treatment, assessment and support for 
alternate pain therapy services (e.g., physical therapy, biofeedback), and provision of naloxone.  
 
7.2 Introduction 
 More than half a million people lost their lives to a drug overdose in the United States 
between 2000 and 2015, as opioid overdose death rates more than tripled.1 In response to these 
rapidly escalating rates, numerous policies and programs aimed at reducing opioid addiction and 
overdose have been implemented.20 Health insurance sector strategies have included prior 
authorizations, maximum quantity limits per prescription, formulary controls, letters to high 
prescribing physicians, and beneficiary “lock-in” programs (LIPs).19 LIPs are increasingly used 
across the country by various health plans with the goal of identifying beneficiaries 
demonstrating potential overutilization of prescription drugs and controlling their access.33,34 
LIPs typically require beneficiaries to use a single prescriber and/or pharmacy to obtain opioids 
and other specific prescription drugs (e.g., benzodiazepines) for a specified period of time, such 
as one year.  
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We previously reported that North Carolina’s (NC) Medicaid LIP was associated with 
reductions in numbers of controlled substance prescriptions, including opioids, dispensed per 
person per month both while enrolled in the LIP and following release from the program, as 
compared to a period prior to lock-in.175 However, dosages of opioids dispensed (in terms of 
average daily morphine milligram equivalents (MMEs)) to beneficiaries were elevated during 
LIP enrollment and in the period soon after release from the program.  
While understanding the average impact of the program across the LIP-enrolled 
population is important, this approach can also mask heterogeneous patterns of LIP response. 
Indeed, prior research indicates that trajectories of substance use vary markedly across 
populations.85-89,176 Analyzing variation in opioid dispensing patterns across the LIP-enrolled 
population can help us better understand who responds to LIPs, and in turn help more effectively 
target limited program resources. In this study, we (1) described heterogeneity in trajectories of 
dispensed average daily MMEs in a LIP-enrolled beneficiary population, and (2) examined 
beneficiary characteristics associated with trajectory patterns. 
 
7.3 Methods 
We analyzed Medicaid claims linked to Prescription Drug Monitoring Program (PDMP) 
records for a cohort of beneficiaries enrolled in the NC Medicaid LIP between October 2010 and 
September 2012 (n= 2,701). Using latent class growth analyses (LCGA)98, we estimated 
trajectories of average daily MMEs of opioids dispensed across months prior to, during, and after 
release from the LIP. We then examined associations between trajectory patterns and 
demographic characteristics, substance use-related characteristics, comorbid conditions, and 
overall healthcare utilization.  
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NC Medicaid LIP 
The NC Medicaid LIP originated in October 2010.173 Medicaid beneficiaries were 
eligible for the LIP if they met any of the following criteria within two consecutive calendar 
months: (1) filling more than six opioid prescriptions, (2) filling more than six benzodiazepine 
prescriptions, or (3) filling opioid or benzodiazepine prescriptions that were written by more than 
three different prescribers.173 Each month, LIP-eligible beneficiaries, as determined from 
Medicaid prescription dispensing information for the previous two months, were prioritized for 
LIP enrollment using a proprietary algorithm combined with a review process by pharmacists. 
Based on this prioritization, approximately 200 of the highest ranking beneficiaries were selected 
for LIP enrollment each month. Beneficiaries were notified of their selection for program 
enrollment and were informed that LIP enrollment would restrict them for a one-year period to 
using one prescriber and one pharmacy location to obtain opioid or benzodiazepine prescriptions. 
Beneficiaries were given 30 days to select a preferred prescriber and pharmacy before 
restrictions began. Those who did not chose a preferred prescriber and pharmacy were assigned 
one of each. 
Data Sources 
As previously described,175 data included NC Medicaid claims linked to records from the 
NC Controlled Substances Reporting System (CSRS), NC’s PDMP. Linked data were obtained 
for all beneficiaries enrolled in the LIP between October 2010 and September 2012. In addition 
to the 12-month LIP period, data were obtained and analyzed for up to 32 months pre-LIP 
(median of 18 months) and up to 12 months post-LIP release (median of 7 months). NC 
Medicaid data included beneficiaries’ demographic characteristics, periods of Medicaid 
enrollment, adjudicated pharmacy and medical claims (i.e., inpatient, outpatient, physician, and 
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prescription drug claims), and assigned LIP enrollment and release dates. NC CSRS records 
included data on all controlled substances (schedules II-V) dispensed to LIP beneficiaries, 
regardless of source of payment (e.g., Medicaid-reimbursed, out-of-pocket). Data were linked 
manually using a standardized protocol that included deterministically matching records based 
on the first five letters of the beneficiary’s last name, date of birth within six months, and the first 
two to three letters of the beneficiary’s first name.83  
A small percentage of Medicaid claims for dispensed prescriptions (<7%) were not 
captured in the CSRS. Linkage of Medicaid claims to CSRS records allowed for a more 
comprehensive enumeration of opioid prescriptions dispensed to beneficiaries. This study was 
approved by the University of North Carolina at Chapel Hill’s Institutional Review Board. 
Study Cohort 
 We established and followed a historical cohort of adults between the ages of 18 and 64 
years who were initially enrolled in the LIP between October 2010 and September 2012 and who 
were living independently (e.g., not in a skilled nursing facility) during lock-in. Beneficiaries in 
our cohort were followed from the first day that they received an opioid prescription on or after 
October 1, 2009 (the first date for which we had data), throughout their period of lock-in, and up 
to one year post-program release or until June 30, 2013 (the last date for which we had data), 
whichever came first. Because we were particularly interested in understanding different 
trajectory paths during and after lock-in, we required cohort beneficiaries to have either remained 
continuously enrolled in the LIP (and therefore also Medicaid) for their assigned one-year LIP 
period or to have remained continuously enrolled in the LIP through June 2013, the last month 
for which we had data (i.e., administrative censoring). We defined continuous enrollment as no 
more than a 7-day gap in Medicaid coverage. To balance sample size and generalizability 
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concerns, there were no requirements regarding continuous Medicaid coverage in the time prior 
to lock-in or in the year after program release. Those with continuous coverage while enrolled in 
the LIP had, on average, close to complete Medicaid coverage prior to enrollment as well.174  
Measures  
Outcome Measure 
 We examined trajectories of average daily MMEs of dispensed opioids across time. 
Average daily MME is a research measure used to compare diverse opioid medication regimens 
using morphine equivalents as a standardized unit.109 To calculate the average daily MME of a 
given opioid prescription, we multiplied the drug’s strength by the quantity received and a 
medication-specific MME conversion factor and divided by the days’ supply received.114 The 
average daily MME for each prescription was then applied to all days for which the prescription 
was to be taken, according to the days’ supply. If a beneficiary had more than one opioid 
prescription active on a given day, the MMEs for all prescriptions to be taken on that day were 
summed. We included MMEs from all sources of payment (e.g., Medicaid-reimbursed, out-of-
pocket). For modeling purposes, we averaged each beneficiary’s average daily MMEs across 
each calendar month. This monthly average measure was then log transformed to obtain an 
approximately normal distribution for improved model estimation, consistent with previous 
research.88 
Covariate Measures 
Covariates included demographic characteristics, substance use-related characteristics, 
comorbid conditions, and overall healthcare utilization.174,175 Demographic characteristics were 
assessed at the time of LIP enrollment and included age, gender, race, urbanicity of the 
beneficiary’s county of residence, and Medicaid eligibility category (e.g., qualified based on 
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disability, as a parent of a dependent child). Substance-use related characteristics, comorbid 
conditions, and healthcare utilization were assessed using a one-year lookback period from the 
date of LIP enrollment and included history of alcohol or other substance use-related disorders, 
history of medication-assisted treatment (MAT) for opioid addiction, history of an overdose 
event, number of unique pharmacies visited, number of emergency department visits, number of 
inpatient admissions, history of specific pain-related diagnoses (e.g., arthritis, back, 
fibromyalgia, sickle cell), history of specific mental health-related diagnoses (e.g., depression, 
anxiety, bipolar), and Charlson comorbidity index. Specific information on variable categories 
and claims-related codes used to define characteristics are available in Appendix B. The 
prevalence of these characteristics in the LIP population have been previously documented (see 
Chapter 5).174 
Analysis 
 Overview of Statistical Models 
We used an application of finite mixture modeling, LCGA, to estimate trajectories of 
average daily MMEs of opioids dispensed to beneficiaries across specific time periods of interest 
(prior to lock-in, during lock-in, and following release from lock-in). LCGA models identify 
clusters of individuals that follow approximately the same trajectory for an outcome of interest 
and can be used as a tool for approximating a complex, unknown distribution of trajectories 
across the larger population.96,98,161 LCGA models permit a discrete approximation of the 
underlying heterogeneity in beneficiary trajectories over time.96,177 
 Model Specification 
As a preliminary step, it was necessary to determine how to model the functional form of 
change in average daily MMEs dispensed over the course of the study period. We considered and 
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evaluated several model functional forms (e.g., linear, quadratic, cubic, various piecewise 
specifications), using an unconditional LCGA model. We determined that a five piece, linear 
piecewise specification provided the best fit. This model aligned with findings from previous 
analyses involving this cohort.175 Knots (i.e., points at which slopes were permitted to change) 
were placed at natural and observed change points, including at the first month of lock-in and at 
the first month of program release. Additionally, extensive previous analyses revealed a specific 
spike period with a sharp rise in dispensed opioid prescriptions (and corresponding MMEs), 
beginning approximately six months prior to lock-in.175 This spike period appeared to represent 
the trigger for LIP enrollment for many of these beneficiaries. The spike generally peaked three 
months prior to enrollment with a decline thereafter. Therefore, knots were also placed at three 
and six months prior to lock-in (see Figure 7.1).  
 After having determined the optimal functional form, we conducted a series of analyses 
to determine how many discrete classes were needed to adequately summarize heterogeneity in 
growth trajectories. We evaluated one through eight class solutions. All models were fit in 
Mplus, version 7.4, using robust maximum likelihood estimation (MLR). The five class solution 
was ultimately selected as the best solution. Full details on criteria used to determine the number 
of meaningful trajectory classes and the model selection process can be found in Appendix D.  
Covariate Associations with Trajectory Classes 
  LCGA models produce probabilities of belonging to each trajectory class for each 
beneficiary. Using these posterior probabilities, we estimated the prevalence of beneficiary 
demographic characteristics, substance use-related characteristics, comorbid conditions, and 
overall healthcare utilization within each trajectory class. For each trajectory class, we calculated 
weighted (i.e., weights were posterior probabilities) counts and percentages for categorical 
 113 
 
covariates and means (with corresponding 25th, 50th, and 75th percentiles) for continuous 
covariates.  
To provide a clearer depiction of covariate relationships with latent classes, we also 
calculated and graphed standardized differences using the largest class as the reference class. 
Additional details on these calculations can be found in Appendix E. All analyses of covariate 
associations with trajectory class were completed in SAS 9.4. 
 
7.4 Results 
All five trajectories demonstrated a large spike in average daily MMEs of opioids 
dispensed during the six months prior to LIP enrollment (Figure 7.1). This escalation period is 
assumed to be the primary trigger for LIP enrollment. We characterize the five trajectory classes 
(C) according to their MME levels prior to the spike and following LIP release as follows: 
C1) start high (approx. >90 avg. daily MMEs), end high (13.1% of the cohort), 
C2) start medium (approx. 20-89 avg. daily MMEs), end medium (13.2%), 
C3) start medium, end low (approx.<20 avg. daily MMEs) (21.5%), 
C4) start low, end medium (22.6%), and, 
C5) start low, end low (29.6%). 
More than half (56%) of the LIP-enrolled cohort appeared to cluster around trajectory 
patterns characterized by a relatively stable level of daily MMEs prior to, during, and following 
the LIP (i.e., C1, C2, and C5). Prior to becoming eligible (i.e. pre-spike) these three trajectory 
groups were at high, medium, and low levels of MMEs respectively, and all three were at 
essentially the same levels post-intervention (i.e., following LIP release). 
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On the other hand, trajectories C3 and C4 were characterized by considerable change 
across periods. Compared to their pre-spike period, C4 (23%) had an unexpected increase in 
MME dosage during lock-in and following release. Of the five groups, only C3 (22%) exhibited 
a decline in dispensed MMEs during the lock-in period.  However, this decline was evident prior 
to the point of actual LIP enrollment (Figure 7.1) and, therefore, a causal association remains 
questionable. 
Covariate Associations with Trajectories 
Covariate similarities and differences were summarized (Tables 7.1, 7.2; Figure 7.2). 
Comparisons of particular interest are presented below.  
C1 and C2 (sustained high or medium MMEs) compared to C5 (sustained low MMEs): 
Approximately one quarter of our cohort tended to obtain average daily MMEs in high or 
medium dosage amounts across all time periods (i.e., C1 and C2). Despite their different MME 
levels, beneficiaries that clustered around these two trajectories tended to be similar in terms of 
their covariate profiles. They were older, on average, than other trajectory classes, and tended to 
have higher levels of chronic pain, disability, and comorbidity. At the other extreme, 
beneficiaries following C5, a trajectory characterized by sustained low levels of MME 
dispensing across time, were the youngest of all classes, had the lowest levels of chronic pain, 
comorbidity, and disability, and had the highest levels of addiction treatment. 
C2 and C3 (both began at medium MMEs, C3 declined while C2 remained level): C2 and 
C3 were relatively similar in pre-spike levels of dispensed MMEs but differed considerably with 
respect to post-spike trajectories. C3 exhibited a large decline in MMEs following the spike in 
opioid dispensing, in contrast to C2’s sustained levels. While beneficiaries who tended to follow 
these patterns were generally similar in terms of average covariate characteristics, beneficiaries 
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clustered around a C3 trajectory had the highest prevalence of overdose events and substance-
related disorder diagnoses prior to LIP enrollment, as well as a relatively high prevalence of 
MAT and mental health disorder diagnoses.  
C4 and C5 (both began at low MMEs, C4 elevated while C5 remained low): C4 and C5 
were similar in pre-spike levels of dispensed MMEs.  However, C5 returned to a low level of 
MME dispensing following the spike, while C4 remained at a heightened level following the 
spike. Most striking was the difference in MAT use associated with these two trajectories: C5 
had the highest use of MAT, nearly four times that of C4. Other notable differences included a 
higher prevalence of beneficiaries receiving Medicaid benefits due to a disability, a higher 
prevalence of severe pain diagnoses, and a higher mean comorbidity index among beneficiaries 
following a C4 trajectory.  
 
7.5 Discussion 
 Among a beneficiary population receiving large numbers of opioid prescriptions, 
considerable heterogeneity existed in the trajectories of opioid dosages (MMEs) dispensed prior 
to, during, and following release from a Medicaid LIP. We found that five trajectory patterns 
provided a suitable summary of the underlying heterogeneity in MME trajectories and that there 
were notable associations between trajectory patterns and beneficiaries’ demographic 
characteristics, substance use-related characteristics, comorbid conditions, and overall healthcare 
utilization. 
Covariate Associations with Trajectories 
While previous research has demonstrated considerable heterogeneity in classes of 
controlled substance users,85-89,176 this is the first study to examine opioid dispensing trajectories 
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within a specific population of beneficiaries exhibiting high opioid utilization who were included 
in an intervention aimed at reducing potential overutilization. Therefore, there is little research to 
which to compare our findings. From a broad perspective, studies have identified similar 
covariates, including mental health disorders, severity of pain conditions, and healthcare 
utilization, associated with dissimilar classes of controlled substance users.86,90 
Key covariate differences between C2 and C3 suggest that declines in C3 opioid 
dispensing post-spike could be attributed to the higher prevalence of overdose events and MAT 
in this class. Specifically, overdose events could have served as an impetus for MAT and the 
observed decline in MMEs prior to and during enrollment for some beneficiaries clustering 
around C3. However, additional research is needed to more closely examine the temporality of 
these associations and to also examine the extent to which mental health disorders and associated 
treatment may or may not have contributed to the declining pattern. Given that the decline began 
prior to enrollment in the LIP, beneficiaries clustered around the C3 pattern might have followed 
a declining pattern post-spike, irrespective of LIP enrollment. Additional work is needed to 
understand whether the LIP had any impact on the decline in C3.  
Compared with beneficiaries in C5, those following a C4 pattern tended to have a greater 
prevalence of pain conditions, disability, and comorbidity. If these beneficiaries experienced an 
onset of new pain conditions, disabilities, and/or comorbidities just prior to meeting LIP 
eligibility, this might help explain why they escalated and remained elevated at the time that they 
did, rather than returning to MME dispensing levels similar to pre-spike levels, like C5. 
Additionally, while it seems likely that the large proportion of MAT may have factored into the 
re-stabilization to low levels of dispensed MMEs observed in the C5 trajectory, the majority of 
beneficiaries clustered around this class did not use MAT. Additional work is needed to 
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understand factors driving the observed spike in opioid dispensing in this population, and reasons 
why certain beneficiaries re-stabilize post-spike while others do not.  
LIP Implications  
LIPs are generally implemented to reduce potential overutilization of opioids among 
beneficiaries; however, our findings suggest limited impact on average trajectories of MMEs 
dispensed to beneficiaries over LIP-related periods. The only class that exhibited a decline in 
dispensed MMEs during the lock-in period was C3; however, this decline was evident prior to 
the point of actual LIP enrollment. These findings cast doubt on the ability of the LIP to 
influence beneficiary trajectories.  
Our findings, combined with early evidence from promising LIP designs,68 suggest that 
there may be modifications LIPs can make to operate more effectively and improve beneficiary 
outcomes. For example, given our finding of a strong association of MAT history with generally 
low MME trajectory patterns, LIP administrators could consider comprehensively integrating a 
range of substance use disorder assessment and treatment services throughout LIP pre-
enrollment and enrollment periods. Additionally, we found that those receiving Medicaid 
benefits due to a disability tended to follow paths characterized by higher levels of dispensed 
MMEs across periods. A focused effort, as part of the LIP, to assess beneficiaries who receive 
Medicaid benefits due to a disability and remain at persistently high levels of MMEs for 
potential opioid tapering, utilization of alternative or complementary pain therapy approaches, 
and possession of naloxone might improve beneficiary outcomes and reduce overdose risk.178  
Limitations 
Our findings should be viewed in light of four limitations. First, we used LCGA as an 
exploratory tool to begin to examine potential underlying heterogeneity in the trajectories of 
 118 
 
dispensed opioid dosages obtained by beneficiaries across LIP-related periods. Research 
suggests that these methods can be vulnerable to model misspecification, and while we used 
several model selection and diagnostic criteria, further analyses in similar LIP populations 
should be conducted to examine the consistency of findings.179,180 Second, while the linked 
Medicaid claims-CSRS database likely captured nearly all opioids dispensed to these patients, 
there are some gaps in understanding patients’ complete opioid acquisition. We do not have 
information on opioid prescriptions acquired across state lines, from pharmacies located on 
military bases or veterans’ administration hospitals, or obtained through illicit sources. Third, the 
extent to which pain-related diagnoses represented actual pain-related conditions is unknown. To 
the extent that some beneficiaries were drug seeking and did not have a painful condition, the 
prevalence of these conditions may be overestimated. However, poor coding of the conditions on 
claims could also lead to underestimation. Fourth, the presence of diagnoses in the year prior to 
LIP enrollment may be underestimated. However, research suggests that inclusion of any 
available data in a lookback period to assess presence of covariates results in less 
misclassification than restricting the data to a common lookback period for all persons.169 
Conclusions 
Understanding heterogeneous patterns in amounts of dispensed opioids and 
corresponding associations with beneficiary characteristics can provide insight into the design 
and implementation of LIPs. Our findings suggest that greater assessment of substance use 
disorders and subsequent referral to MAT may lead some beneficiaries to follow lower risk 
opioid dispensing trajectories. Additionally, administrators might consider assessing 
beneficiaries found to follow persistently high MME trajectories, including those with 
disabilities, severe pain diagnoses, and high levels of comorbidity, for uptake of alternate pain 
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therapy services (e.g., physical therapy, biofeedback) and other overdose risk reduction strategies 
(e.g., access to naloxone). Finally, additional research to understand factors that drive spikes in 
opioid dispensing and to identify other intervention components that could beneficially alter 
opioid trajectories may help improve LIP designs and ultimately beneficiaries’ outcomes. 
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Figure 7.1 Trajectories^ of log of average daily morphine milligram equivalents (MME) of opioids dispensed to beneficiaries enrolled 
in the North Carolina Medicaid “lock-in” program per month, October 2009-June 2013 (n=2,701) 
 
^ Estimated means from five class, five-piece linear piecewise latent class growth analysis model 
C=Class. Percentages are latent class proportions based on posterior probabilities. Grey vertical lines indicate where knots were placed in the piecewise model. 
Pre-spike period= more than 6 months prior to “lock-in” program enrollment; Spike period= 0-6 months prior to “lock-in” program enrollment; “Lock-in” 
program period= 12-month enrollment period; Post-release period= 12 months after disenrollment from the “lock-in” program 
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Table 7.1 Weighted* counts, percentages, and means for characteristics of each of the five latent classes representing different 
trajectories in the log of average daily morphine milligram equivalents (MME) of opioids dispensed to beneficiaries enrolled 
in the North Carolina Medicaid “lock-in” program per month, October 2009-June 2013 
 
Total Cohort 
(n=2,701) 
Start high, end 
high (C1)  
(n=353.0; 
13.1%)* 
Start medium, 
end medium 
(C2) (n=357.6; 
13.2%)* 
Start medium, 
end low (C3)  
(n=581.3; 
21.5%)* 
Start low, end 
medium (C4) 
(n=609.4; 
22.6%)* 
Start low, 
end low 
(C5) 
(n=799.8; 
29.6%)* 
  
N (%) for categorical variables; Mean (25th pct, median, 75th pct) for continuous 
variables 
DEMOGRAPHICS^       
Age (years) 38.7 (30, 38, 47) 
43.6 (37, 44, 
52) 
43.6 (36, 44, 
51) 
39.5 (31, 39, 
47) 
38.6 (31, 38, 
46) 
33.9 (27, 32, 
40) 
Gender       
Women 1,896 (70.2) 216.2 (61.3) 233.3 (65.3) 386.9 (66.6) 446.3 (73.2) 613.3 (76.7) 
Men 805 (29.8) 136.8 (38.8) 124.2 (34.7) 194.4 (33.4) 163.1 (26.8) 186.5 (23.3) 
Race       
White 1,999 (74.0) 268.0 (75.9) 246.4 (68.9) 424.8 (73.1) 433.4 (71.1) 626.4 (78.3) 
Black 550 (20.4) 66.9 (19.0) 86.3 (24.1) 116.6 (20.1) 133.6 (21.9) 146.5 (18.3) 
Other 152 (5.6) 18.0 (5.1) 24.9 (7.0) 39.9 (6.9) 42.3 (7.0) 26.9 (3.4) 
Urbanicity of county of 
residence 
      
Counties in metro areas of ≥ 1 
mill. pop.  
675 (25.0) 65.9 (18.7) 86.1 (24.1) 137.5 (23.7) 161.4 (26.5) 224.1 (28.0) 
Counties in metro areas of < 1 
mill. pop. 
1,268 (47.0) 180.8 (51.3) 162.3 (45.4) 269.7 (46.4) 276.9 (45.4) 378.3 (47.3) 
Nonmetro, urban pop. of ≥ 
20,000 
444 (16.4) 54.2 (15.4) 73.3 (20.5) 102.8 (17.7) 111.7 (18.3) 102.0 (12.8) 
  
1
2
2
 
Nonmetro, urban pop. of 
<20,000 or rural pop. 
314 (11.6) 51.9 (14.7) 35.9 (10.1) 71.4 (12.3) 59.3 (9.7) 95.4 (11.9) 
Medicaid eligibility category       
Aid to families with dependent 
children 
1,389 (51.4) 119.4 (33.8) 135.5 (37.9) 267.0 (45.9) 347.9 (57.1) 519.2 (64.9) 
Aid to disabled 1,282 (47.5) 232.5 (65.9) 219.0 (61.3) 311.2 (53.5) 259.6 (42.6) 259.7 (32.5) 
Aid for other reasons (e.g., 
aid to blind) 
30 (1.1) 1 (0.3) 3.0 (0.8) 3.2 (0.6) 1.9 (0.3) 20.9 (2.6) 
       
SUBSTANCE USE-
RELATED † 
      
Alcohol-related disorder 174 (6.4) 18.5 (5.3) 30.8 (8.6) 38.4 (6.6) 35.0 (5.7) 51.2 (6.4) 
Other substance-related 
disorder 
870 (32.2) 110.3 (31.2) 82.7 (23.1) 214.7 (36.9) 171.9 (28.2) 290.4 (36.3) 
Medication-assisted 
treatment (MAT)  
273 (10.1) 7.5 (2.1) 4.1 (1.1) 43.8 (7.5) 37.7 (6.2) 180.0 (22.5) 
Medication or drug-related 
overdose 
193 (7.2) 29.8 (8.4) 23.1 (6.5) 58.2 (10.0) 33.0 (5.4) 49.0 (6.1) 
       
HEALTH CARE 
UTILIZATION † 
      
Number of unique 
pharmacies from which   
Medicaid-reimbursed 
prescriptions were  
obtained  
4.2 (2, 4, 6) 3.7 (2, 3, 5) 4.0 (2, 4, 5) 4.4 (3, 4, 6) 4.3 (3, 4, 6) 4.2 (3, 4, 5) 
  
1
2
3
 
Emergency department 
visits  
9.9 (3, 6, 13) 5.5 (1, 3, 7) 9.4 (2, 5, 12) 10.8 (3, 7, 14) 10.3 (3, 7, 13) 11.3 (4, 8, 14) 
Inpatient admissions  1.3 (0, 1, 2) 1.6 (0, 1, 2) 1.5 (0, 1, 2) 1.6 (0, 1, 2) 1.2 (0, 1, 2) 1.0 (0, 1, 1) 
       
PAIN-RELATED 
DIAGNOSES † 
      
Any joint pain or arthritis 2,452 (90.8) 325.4 (92.2) 338.9 (94.8) 549.3 (94.5) 571.7 (93.8) 666.7 (83.4) 
Back pain 2,253 (83.4) 308.4 (87.4) 309.0 (86.4) 504.3 (86.8) 535.0 (87.8) 596.3 (74.6) 
Neck pain 1,124 (41.6) 141.4 (40.1) 165.4 (46.3) 252.9 (43.5) 277.3 (45.5) 287.1 (35.9) 
Headache/migraine pain 589 (21.8) 63.3 (17.9) 80.1 (22.4) 131.6 (22.6) 146.5 (24.0) 167.5 (21.0) 
Fibromyalgia, chronic pain, 
or fatigue 
1,443 (53.4) 261.1 (74.0) 230.8 (64.5) 363.1 (62.5) 353.5 (58.0) 234.6 (29.3) 
Rheumatoid arthritis or 
osteoarthritis 
706 (26.1) 144.5 (41.0) 139.0 (38.9) 168.0 (28.9) 160.0 (26.3) 94.4 (11.8) 
Sickle cell 50 (1.9) 17.3 (4.9) 9.8 (2.7) 11.7 (2.0) 10.0 (1.6) 1.2 (0.2) 
       
MENTAL HEALTH-RELATED DIAGNOSES † 
Depression 1,675 (62.0) 193.6 (54.9) 221.6 (62.0) 364.0 (62.6) 388.0 (63.7) 508.8 (63.5) 
Anxiety disorder 1,184 (43.8) 123.2 (34.9) 136.6 (38.2) 288.6 (49.6) 275.7 (45.2) 360.0 (45.0) 
Other serious mental health 
disorder (e.g., bipolar, 
schizophrenia) 
751 (27.8) 59.5 (16.9) 71.6 (20.0) 189.1 (32.5) 172.9 (28.4) 257.9 (32.3) 
       
COMORBID CONDITION 
INDEX † 
      
Mean Charlson 
comorbidity index 
0.92 (0, 0, 1) 1.31 (0, 1, 2) 1.20 (0, 1, 2) 0.98 (0, 0, 1) 0.93 (0, 0, 1) 0.57 (0, 0, 1) 
pct= percentile; C= class 
* Weights are estimated posterior probabilities for belonging to a given class 
^ Assessed at the time of “lock-in” program enrollment 
† Assessed using a one-year lookback period from the date of “lock-in” program enrollment 
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Figure 7.2 Standardized differences* in North Carolina Medicaid “lock-in” program-enrolled 
beneficiary characteristics by latent class, using class 5 (i.e., “low MME other than spike period” 
class) as the reference group  
 
MAT= medication-assisted treatment; ED= emergency department; RA/OA= rheumatoid arthritis/osteoarthritis; 
MH= mental health; Class 1= start high, end high; Class 2= start medium, end medium; Class 3= start medium, end 
low; Class 4= start low, end medium; Class 5= start low, end low 
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* Refer to Appendix E for details on standardized difference calculations. Briefly, standardized differences provide a 
measure of the similarity or dissimilarity of two groups with respect to specific covariates. For example, for “other 
substance disorders,” the figure indicates that beneficiaries who cluster around Classes 1, 2, and 4 have a lower 
prevalence of substance disorders than those who cluster around Class 5, and beneficiaries who cluster around Class 
3 have a somewhat higher prevalence of substance disorders than those who cluster around Class 5. 
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Table 7.2 Key characteristics of beneficiaries enrolled in the North Carolina Medicaid “lock-in” 
program by latent class (n=2,701) 
Latent class 
number/description 
Summary of key characteristics associated with trajectory pattern 
C1: Start high, end 
high  
Older than C3-5; highest proportion of men; highest prevalence 
receiving Medicaid due to a disability; lower prevalence of MAT 
compared to C3-5; lowest mean ED visits; highest prevalence of 
severe pain diagnoses; lowest prevalence of mental health disorders; 
highest mean comorbidity index 
C2: Start medium, 
end medium 
Similar to C1 in many characteristics (e.g., age, gender, Medicaid 
eligibility category, pain diagnoses); different than C1 in greater use of 
ED; slightly lower prevalence of other substance-related disorder 
diagnoses 
C3: Start medium, 
end low 
Younger than C1&2; less disability than C1&2; greater use of MAT 
than C1&2; highest prevalence of other substance use-related 
disorders and overdose; greater use of ED than C1&2 and similar to 
C4&5; higher prevalence of mental health disorders than C1&2 and 
similar to C4&5 
C4: Start low, end 
medium 
Similar in age to C3, older than C5; larger proportion of women than 
C1-3, similar to C5; lower prevalence of disability than C1-3, more 
than C5; similar use of MAT to C3 but lower than C5; similar 
prevalence of pain diagnoses to C3, higher than C5; similar prevalence 
of mental health diagnoses to C3&5; higher mean comorbidity index 
than C5, similar to C3 
C5: Start low, end 
low 
Younger than C1-C4; highest prevalence of women; lowest prevalence 
of disability; very high prevalence of MAT (highest of any class); 
highest use of EDs; lowest prevalence of severe pain diagnoses; high 
prevalence of mental health disorders, similar to C3&4 and higher than 
C1&2; lowest comorbidity index 
C= class (trajectory); MAT= medication-assisted treatment; ED= emergency department 
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CHAPTER 8—DISCUSSION 
 
8.1 Overall Findings 
 In this dissertation, we had two primary aims: 1) to assess the impact of exposure to the 
NC MLIP on numbers of dispensed CS prescriptions and the dosages of opioids dispensed in the 
year following release from the MLIP (see Chapter 6) and 2) to examine heterogeneity in 
beneficiaries’ trajectories of dispensed opioid dosages across periods prior to, during, and 
following release from the MLIP (see Chapter 7).  
 To inform both Aim 1 and Aim 2 analyses, including the construction of the analytic 
cohort for these aims, we first conducted a detailed analysis of the beneficiaries eligible for, 
enrolled in, and retained in the MLIP (see Chapter 5). We found that compared to beneficiaries 
who were eligible for but not enrolled in the MLIP, enrolled beneficiaries were more likely to 1) 
have substance use and mental health disorders, 2) obtain controlled substances from multiple 
pharmacies, and 3) visit emergency departments. They were also less likely to receive Medicaid 
benefits due to a disability or to be diagnosed with cancer or other severe comorbid conditions. 
We also found that compared to those who completed the 12-month MLIP, those who exited the 
MLIP early (due to loss of Medicaid benefits) were younger and more likely to 1) obtain 
controlled substances from multiple pharmacies, 2) reside in counties with high opioid overdose 
death rates, and 3) have less stable Medicaid coverage prior to MLIP enrollment.  
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 To accomplish Aim 1 (see Chapter 6), we then constructed a cohort of beneficiaries 
enrolled in the MLIP for a full 12 months (or enrolled continuously until administrative 
censoring). Based on findings described above, we restricted the analytic cohort in this way to 
avoid conflating program effects for those who remained continuously enrolled in the MLIP and 
those who exited the MLIP prior to completion. Using GEE to estimate program effects on 
dispensed CS, we found that prescriptions for opioids and other CS spiked in the 6 months prior 
to MLIP enrollment, which was a trigger for MLIP enrollment. Compared to the pre-spike period 
(>6 months prior to MLIP enrollment), numbers of dispensed CS per month during and 
following release from the MLIP were slightly lower (count difference (CD) per person-month: -
0.05; 95% CI: -0.11, 0.01 and CD: -0.23; 95% CI: -0.31, -0.15, respectively). Stratification by 
payer source revealed that decreases in Medicaid-reimbursed prescriptions during enrollment and 
following release were offset considerably by increases in non-Medicaid-reimbursed 
prescriptions (e.g., out-of-pocket payments) during these periods. Notably, we also found that 
beneficiaries’ average daily MMEs of dispensed opioids were elevated both during and 
following release from the MLIP, compared to the pre-spike period (mean difference (MD): 
18.7; 95% CI: 13.9, 23.6 and MD: 11.1; 95% CI: 5.1, 17.1, respectively). Stratification by payer 
source also revealed increases in average daily MMEs obtained from non-Medicaid-reimbursed 
prescriptions during MLIP enrollment with a persistent impact following release. 
 Finally, in Aim 2 (see Chapter 7), we examined heterogeneity in beneficiaries’ 
trajectories of average daily MMEs of dispensed opioids across periods prior to, during, and 
following release from the MLIP. Using LCGA models, we found that five trajectory patterns 
appeared to appropriately describe the underlying heterogeneity in average daily MME 
trajectories. All patterns demonstrated a spike in MMEs of dispensed opioids in the six months 
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prior to lock-in, which clearly constituted a trigger for MLIP enrollment. However, the patterns 
were dissimilar both in regards to overall starting values (intercepts) and slopes. We described 
the five patterns as: 1) high, sustained MMEs across all MLIP-related periods (13.1% of the 
cohort); 2) moderately high, stable MMEs across all MLIP-related periods (13.2%); 3) large 
decline in MMEs following spike (21.5%); 4) low MMEs prior to spike with sustained, 
moderately high MMEs following spike (22.6%); and 5) low MMEs across all periods, other 
than spike (29.6%). We also found that several covariates were associated with the probability of 
following specific trajectory patterns. For example, compared to the trajectory with low MMEs 
across all periods, the trajectory of high, sustained MMEs was associated with older age, male 
sex, greater likelihood of receiving Medicaid benefits due to a disability, low use of MAT for 
opioid addiction in the year prior to lock-in, fewer ED visits but more inpatient admissions in the 
year prior to lock-in, increased prevalence of severe pain diagnoses (e.g., chronic pain, 
rheumatoid arthritis/osteoarthritis, sickle cell), higher mean comorbidity index, and lower 
prevalence of mental health disorders. 
 
8.2 Limitations 
 While we have described the specific limitations of each analysis conducted as part of 
this dissertation in the “Discussion” subsections of Chapters 5-7, we briefly summarize some of 
the overall limitations below.  
First, due to the intensive work required to link Medicaid claims and CSRS records, only 
beneficiaries enrolled in the MLIP at some point between October 2010 and September 2012 had 
their data linked and were captured in the analytic data set. In other words, we did not have 
linked data on persons who were never “exposed” to the MLIP. While this group would have 
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been useful as a control, we compensated in Aim 1 analyses by incorporating a novel method to 
control for changes in secular trend over time using Medicaid claims data from those eligible but 
not enrolled in the MLIP. Moreover, our repeated measures analyses in which everyone 
contributed data for a period prior to MLIP enrollment allows for persons to serve as their own 
control in a sense. This combination of design and analytic control measures was expected to 
reduce bias in our longitudinal analyses, similar to the use of a traditional control group. In Aim 
2 analyses, complete data on all MMEs acquired by those never “exposed” to the MLIP would 
have been also useful. However, in Section 8.5 (“Future Research Directions”), we discuss how 
Medicaid claims from the MLIP-eligible but never enrolled cohort was again used in sensitivity 
analyses to further explore Aim 2 trajectory findings. 
 Second, while the CSRS database captures almost all CS dispensed to beneficiaries, there 
were still some gaps in understanding beneficiaries’ complete CS use. We do not have 
information on CS prescriptions acquired across state lines or those obtained through illicit 
sources. Moreover, we found that a small percentage (<7%) of CS claims in Medicaid did not 
have a matching record in the CSRS. However, previous analyses revealed no obvious signs of 
systematic missingness with respect to these records.79 Lastly, as with any pharmacy claims-
based analyses, we cannot assume that all dispensed CS were actually consumed by the 
beneficiary. 
 Third, as in most studies, there is the chance of residual confounding resulting from 
incomplete control of variables on biasing “paths” between MLIP exposure and our CS-related 
outcomes. While we examined the impact of adjusting for several potential confounders on our 
measures of association in our Aim 1 analyses, adjustments had to be carried out one at a time, 
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due to modeling constraints. In other words, we were unable to examine the impact of including 
a minimally sufficient set of potential confounders in a model all at the same time.  
 Finally, LCGA and other growth curve modeling methods are novel methods that (like 
other advanced methods) can be vulnerable to model misspecification.179,180 However, we 
included several model selection and diagnostic criteria to help us achieve our goal of 
understanding the underlying heterogeneity in trajectories of beneficiaries’ opioid dosages over 
time. Still, further analyses in similar MLIP populations should be conducted to examine the 
consistency of findings.  
 
8.3 Strengths 
 This dissertation makes a unique and important contribution to the prescription opioid-
related policy literature. We utilized a unique, linked data set to answer critical questions about 
the impacts of a MLIP. This large, multi-year data set allowed us to examine sustained effects of 
NC’s MLIP, filling a key gap in the literature with respect to understanding larger program 
impacts. This dissertation was also innovative in its application of advanced methods to the 
question of whether the trajectories of dispensed opioid dosages changed across periods prior to 
MLIP enrollment, during lock-in, and following lock-in release for different strata of the 
beneficiary population. This study is the first to explore such heterogeneity across MLIP-related 
periods. The findings from this dissertation, combined with key results from previous analyses of 
this data, provide a foundation that will inform recommendations for future MLIP policy 
improvements.  
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8.4 Policy Implications 
Overall, the NC MLIP appears to generally identify a high-risk subpopulation of 
beneficiaries with many comorbidities (e.g., substance use, mental health, pain). However, the 
program, in its current form, was associated with unintended consequences, not only while 
enrolled but also following release. We found that the MLIP was associated with acquiring a 
greater proportion of CS prescriptions using non-Medicaid payment sources both during MLIP 
enrollment and following release, as compared to a pre-MLIP enrollment period. Moreover, 
beneficiaries acquired greater dosages of dispensed opioids, in terms of average daily MMEs, 
from both Medicaid and non-Medicaid payment sources. 
These findings further suggest that the MLIP may result in reduced opioid dosages for 
few beneficiaries. We found that nearly 80% of the MLIP-enrolled cohort tended to cluster 
around trajectory patterns characterized by relatively stable or increasing MME dosages during 
lock-in and following release, as compared to prior to enrollment (and prior to the unstable spike 
period that triggered enrollment). Moreover, the only trajectory pattern characterized by a 
decline in dispensed MMEs during the lock-in period exhibited this decline prior to the point of 
actual MLIP enrollment. Therefore, our findings cast doubt on the ability of the MLIP to 
influence beneficiary trajectories of dispensed MMEs. 
Taken together, the results chapters of this dissertation suggest that MLIP-enrolled 
beneficiaries may benefit from provision and coordination of additional services (e.g., screening 
and connection to substance abuse, mental health, and alternative pain therapy services) offered 
as part of the MLIP. Such services might help address important unintended consequences and 
increase the overall utility of these programs. Refining MLIPs to increase provider utilization of 
PDMP data may help improve coordination of care and reduce unintended program impacts 
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(e.g., increases in using non-Medicaid payment).  Recent Substance Abuse and Mental Health 
Services Administration-funded projects, entitled PDMP Electronic Health Records Integration 
and Interoperability Expansion projects, in nine states suggest that increased integrated of PDMP 
data into health information exchanges, electronic health record systems, and/or pharmacy 
dispensing software systems can streamline provider access and increase provider PDMP use.181 
NC could consider examining the growing evidence base from projects, such as these, to inform 
improved PDMP integration with Medicaid and other systems throughout the state. 
Finally, given that all programs have finite resources, our findings of heterogeneous 
patterns in dosages of dispensed opioids and associations with beneficiary characteristics provide 
insight into how MLIP administrators could begin to further focus program resources. Our 
findings suggest that greater assessment of substance use disorders and subsequent referral to 
MAT may lead some beneficiaries to follow lower risk opioid dispensing trajectories. 
Additionally, administrators might consider assessing beneficiaries found to follow persistently 
high MME trajectories, including those with disabilities, severe pain diagnoses, and high levels 
of comorbidity, for uptake of alternate pain therapy services (e.g., physical therapy, biofeedback) 
and other overdose risk reduction strategies (e.g., access to naloxone).  
 
8.5 Public Health Impact 
In this dissertation, we conducted the first studies to examine the sustained impacts of a 
MLIP and to gain a detailed understanding of heterogeneity in pre-, during, and post-MLIP 
opioid dispensing patterns. By making use of a unique linked database and innovative methods, 
findings from this dissertation can be used to guide health policy to help address prescription 
opioid misuse, addiction, and overdose. 
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Even small changes in the dosages of opioid prescriptions filled can translate to larger 
impacts beyond Medicaid. Research shows that among all those prescribed opioids, 
approximately 80% are prescribed low doses (<100 MMEs per day) by a single prescriber, and 
they experience about 20% of opioid-related overdoses.138,182 An additional 10% of are 
prescribed high does (≥100 MMEs per day) by a single prescriber and experience about 40% of 
overdoses.111,112 The remaining 10% obtain opioids from multiple prescribers and have high 
daily doses.122 These patients represent a notable proportion of the types of patients who are 
enrolled in programs like MLIPs. Research shows they are not only at high risk of overdose 
themselves but may also be involved in the diversion of opioids to others.122 In fact, studies from 
West Virginia, Ohio, and Utah have found that 25%-66% of those who died of a prescription 
opioid overdose used opioids that were originally prescribed to someone else, and national 
estimates have shown that nearly 70% of nonmedical opioid users report getting their opioids 
from a friend or relative, rather than a doctor.118,122,183,184 Based on these studies and others, 
agencies like the CDC have recommended that overdose prevention efforts focus on those using 
high doses and seeking opioids from multiple prescribers in order to reduce the supply diverted 
to the larger community.185 Therefore, while this dissertation focused on a specific and relatively 
small population, it is important to note that program impacts also likely have ancillary effects on 
the overall opioid use, misuse, and overdose in NC communities. 
 
8.6 Future Research Directions 
 Findings from this dissertation indicate several areas for future research. We highlight 
four key areas below. 
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First, research on identification of optimal MLIP eligibility criteria is needed. While we 
found that overall MLIP enrollment processes appeared to identify a high-risk beneficiary 
population who might benefit for improved coordination of services, we also found specific 
trajectory patterns characterized by beneficiaries who were routinely dispensed low dosages of 
opioids (other than a confined spike in dispensing). It may be that MLIP resources are not 
effectively used by enrolling those who cluster around trajectories of routinely low opioid 
dispensing, and research is needed to examine how best to identify beneficiaries with the 
potential to benefit the most from a MLIP.   
 Second, further research is needed to understand contributing factors to spikes in opioid 
and CS dispensing. We found that spikes in numbers and dosages of CS dispensed, in the months 
just prior to MLIP enrollment, were not unique to MLIP-enrolled population, but also occurred 
in Medicaid beneficiaries who met the MLIP eligibility criteria but were not enrolled (see 
Appendix A). These spike periods revealed important information regarding the average CS 
utilization trajectory leading to eligibility for the MLIP; however, they also led us to call into 
question the suitability of current MLIP eligibility and enrollment processes and the overall 
impacts of the MLIP. Understanding whether some beneficiaries experience an isolated spike in 
dispensing due to relocation, legitimate changes in providers, or a brief episode in breakthrough 
pain that largely resolves itself, as opposed to repeated spikes in opioid dispensing behaviors 
indicative of potential diversion or illegitimate use, could help further focus enrollment criteria 
and program design. 
 Third, while this dissertation provided important insights on sustained and differential 
impacts of the MLIP on CS prescriptions and opioid dosages dispensed, additional work is 
needed to also examine MLIP impacts on beneficiary health outcomes, such as overdose, and use 
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of other key health services, such as substance use disorder treatment (e.g., MAT).186 Given our 
findings of increased dispensed MMEs, on average, during and following release from lock-in 
and previous research suggesting a dose-dependent relationship between average daily MMEs 
and opioid overdose risk 110-112, future studies are needed to explore potential changes in 
overdose risk across MLIP-related periods. Additionally, given our finding that nearly a quarter 
of MLIP enrollees had a diagnosis of a substance use-related disorder in the year prior to 
enrollment, research on the availability and use of substance use disorder treatment, such as 
medication-assisted therapy, prior to, during, and following MLIP release is warranted. 
 Finally, additional work is needed to understand specific MLIP impacts on heterogeneous 
opioid dispensing and health outcome trajectories. Our finding that average opioid dosage 
trajectories were generally characterized by relatively stable or increasing MME patterns during 
lock-in and following release, as compared to prior to MLIP enrollment, indicated that the 
program may have had little influence on opioid trajectories. To examine this further, we 
conducted sensitivity analyses in a MLIP-eligible, but never enrolled, population of Medicaid 
beneficiaries (Appendix F). These analyses revealed similar trajectory patterns to the MLIP-
enrolled, and similar covariate associations with patterns, also suggesting little influence of the 
program on overall trajectories and potentially greater influence from covariate profiles. 
Sensitivity analyses were limited in that 1) we did not have CSRS records on those who were 
never enrolled in the MLIP, only Medicaid claims and 2) the time axis inevitably differed from 
our primary analysis. In our primary analysis, the MLIP-enrolled cohort was examined from time 
until/from MLIP enrollment; however, the never enrolled cohort could only be examined using 
time until/from first meeting MLIP eligibility criteria. Therefore, while initial findings suggest 
little program influence on heterogeneous trajectories, studies designed to specifically analyze 
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MLIP impacts on trajectories of not only opioid dispensing but also health outcomes (e.g., 
overdose) are needed.  
 
8.7 Summary 
 In this dissertation, we 1) examined the sustained impact of the NC MLIP on dispensed 
CS and dosages of opioids dispensed (in terms of MMEs) and 2) examined whether trajectories 
of MMEs differed across time prior to, during, and following release from the MLIP for different 
strata of the population. Data included NC Medicaid claims linked to records from NC’s PDMP 
from October 2009 through June 2013.   
 We found that compared to a period of stable CS dispensing prior to MLIP enrollment, 
the MLIP reduced the average numbers of CS dispensed both during lock-in and following 
release. However, the program was also associated with increased acquisition of dispensed CS 
using non-Medicaid payment (e.g., out-of-pocket) both during lock-in and following release. 
Moreover, beneficiaries acquired greater MMEs of dispensed opioids from both Medicaid and 
non-Medicaid payment sources during lock-in and following release.  
 We also found that considerable heterogeneity existed in trajectories of MMEs of 
dispensed opioids across time prior to, during, and following release from the MLIP. Five 
trajectory patterns appeared to sufficiently describe underlying heterogeneity. All patterns 
demonstrated a spike in MMEs in the six months prior to lock-in, constituting a trigger for MLIP 
enrollment; however, patterns were dissimilar in overall starting values and slopes. While the 
trajectories indicated that the MLIP may have had little influence on MME patterns across time, 
strong associations between trajectory patterns and beneficiary characteristics were evident. 
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Findings from this dissertation will help inform the development of future MLIP improvements 
both in NC and across the US. 
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APPENDIX A—AVERAGE DAILY MORPHINE MILIGRAM EQUIVALENTS (MMEs) 
AMONG BENEFICIARIES ENROLLED IN THE NORTH CAROLINA MEDICAID 
“LOCK-IN” PROGRAM (MLIP), BY SOURCE OF PAYMENT, AND AMONG 
ELIGIBLE BUT NEVER MLIP-ENROLLED BENEFICIARIES BY TIME 
UNTIL/FROM FIRST MEETING MLIP-ELIGIBILITY CRITERIA 
 
 
Note: MLIP-eligibility criteria defined as receiving >6 opioid or benzo prescriptions in a 2-month period. 
MLIP prescriber criterion could not be evaluated in the data available. See Section 5.5 for more 
information. 
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APPENDIX B—DETAILS ON COVARIATE CATEGORIES AND CLAIMS-RELATED 
CODES USED TO DEFINE BENEFICIARY CHARACTERISTICS 
 
DEMOGRAPHICS 
 Age Continuous variable. Measured at time of Medicaid lock-in program 
(MLIP) enrollment in years. 
 Gender Male or female. Measured at time of MLIP enrollment. 
 Race White, black, or other. “Other” included Asian, Hispanic, American 
Indian, Pacific Islander or Native, among others. Measured at time of 
MLIP enrollment. 
 Urbanicity of 
county of 
residence 
The U.S. Department of Agriculture’s 2013 rural-urban continuum 
codes were used to classify counties according to urbanicity. This 
classification system assigns categories to metropolitan counties based 
on their population size and assigns categories to nonmetropolitan 
counties based on their degree of urbanization and how close they are 
to a metropolitan area; there are nine categories. These nine categories 
were collapsed to four in our analysis: 1) counties in metropolitan 
areas of greater than or equal to 1 million people; 2) counties in 
metropolitan areas of less than 1 million people; 3) non-metropolitan, 
urban counties with a population of greater than or equal to 20,000 
people; and 4) non-metropolitan, urban counties with a population of 
less than 20,000 people or rural counties. For more information, see: 
https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/. 
County of residence was measured at time of MLIP enrollment.  
 Overdose death 
rate in county of 
residence 
County overdose death rates were obtained from the North Carolina 
(NC) Division of Public Health. Death rates were averaged over the 
period of 2008 through 2013 and counties were grouped into quintiles 
according to their average rate. Death rates were reported as per 
100,000 population per year, and categories were defined as: 20.0-
32.2; 15.0-19.9; 11.1-14.9; 8.7-11.0; and 2.6-8.6. County of residence 
was measured at time of MLIP enrollment. 
 Medicaid 
eligibility category 
code 
Medicaid eligibility categories provide information on criteria met to 
qualify for Medicaid benefits. Medicaid benefits are available to NC 
residents who are pregnant and have household incomes up to 196% 
of the federal poverty level; parents who have dependent children and 
have a household income up to 45% of the federal poverty level (e.g., 
for a family of three, income cannot exceed $667/month); blind 
persons; and persons under the age of 65 years who are unable to work 
due to a severe disability that is expected to last at least 12 months. In 
our analysis, categories were collapsed and defined as: 1) aid to 
families with dependent children; 2) aid to disabled; and 3) aid for 
other reasons (e.g., blind, pregnant women). For more information, 
see: https://dma.ncdhhs.gov/medicaid/get-started/eligibility-for-
medicaid-or-health-choice. Measured at time of MLIP enrollment.    
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 Medicaid class 
code 
Class codes provide further information on Medicaid qualification. 
Most Medicaid beneficiaries qualify for Medicaid under a 
“categorically needy” class code, indicating that certain income 
requirements were met as determined by the specific aid category 
(e.g., families with dependent children, disabled). However, other 
routes through which individuals may qualify include a “medically 
needy” classification in which a person may have not satisfied 
financial eligibility requirements (i.e., their income was too high) but 
significant medical expenses reduced their income below a certain 
level that then qualified them as "medically needy.” For more 
information, see: https://dma.ncdhhs.gov/medicaid/get-
started/eligibility-for-medicaid-or-health-choice. Measured at time of 
MLIP enrollment.  
SUBSTANCE USE-RELATED 
 Alcohol-related 
disorder 
Used Agency for Healthcare Research and Quality's (AHRQ) Clinical 
Classification Software (CCS) definition. Required at least 1 inpatient 
or 2 non-inpatient claims with specific ICD-9-CM diagnosis codes that 
appear more than once over a time span exceeding 30 days. Specific 
codes included: 291.0, 291.1, 291.2, 291.3, 291.4, 291.5, 291.8, 
291.81, 291.82, 291.89, 291.9, 303.00, 303.01, 303.02, 303.03, 
303.90, 303.91, 303.92, 303.93, 305.00, 305.01, 305.02, 305.03, 
357.5, 425.5, 535.3, 535.30, 535.31, 571.0, 571.1, 571.2, 571.3, 
760.71, 980.0. For more information, see: https://www.hcup-
us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Measured using a one-year 
lookback period from time of MLIP enrollment.  
 Other substance-
related disorder 
Used AHRQ's CCS definition. Required at least 1 inpatient or 2 non-
inpatient claims with specific ICD-9-CM diagnosis codes that appear 
more than once over a time span exceeding 30 days. Specific codes 
included: 292.0, 292.11, 292.12, 292.2, 292.81, 292.82, 292.83, 
292.84, 292.85, 292.89, 292.9, 304.00, 304.01, 304.02, 304.03, 
304.10, 304.11, 304.12, 304.13, 304.20, 304.21, 304.22, 304.23, 
304.30, 304.31, 304.32, 304.33, 304.40, 304.41, 304.42, 304.43, 
304.50, 304.51, 304.52, 304.53, 304.60, 304.61, 304.62, 304.63, 
304.70, 304.71, 304.72, 304.73, 304.80, 304.81, 304.82, 304.83, 
304.90, 304.91, 304.92, 304.93, 305.20, 305.21, 305.22, 305.23, 
305.30, 305.31, 305.32, 305.33, 305.40, 305.41, 305.42, 305.43, 
305.50, 305.51, 305.52, 305.53, 305.60, 305.61, 305.62, 305.63, 
305.70, 305.71, 305.72, 305.73, 305.80, 305.81, 305.82, 305.83, 
305.90, 305.91, 305.92, 305.93, 648.30, 648.31, 648.32, 648.33, 
648.34, 655.50, 655.51, 655.53, 760.72, 760.73, 760.75, 779.5, 
965.00, 965.01, 965.02, 965.09, V65.42. For more information, see: 
https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Measured 
using a one-year lookback period from time of MLIP enrollment. 
 Medication-
assisted treatment 
Any prescription claim for a buprenorphine product indicated for use 
of opioid addiction treatment (i.e., medication assisted treatment) or 
any mention of Current Procedural Terminology (CPT) code H0020, 
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“Alcohol and/or drug services; methadone administration and/or 
service (provision of the drug by a licensed program).” Measured 
using a one-year lookback period from time of MLIP enrollment. 
 Medication or 
drug-related 
overdose 
Used ICD-9-CM definition for medication and drug-related overdoses 
developed by the NC Division of Public Health, in collaboration with 
the University of North Carolina’s Injury Prevention Research Center, 
through a Centers for Disease Control and Prevention-funded 
surveillance quality improvement initiative to improve injury 
surveillance for outcomes, such as overdoses. Definitions were 
developed using existing state and national organization definitions; 
advice from content experts in injury epidemiology, surveillance 
methods, and public health informatics; and end user feedback. 
Definition included any mention of the following ICD-9-CM diagnosis 
codes 960-979 or e-codes E850-E858, E950.0-E950.5, E962.0, 
E980.0-E980.5. For more information, see: 
http://www.injuryfreenc.ncdhhs.gov/DataSurveillance/Poisoning.htm. 
Measured using a one-year lookback period from time of MLIP 
enrollment.   
HEALTH CARE UTILIZATION 
 Number of unique 
pharmacies from 
which Medicaid-
reimbursed 
prescriptions were 
obtained 
Includes all unique pharmacies that a beneficiary visited in the year 
prior to enrollment in the lock-in program, according to Medicaid 
claims data. We did not have reliable information on pharmacies 
visited using Controlled Substances Reporting System (CSRS) 
records.  
 Maximum number 
of unique 
pharmacies from 
which Medicaid-
reimbursed 
prescriptions were 
obtained in 1 
month 
Provides information on the maximum number of unique pharmacies 
visited in a one calendar month period in the year prior to enrollment 
in the MLIP, according to Medicaid claims data. We did not have 
reliable information on pharmacies visited using CSRS records. 
 Emergency 
department visits 
Claims with the following revenue center codes RC450, RC451, 
RC456, RC459, RC981 or Current Procedural Terminology (CPT) 
codes 99281-99285 were flagged as emergency department-related. 
Multiple claims with the same header start date, header end date, 
and/or service date for a given beneficiary were counted only once to 
obtain a total number of unique emergency department visits (i.e., to 
avoid double-counting visits). Measured using a one-year lookback 
period from time of MLIP enrollment. 
 Inpatient 
admissions 
Unique inpatient admissions were summed across the year prior to 
MLIP enrollment. Claims with a place of service code= “inpatient” 
were counted. Multiple claims with the same header start date, header 
end date, and/or service date for a given beneficiary were counted 
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once only to obtain a total number of inpatient admissions (i.e., to 
avoid double-counting). 
 Days with 
Medicaid coverage 
Using information from beneficiaries’ Medicaid eligibility files, 
summed the number of days in the year prior to MLIP enrollment in 
which each beneficiary had Medicaid coverage. 
PAIN-RELATED DIAGNOSES 
 Any joint pain of 
arthritis 
Required any mention of specific ICD-9-CM diagnosis codes: >=710 
and <720 or >=725 and <740. See: Sullivan MD, Edlund MJ, Fan M-
Y, et al. Trends in use of opioids for non-cancer pain conditions 2000-
2005 in Commercial and Medicaid insurance plans: The TROUP 
study. Pain 2008;138:440-449 for additional details. Measured using a 
one-year lookback period from time of MLIP enrollment. 
 Back pain Required any mention of specific ICD-9-CM diagnosis codes: 721.3x–
721.9x, 722.2x, 722.30, 722.70, 722.80, 722.90, 722.32, 722.72, 
722.82, 722.92, 722.33, 722.73, 722.83, 722.93, 724.xx, 737.1, 737.3, 
738.4, 738.5, 739.2, 739.3, 739.4, 756.10, 756.11, 756.12, 756. 13, 
756.19, 805.4, 805.8, 839.2, 839.42, 846, 846.0, 847.1, 847.3, 847.2, 
847.9. See: Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in use of 
opioids for non-cancer pain conditions 2000-2005 in Commercial and 
Medicaid insurance plans: The TROUP study. Pain 2008;138:440-449 
for additional details. Measured using a one-year lookback period 
from time of MLIP enrollment. 
 Neck pain Required any mention of specific ICD-9-CM diagnosis codes: 721.0X, 
721.1X, 722.0X, 722.31, 722.71, 722.81, 722.91, 723.XX, 839.0, 
839.1, 847.0. See: Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in 
use of opioids for non-cancer pain conditions 2000-2005 in 
Commercial and Medicaid insurance plans: The TROUP study. Pain 
2008;138:440-449 for additional details. Measured using a one-year 
lookback period from time of MLIP enrollment. 
 Headache/migraine 
pain 
Required any mention of specific ICD-9-CM diagnosis codes: >=346 
and <347, or 307.81. See: Sullivan MD, Edlund MJ, Fan M-Y, et al. 
Trends in use of opioids for non-cancer pain conditions 2000-2005 in 
Commercial and Medicaid insurance plans: The TROUP study. Pain 
2008;138:440-449 for additional details. Measured using a one-year 
lookback period from time of MLIP enrollment. 
 Fibromyalgia, 
chronic pain, or 
fatigue 
Centers for Medicare & Medicaid Services’ (CMS) Chronic 
Conditions Data Warehouse definition used. Definition required at 
least 1 inpatient or 2 non-inpatient claims with specific ICD-9 
diagnosis codes appearing more than once over a time span exceeding 
30 days. Specific codes included: 338.2, 338.21, 338.22, 338.23, 
338.29, 338.3, 338.4, 780.7, 780.71, 729.1, 729.2. For more 
information, see: https://www.ccwdata.org/web/guest/condition-
categories. Measured using a one-year lookback period from time of 
MLIP enrollment. 
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 Rheumatoid 
arthritis or 
osteoarthritis 
Used Centers for Medicare & Medicaid Services’ (CMS) Chronic 
Conditions Data Warehouse (CCW) definition with slight 
modification. Required at least 1 inpatient or 2 non-inpatient claims 
with specific ICD-9-CM diagnosis codes appearing more than once 
over a time span exceeding 30 days. Specific codes included: 714.0, 
714.1, 714.2, 714.30, 714.31, 714.32, 714.33, 715.00, 715.04, 715.09, 
715.10, 715.11, 715.12, 715.13, 715.14, 715.15, 715.16, 715.17, 
715.18, 715.20, 715.21, 715.22, 715.23, 715.24, 715.25, 715.26, 
715.27, 715.28, 715.30, 715.31, 715.32, 715.33, 715.34, 715.35, 
715.36, 715.37, 715.38, 715.80, 715.89, 715.90, 715.91, 715.92, 
715.93, 715.94, 715.95, 715.96, 715.97, 715.98, 720.0, 721.0, 721.1, 
721.2, 721.3, 721.90, 721.91. For more information, see: 
https://www.ccwdata.org/web/guest/condition-categories. Measured 
using a one-year lookback period from time of MLIP enrollment. 
 Sickle cell Used definition consistent with AHRQ’s CCS and the previous 
research (see: Reeves S, Garcia E, Kleyn M, et al. Identifying sickle 
cell disease cases using administrative claims. Academic Pediatrics 
2014;14(5 Suppl):S61-67.). Required at least 1 inpatient or 2 non-
inpatient claims with specific ICD-9 diagnosis codes that appear more 
than once over a time span exceeding 30 days. Specific codes 
included: 28241 28242 28260 28261 28262 28263 28264 28268 
28269. Measured using a one-year lookback period from time of 
MLIP enrollment. 
MENTAL HEALTH-RELATED DIAGNOSES 
 Depression Used CMS CCW definition. Required at least 1 inpatient, skilled 
nursing facility, home health agency, hospital outpatient, or 
service/carrier claims with specific ICD-9-CM diagnosis codes. 
Specific codes included: 296.20, 296.21, 296.22, 296.23, 296.24, 
296.25, 296.26, 296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 
296.36, 300.4, 311, V79.0. For more information, see “Original CCW 
Chronic Condition Algorithms” found at: 
https://www.ccwdata.org/web/guest/condition-categories. Measured 
using a one-year lookback period from time of MLIP enrollment. 
 Anxiety disorder Used CMS CCW definition. Required at least 1 inpatient or 2 non-
inpatient claims with specific ICD-9 diagnosis codes appearing more 
than once over a time span exceeding 30 days. Specific codes 
included: 293.84, 300.00, 300.01, 300.02, 300.09, 300.10, 300.20, 
300.21, 300.22, 300.23, 300.29, 300.3, 300.5, 300.89, 300.9, 308.0, 
308.1, 308.2, 308.3, 308.4, 308.9, 309.81, 313.0, 313.1, 313.21, 
313.22, 313.3, 313.82, 313.83. For more information, see: 
https://www.ccwdata.org/web/guest/condition-categories. Measured 
using a one-year lookback period from time of MLIP enrollment. 
 Other serious 
mental health 
disorder (includes 
bipolar, 
Used CMS CCW definitions. Required at least 1 inpatient or 2 non-
inpatient claims with specific ICD-9 diagnosis codes appearing more 
than once over a time span exceeding 30 days. Specific codes 
included: 293.81, 293.82, 295.00, 295.01, 295.02, 295.03, 295.04, 
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personality, 
schizophrenia or 
other psychotic, 
and post-traumatic 
stress disorders) 
295.05, 295.10, 295.11, 295.12, 295.13, 295.14, 295.15, 295.20, 
295.21, 295.22, 295.23, 295.24, 295.25, 295.30, 295.31, 295.32, 
295.33, 295.34, 295.35, 295.40, 295.41, 295.42, 295.43, 295.44, 
295.45, 295.50, 295.51, 295.52, 295.53, 295.54, 295.55, 295.60, 
295.61, 295.62, 295.63, 295.64, 295.65, 295.70, 295.71, 295.72, 
295.73, 295.74, 295.75, 295.80, 295.81, 295.82, 295.83, 295.84, 
295.85, 295.90, 295.91, 295.92, 295.93, 295.94, 295.95, 296.00, 
296.01, 296.02, 296.03, 296.04, 296.05, 296.06, 296.10, 296.11, 
296.12, 296.13, 296.14, 296.15, 296.16, 296.40, 296.41, 296.42, 
296.43, 296.44, 296.45, 296.46, 296.50, 296.51, 296.52, 296.53, 
296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 
296.65, 296.66, 296.7, 296.80, 296.81, 296.82, 296.89, 296.90, 
296.99, 297.0, 297.1, 297.2, 297.3, 297.8, 297.9, 298.0, 298.1, 298.2, 
298.3, 298.4, 298.8, 298.9, 301.0, 301.10, 301.11, 301.12, 301.13, 
301.20, 301.21, 301.22, 301.3, 301.4, 301.50, 301.51, 301.59, 301.6, 
301.7, 301.81, 301.82, 301.83, 301.84, 301.89, 301.9, 309.81. For 
more information, see: https://www.ccwdata.org/web/guest/condition-
categories. Measured using a one-year lookback period from time of 
MLIP enrollment. 
OTHER COMORBID CONDITIONS 
 Mean Charlson 
comorbidity index 
The Charlson Comorbidity Index (CCI) is a method of categorizing 
comorbidities based on ICD codes. Each comorbidity is associated 
with a weight (from 1 to 6), and weights are based on the adjusted risk 
of mortality or resource use. CCI scores are calculated by summing an 
individual’s weights; a score of zero indicates no comorbidities were 
detected. We used Quan’s enhanced CCI macro which looks at 17 
comorbidities. An individual comorbidity was considered present if 
there was at least 1 inpatient or 2 non-inpatient claims with the 
specific ICD-9 diagnosis codes that appeared more than once over a 
time span exceeding 30 days. Additional details on the index and 
specific comorbidities included can be found in: Quan H, Sundararajan 
V, Halfon P, et al. Coding algorithms for defining comorbidities in 
ICD-9-CM and ICD-10 administrative data. Medical Care 
2005;43(11):1130-1139. 
 Cancer Used Quan et al., 2005 definition. Required at least 1 inpatient or 2 
non-inpatient claims with specific ICD-9 diagnosis codes appearing 
more than once over a time span exceeding 30 days. Specific codes 
included: 140-165, 170-172, 174-176, 179-208, 238.6. Additional 
details can be found in: Quan H, Sundararajan V, Halfon P, et al. 
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-
10 administrative data. Medical Care 2005;43(11):1130-1139. 
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APPENDIX C—TEMPORAL TREND MEASURE CONSTRUCTION FOR AIM 1 
ANALYSES 
 
Temporal trends over calendar time exist in the overall population in terms of access to 
opioids and related effects. To help for confounding due to temporal changes over calendar time, 
we developed a set of temporal trend measures. These temporal trend measures were included in 
all models. We generated these measures from temporal trends in outcome measures in the 
population of Medicaid beneficiaries who were eligible to enter the LIP, but who were not 
enrolled. The creation of temporal trend measures occurred in five steps:  
1. We assigned a “program day” (e.g., MLIP day #-1 for the day prior to MLIP 
enrollment, MLIP day #0 for the first day of lock-in) for each day that a beneficiary 
was in our study.  
2. We extracted the calendar month and year underlying that “program day.” For 
example, one person’s first day in the MLIP might have been 11/1/2010 (11/2010 
would have been extracted) and another’s might have been 5/1/2012 (5/2012 would 
have been extracted).  
3. We constructed a cohort of Medicaid beneficiaries eligible for MLIP enrollment, 
according to MLIP enrollment criteria, but never enrolled during the study period. We 
identified the MLIP-eligible population by examining Medicaid-reimbursed 
prescription fills from June 2010 through December 2012 to determine who would 
have been eligible for MLIP enrollment when the program began in October 2010 
through the end of our dataset in June 2013.  For each two calendar month period, we 
examined the number of opioid and benzodiazepine prescriptions obtained by each 
beneficiary. Consistent with MLIP eligibility criteria, beneficiaries with more than six 
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opioid or benzodiazepine prescriptions in a consecutive two-month period were 
defined as MLIP-eligible. While beneficiaries could also become eligible by obtaining 
these prescriptions from more than three unique prescribers, the data available did not 
provide accurate information on numbers of unique prescribers. Therefore, we were 
unable to use the third criterion in constructing our MLIP-eligible population. 
However, given that almost all of the MLIP-enrolled cohort met the first criterion (i.e., 
more than six opioid prescriptions) and given that there were likely relatively few 
people who visited several unique prescribers but did not also meet the prescription 
thresholds, we would not expect this missing information to have excluded many 
beneficiaries.  
4. We calculated the mean of each outcome measure for each calendar month and year 
combination within the eligible but never MLIP-enrolled cohort.  
5. We matched the mean of each calendar month/year in the never MLIP-enrolled cohort 
to the calendar month/year represented within each “program day” of our MLIP-
enrolled study cohort. Ultimately, we generated a temporal trend measure that allowed 
us to disentangle changes in outcomes occurring over calendar time from changes 
occurring over MLIP “program time” by controlling for changes in outcome measures 
over calendar time in a similar but never MLIP-enrolled population. 
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APPENDIX D—CRITERIA USED TO DETERMINE NUMBER OF MEANINGFUL 
TRAJECTORY CLASSES IN LATENT CLASS GROWTH ANALYSES AND MODEL 
SELECTION PROCESS 
 
All LCGA models were fit in Mplus, version 7.4, using robust maximum likelihood 
estimation (MLR). Since research shows that the maximum likelihood function for finite mixture 
models is prone to settling on local maxima solutions, all models were fit using several 
maximum likelihood start values.160,187 We specified that models begin with 100 random starts, 
optimizing the best 20, and we confirmed that the best log-likelihood values were duplicated 
across start values.  
To determine the number of meaningful trajectory classes, we used several criteria: 
likelihood ratio tests (LRT), information criteria, measures of entropy, class size, and 
interpretability.160 The Lo-Mendell-Rubin LRT was used to compare models with j trajectory 
classes as compared to j+1 trajectory classes with a statistical cutpoint set at α=0.05.188 Test 
statistics with corresponding p-values less than 0.05 led us to favor the model with j+1 trajectory 
groups. We used Akaike’s Information Criterion (AIC), Bayesian Information Criterion (BIC), 
and sample-size adjusted BIC (ssBIC) to assess model fit; models with lower information criteria 
were favored over those with higher criteria. Entropy, a measure of latent class separation that 
ranges from 0 to 1, was also considered.189 A larger entropy value indicates better separation, and 
models with entropy values greater than 0.8 are generally regarded as having high and suitable 
entropy.190 Finally, as a guide to our final model choice we considered general interpretability 
and class size, with no class having less than a 5% prevalence to avoid unstable or obscure 
classes. 
The five class solution was ultimately selected as the best solution (see Table below). As 
commonly observed191, the AIC, BIC, and ssBIC improved with the addition of each class; 
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however, only marginal gains were observed after the addition of the fourth or fifth class. The 
Lo-Mendell-Rubin LRT favored up to a six class solution, as did estimates of the smallest class 
size. Models specified with seven and eight classes were associated with smallest class sizes that 
were potentially indicative of unstable or obscure class solutions. Graphical comparisons 
between the five and six class solutions revealed that for the six class solution, there were strong 
similarities between two of the trajectory classes (i.e., parallel lines with a slight level shift). 
Therefore, the five class solution was selected as the best overall solution, and was determined to 
achieve the best balance of comprehensiveness with interpretability and parsimony. 
 
TABLE. Model fit statistics for linear piecewise latent class growth analysis model estimating 
trajectories in the log of average daily morphine milligram equivalents (MMEs) of opioids 
dispensed to beneficiaries enrolled in the North Carolina Medicaid “lock-in” program per month 
Latent 
classes 
AIC BIC ssBIC Lo-Mendell-
Rubin LRT p-
value 
Entropy Smallest 
class 
size 
1 418,435 418,477 418,454 N/A N/A N/A 
2 367,304 367,393 367,345 <0.001 0.98 0.42 
3 348,124 348,259 348,186 0.012 0.98 0.18 
4 338,468 338,651 338,553 0.016 0.97 0.11 
5 330,825 331,055 330,931 0.006 0.97 0.13 
6 324,640 324,918 324,769 0.026 0.97 0.11 
7 319,866 320,190 320,015 0.306 0.97 0.05 
8 316,638 317,010 316,810 0.251 0.97 0.04 
Note: model specified with five linear pieces 
AIC= Akaike’s Information Criterion; BIC= Bayesian Information Criterion; ssBIC=sample-size adjusted 
BIC; LRT= likelihood ratio test 
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APPENDIX E—CALCULATION OF STANDARDIZED DIFFERENCES 
 
Standardized differences provide a measure of the similarity or dissimilarity of two 
groups with respect to specific covariates. For continuous and binary covariates, standardized 
differences were used to compare the means of two groups in units of the pooled standard 
deviation of the two groups. For categorical variables with more than two levels, an overall 
standardized difference was calculated, using a multivariate Mahalanobis distance method.168 In 
order to calculate standardized differences, we assigned beneficiaries to the class for which they 
had the highest posterior probability of belonging. While this method, known as modal 
assignment, has been criticized for removing the uncertainty of latent classification,192,193 the 
classification uncertainty for most beneficiaries in our cohort was very small (see Table below). 
As an additional check, we recalculated the counts, percentages, and means shown in Table 7.1, 
using modal assignment instead of posterior probability weights and found very little difference. 
Therefore, any error introduced by modal assignment to calculate standardized differences was 
likely minimal. 
 
TABLE. Average latent class probabilities for most likely latent class membership 
Most likely 
latent class 
Mean Standard 
deviation 
25th 
percentile 
Median 75th 
percentile 
1 0.993 0.049 1.000 1.000 1.000 
2 0.979 0.069 0.999 1.000 1.000 
3 0.968 0.090 0.996 1.000 1.000 
4 0.969 0.084 0.996 1.000 1.000 
5 0.989 0.053 1.000 1.000 1.000 
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APPENDIX F—SENSITIVITY ANALYSES OF TRAJECTORIES OF OPIOID 
DOSAGES (MEASURED IN MORPHINE MILIGRAM EQUIVALENTS (MMEs)) 
DISPENSED TO BENEFICIARIES ELIGIBLE FOR THE NORTH CAROLINA 
MEDICAID “LOCK-IN” PROGRAM (MLIP) BUT NEVER ENROLLED 
 
Sensitivity Analysis Methods 
 To examine the extent to which opioid dispensing trajectory findings were unique to 
beneficiaries enrolled in the MLIP (and potentially influenced by the MLIP), we fit similar 
models in a MLIP-eligible, but never enrolled cohort. Details on the formation of an eligible but 
never MLIP-enrolled cohort, as well as characteristics of these beneficiaries were previously 
reported in Chapter 5.  
Previous analyses of MLIP-eligible and enrolled and MLIP-eligible and never enrolled 
cohorts revealed a similar overall pattern in average daily MMEs prior to and immediately 
following the point at which MLIP eligibility criteria were met.175 Specifically, both MLIP-
enrolled and never enrolled cohorts exhibited an escalation in average daily MMEs, triggering of 
MLIP criteria, and a nearly equal de-escalation in MMEs (regardless of enrollment in the MLIP). 
Because of these similarities, we were interested in examining whether potential underlying 
heterogeneity in trajectories for these two cohorts was also similar, which could provide some 
indication of the extent to which the MLIP influenced trajectory patterns.  
Using a five piece, linear piecewise LCGA model specification similar to the model 
chosen for our MLIP-enrolled cohort, we examined the extent to which trajectory patterns, 
prevalences of patterns, and covariate associations with patterns in the never enrolled cohort 
were consistent with those in the MLIP-enrolled cohort.  
Sensitivity Analysis Results 
 Sensitivity analyses in the similar, but never MLIP-enrolled, cohort of Medicaid 
beneficiaries revealed similar trajectory patterns and pattern prevalences (Figure F). While the 
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actual prevalences of many covariates differed, covariate associations with patterns were 
generally similar between the MLIP-enrolled and never enrolled cohorts (Table F). For example, 
among the MLIP-enrolled, the prevalences of rheumatoid arthritis or osteoarthritis by class were 
41%, 39%, 29%, 26%, and 12% for classes 1 to 5, respectively (Table 7.1). Among those eligible 
but never enrolled, prevalences were 29%, 27%, 23%, 16%, and 8% for classes 1 to 5, indicating 
different prevalence levels but similar associations with class (Table F). Notable differences in 
covariate associations included history of MAT and cancer diagnoses. History of MAT was 
strongly associated with class among the enrolled but not among the never enrolled. Overall 
prevalences of cancer were much higher in the never enrolled than enrolled. 
Sensitivity Analysis Limitations 
Two limitations to this analysis should be noted: 1) we did not have CSRS records on 
those who were not enrolled, only Medicaid claims and 2) the time axis inevitably differed from 
our primary analysis. In our primary analysis, the MLIP-enrolled cohort was examined from time 
until/from MLIP enrollment; however, the never enrolled cohort could only be examined using 
time until/from first meeting MLIP eligibility criteria. Further analyses that 1) constrained 
MLIP-enrolled models to only Medicaid-reimbursed MMEs and 2) altered the time axis in 
MLIP-enrolled models to time until/from first meeting MLIP eligibility criteria revealed that 
findings were not sensitive to these two limitations.
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FIGURE F. Trajectories of log of average daily morphine milligram equivalents (MMEs) of opioids dispensed* per month to 
beneficiaries eligible for the North Carolina Medicaid “lock-in” program but never enrolled, October 2009-June 2013 (n=11,600) 
  
* Only from Medicaid-reimbursed opioid prescriptions.  
10.9% 
12.6% 
23.1% 
21.0% 
32.4% 
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TABLE F. Weighted* counts, percentages, and means for characteristics of each of the five latent classes representing different 
trajectories in the log of average daily morphine milligram equivalents (MME) of opioids dispensed# to beneficiaries eligible for the 
North Carolina Medicaid “lock-in” program but never enrolled, October 2009-June 2013 (n=11,600) 
 
Start high, end 
high (C1)  
(n=1,272; 
10.9%)* 
Start medium, 
end medium 
(C2) (n=1,484; 
12.6%)* 
Start medium, 
end low (C3)  
(n=2,415; 
21.0%)* 
Start low, end 
medium (C4) 
(n=2,633; 
23.1%)* 
Start low, end 
low (C5) 
(n=3,796; 
32.4%)* 
 
N (%) for categorical variables; Mean (25th pct, median, 75th pct) for continuous 
variables 
DEMOGRAPHICS^      
Age (years) 
46.5 (39, 48, 
55) 
45.2 (37, 46, 
54) 
43.8 (36, 45, 
53) 
40.0 (31, 39, 
49) 
35.6 (26, 33, 
43) 
Gender      
  Women 728.7 (57.8) 901.8 (61.7) 1,393.6 (57.1) 1,781.7 (66.5) 2,567.2 (68.3) 
  Men 533.0 (42.2) 560.3 (38.3) 1,046.2 (42.9) 896.8 (33.5) 1,190.8 (31.7) 
Race      
  White 993.0 (78.7) 1,050.5 (71.9) 1,803.6 (73.9) 1,996.4 (74.5) 2,841.5 (75.6) 
  Black 184.1 (14.6) 315.4 (21.6) 516.3 (21.2) 552.9 (20.6) 748.3 (19.9) 
  Other 84.7 (6.7) 96.1 (6.6) 119.9 (4.9) 129.1 (4.8) 168.2 (4.5) 
Urbanicity of county of residence      
  Counties in metro areas of ≥ 1 million 
population 
276.2 (21.9) 303.3 (20.8) 571.8 (23.4) 627.9 (23.4) 873.8 (23.3) 
  Counties in metro areas of < 1 million 
population 
556.7 (44.1) 698.2 (47.8) 1,126.4 (46.2) 1,215.8 (45.4) 1,763.9 (46.9) 
  Nonmetro, urban population of ≥ 
20,000 
235.7 (18.7) 266.0 (18.2) 399.7 (16.4) 495.1 (18.5) 611.5 (16.3) 
Nonmetro, urban population of <20,000 
or rural population 
193.2 (15.3) 194.5 (13.3) 340.7 (14.0) 339.5 (12.7) 504.1 (13.4) 
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Overdose death rate in county of 
residence (per 100,000 person-years) 
     
  20.0-32.2  245.8 (19.5) 281.5 (19.3) 500.0 (20.5) 552.5 (20.6) 755.2 (20.1) 
  15.0-19.9  230.7 (18.3) 345.4 (23.6) 625.8 (25.7) 738.0 (27.6) 1,078.0 (28.7) 
  11.1-14.9  324.6 (25.7) 341.4 (23.4) 486.3 (19.9) 508.5 (19.0) 704.2 (18.7) 
  8.7-11.0  273.6 (21.7) 326.9 (22.4) 504.5 (20.7) 552.1 (20.6) 763.8 (20.3) 
  2.6-8.6  187.0 (14.8) 166.8 (11.4) 322.0 (13.2) 327.0 (12.2) 452.2 (12.0) 
Medicaid eligibility category code      
  Aid to families with dependent children 361.4 (28.6) 590.6 (40.4) 935.0 (38.3) 1,558.1 (58.2) 2,357.9 (62.7) 
  Aid to disabled 897.4 (71.1) 855.5 (58.5) 1,480.7 (60.7) 1,045.3 (39.0) 1,140.1 (30.3) 
Aid for other reasons (e.g., aid to blind, 
aid to pregnant women) 
3.0 (0.2) 15.9 (1.1) 24.1 (1.0) 74.0 (2.8) 259.9 (6.9) 
Medicaid class code      
  Categorically needy 1,195.3 (94.7) 1,353.9 (92.6) 2,151.1 (88.2) 2,441.8 (91.2) 3,416.0 (90.9) 
  Medically needy 58.8 (4.7) 103.5 (7.1) 270.5 (11.1) 223.9 (8.4) 321.3 (8.6) 
Other 7.6 (0.6) 4.7 (0.3) 18.2 (0.8) 12.8 (0.5) 20.6 (0.6) 
      
SUBSTANCE USE-RELATED †      
Alcohol-related disorder 58.8 (4.7) 97.4 (6.7) 205.0 (8.4) 189.1 (7.1) 220.7 (5.9) 
Other substance-related disorder 208.5 (16.5) 187.2 (12.8) 419.8 (17.2) 345.1 (12.9) 405.3 (10.8) 
Medication-assisted treatment (MAT)  29.5 (2.3) 15.7 (1.1) 79.3 (3.3) 59.5 (2.2) 66.1 (1.8) 
Medication or drug-related overdose 55.6 (4.4) 45.6 (3.1) 95.5 (3.9) 94.9 (3.5) 114.5 (3.1) 
      
HEALTH CARE UTILIZATION †      
Emergency department visits  2.5 (0, 1, 3) 3.6 (1, 2, 5) 4.2 (1, 2, 5) 4.7 (1, 3, 6) 4.7 (1, 3, 6) 
Inpatient admissions  1.0 (0, 0, 1) 1.1 (0, 1, 1) 1.4 (0, 1, 2) 1.0 (0, 0, 1) 0.8 (0, 0, 1) 
Days with Medicaid coverage 
329.6 (365, 
365, 365) 
311.3 (275, 365, 
365) 
311.3 (273, 365, 
365) 
307.1 (273, 
365, 365) 
295.4 (242, 
365, 365) 
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PAIN-RELATED DIAGNOSES †      
  Any joint pain or arthritis 1,079.7 (85.6) 1,290.6 (88.3) 2,046.6 (83.9) 2,205.3 (82.3) 2,684.7 (71.4) 
  Back pain 946.4 (75.0) 1,025.5 (70.2) 1,631.9 (66.9) 1,714.4 (64.0) 2,005.7 (53.4) 
  Neck pain 427.9 (33.9) 451.4 (30.9) 737.6 (30.2) 759.7 (28.4) 775.4 (20.6) 
  Headache/migraine pain 141.7 (11.2) 229.9 (15.7) 317.0 (13.0) 411.8 (15.4) 500.0 (13.3) 
  Fibromyalgia, chronic pain, or fatigue 751.8 (59.6) 610.8 (41.8) 1,103.2 (45.2) 780.2 (29.1) 596 (15.9) 
  Rheumatoid arthritis or osteoarthritis 373.0 (29.6) 403.2 (27.6) 544.4 (22.3) 417.6 (15.6) 294.7 (7.8) 
  Sickle cell 25.8 (2.0) 10.5 (0.7) 26.3 (1.1) 14.4 (0.5) 9.9 (0.3) 
      
MENTAL HEALTH-RELATED 
DIAGNOSES † 
     
  Depression 585.8 (46.4) 657.5 (45.0) 1,170.9 (48.0) 1,180.1 (44.1) 1,530.6 (40.7) 
  Anxiety disorder 353.9 (28.1) 382.4 (26.2) 633.8 (26.0) 673.3 (25.1) 797.7 (21.2) 
Other serious mental health disorder 
(includes bipolar, personality, 
schizophrenia or other psychotic, and 
post-traumatic stress disorders) 147.5 (11.7) 232.0 (15.9) 407.4 (16.7) 427.9 (16.0) 644.2 (17.1) 
      
OTHER COMORBID CONDITIONS †      
  Mean Charlson co-morbidity index 2.3 (0, 1, 3) 1.7 (0, 1, 3) 2.8 (0, 1, 4) 1.5 (0, 0, 2) 0.9 (0, 0, 1) 
  Cancer 244.2 (19.4) 186.3 (12.7) 604.5 (24.8) 314.0 (11.7) 230.9 (6.1) 
pct= percentile; C= class 
* Weights are estimated posterior probabilities for belonging to a given class 
# Only includes opioids dispensed and paid for through Medicaid reimbursement 
^ Assessed at the time of “lock-in” program enrollment 
† Assessed using a one-year lookback period from the date of “lock-in” program enrollment
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